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CD4+ T cells require heterogeneity in effector responses to respond effectively to the
diversity of pathogenic challenge. The fate decisions made by naive CD4+ T cells
occur on first encounter with antigen. Activation via the T cell receptor (TCR)
selects for antigen specificity while the influence of TCR/MHC/peptide avidity and
co-stimulatory signals via CD28, CD40L, OX40, ICOS, CTLA-4, and cytokines
determine differentiation into Thl/Th2, memory or regulatory/anergic cells. The
identification of components of the Notch signalling pathway, central to cell fate
determination in embryogenesis, in the mammalian immune system has expanded
current thinking on the specification of effector cell phenotype. This thesis was thus
designed to test the hypothesis that Notch signalling is able to influence CD4+ T cell
effector function.
Activation of purified murine CD4+ T cells enhanced expression of the Notch target
gene hesl and induced differential expression of Notch receptors and ligands
compared to unstimulated cells. Surface staining for Notch 1 revealed that
unstimulated cells expressed this receptor at the membrane. Activation of T cells
induced capping ofNotchl, which was found to co-localise with CD4.
Capping of surface Notch and co-localisation with CD4 upon T cell activation was
reminiscent of immunological synapse formation, suggesting that Notch may interact
directly with T cell receptor signaling. Notch signalling was attenuated in CD4+ T
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cells using a y-secretase inhibitor, allowing assessment of Notch function in
determining effector function. Notch signal inhibition in the context of anti-CD3-Ab
stimulation, resulted in inhibition of TNFa, IFNy, IL-4 and IL-10 secretion.
Blockade of Notch signalling where cells were stimulated with anti-CD3/28-Ab did
not down-regulate TNFa, IFNy or IL-4 secretion, but IL-10 was inhibited. Notch
signalling may thus be important as a co-stimulator when CD28 signalling is
limiting. Of note is the requirement of Notch signalling in the induction of the
immunoregulatory cytokine IL-10, known to be related to T reg cell activity.
Naturally occurring CD25+CD4+ T regulatory cells and in vitro generated Trl cells
were examined for expression of Notch pathway components to ascertain if Notch
may be involved in mediating regulatory function. Both populations were found to
express higher levels of the Notch ligand Deltal than non-regulatory CD4+ T cells.
Inhibition of Notch signalling did not affect the ability of CD25+CD4+ T cells to
regulate proliferation of CD4+CD25" T cells, but did reduce secretion of IL-10.
These findings indicate that Notch receptors and ligands are expressed by CD4+ T
cells. Notch may also be a component of the immune synapse and potentially
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APC antigen presenting cell
APP amyloid precursor protein
bHLH basic helix-loop-helix
bp base pair
BSA bovine serum albumin
BM bone marrow
C. elegans Caenorhabditis elegans
Ca2+ calcium ion
CBF-1 C promoter binding factor-1
CD cluster of differentiation
CD40L CD40 ligand
cDNA complementary DNA
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CSL CBF-1, Su(H), LAG-1
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CTLA-4 cytotoxic T lymphocyte-associated antigen-4
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Der p Dermatophagoides pteronyssinus
Der pi Der p type 1 allergen
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EDTA Ethylenediaminetetraacetic acid
EGFP enhanced green fluorescent protein
ELISA enzyme linked immunosorbant assay
Erk extracellular signal receptor regulated kinase
E(spl) enhancer of split
FAM 6-carboxyfluorescein
FCS foetal calf serum
FITC fluorescein isothiocyanate
g gravitational force
GFP green fluorescent protein
GM-CSF granulocyte/macrophage colony stimulating factor
GSK glycogen synthase kinase
hes hairy/enhancer of split
ICAM intercellular adhesion molecule




ITAM immunoreceptor tyrosine-based activation motif
Jnk Jun N terminal kinase
kb kilobases
LFA lymphocyte functional antigen
LPS lipopolysaccharide
MACS magnetic cell sorting
MCMV murine cytomegalovirus
mg milligram
ME1C major histocompatibility complex
ml millilitre
MOI multiplicity of infection
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mRNA messenger RNA
NFAT nuclear factor of activated T cells
NFkB nuclear factor kappaB
NICD notch intracellular domain
NICD1 notch 1 intracellular domain
NICD3 notch3 intracellular domain
NK natural killer cell
°C degrees centigrade
PBS phosphate buffered saline
PCR polymerase chain reaction
PE phycoerythrin
PI phosphoinositide
PKC protein kinase C
PLCy phospholipase C gamma
RAM RBP-J association molecule
RANK receptor activator ofNFkB
RBC red blood cell
RBP-Jk recombination-signal binding protein Jk




RT-PCR reverse transcriptase polymerase chain reaction
SLP-76 src-homology2-domain containing leukocyte phosphoprotein of 76kD
SMAC supra-molecular cluster (c or pSMAC: central or peripheral SMAC)
SP single positive
TAMRA 6-carboxytetramethylethylenediamine
TCR T cell receptor
TGFp transforming growth factor beta
Th T helper
Ta annealing temperature
TAE Tris acetate and lOmM EDTA
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T-ALL T acute lymphoblastic leukaemia
TNF tumour necrosis factor
Trl Type 1 regulatory T cell
TRANCE TNF-related activation induced cytokine




ZAP-70 zeta associated protein of 70kD
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1 Introduction
The mammalian immune system consists of an array of cells evolved to provide
protection against pathogens. Flexibility within the immune system allows
differentiation between harmful and innocuous antigens, and cell fate decisions have
to be made to produce the appropriate response. Although the innate immune
response is crucial in preventing infection, the adaptive response provides specificity
and memory, enhancing the overall efficiency of the host defence mechanisms.
Dendritic cells (DCs) act to bridge innate and adaptive immunity, transmitting
signals received directly from pathogens and inflamed tissues to CD4+ T cells that
translate this information into a response specific for the pathogen. Once the decision
to respond to specific antigen is made, CD4+ T cells proliferate and differentiate into
effector cells. Development of an appropriate CD4+ T effector phenotype is crucial in
determining the outcome of a response directing adaptive immunity and augmenting
innate responses. Circumstantial evidence suggests that Notch signalling may
influence the role CD4+ T cells play in an immune response.
The Notch pathway is classically associated with cell fate choices during
development, however, the effects of Notch signalling extend beyond embryonic
patterning and into regulation of the mature immune system. Notch signalling
regulates differentiation of macrophages, dendritic cells (DCs), and lymphocytes. A
large body of evidence details the critical role of Notch in controlling thymocyte
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development where it promotes T versus B lymphocyte lineage commitment,
determines T cell receptor usage and influences expression of CD4 and CD8.
Given its importance in the development of CD4+ T cells, it was hypothesised that
Notch signalling has a role in differentiation of the mature, peripheral CD4+ T cell.
By influencing the effector profile/Th phenotype of activated CD4+ T cells, Notch
signalling may provide an important link establishing an immune response.
On beginning work for this thesis, the only direct evidence linking Notch signalling
and CD4+ T cell function was derived within our own laboratory. Induction ofNotch
signalling in vivo was capable of generating a population of CD4+ T cells capable of
regulating immune responses to house dust mite allergens (1). The aim of this thesis
was to clarify the role of Notch signalling in relation to CD4+ T cell function. In vitro
studies were used to establish whether Notch has a role in normal CD4+ T cell
responses. By means of an introduction, background information regarding the
activation and differentiation of CD4+ T cells is detailed. An overview of the Notch
signalling pathway is also provided and is followed by information pertaining to
Notch activity in T lineage cells.
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1.1 Activation of CD4+ T cells
T cell activation is dependent upon transduction of specific surface receptor
interactions into new gene transcription and translation. CD4+ T cell activation
follows recognition of specific antigenic peptides presented in the context of MHC
class II (signal 1) and additional co-stimulation (signal 2) received from professional
antigen presenting cells (APCs). Although both macrophages and B cells are capable
of presenting antigen to CD4+ T cells, it is believed that the main APCs responsible
for priming nai've T cells are dendritic cells (DCs). Antigen bearing DC migration to
lymphoid tissue allows nai've CD4+ T cells to sample peptide/MHC class II
complexes by means of a clonally-specific antigen-binding surface receptor, the T
cell receptor (TCR). The major source of costimulatory signalling is accepted to be
via CD28 ligation by either CD80 or CD86 (B7.1, B7.2). However, a number of
other costimulatory molecules are involved in focussing the interaction between T
cell and APC and the modulation of subsequent gene expression.
1.1.1 T cell receptor signalling (signal 1)
The TCR complex consists of a multichain complex of six or more distinct
polypeptides (Figure 1.1). The clonotypic antigen recognition portion (TCR) of the
complex consists of a polymorphic a and P chain heterodimer, lacking signalling
capability. Signal transduction is reliant on the invariant CD3 complex. CD3
associates with the TCRaP as an s chain dimerised with either y or §. Each chain
contains a single ITAM (immunoreceptor tyrosine-based activation motif). An
additional six ITAMs are present on the £, chain homodimer (Figure 1.1).
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Figure 1.1: The T cell receptor and co-receptor complex. The disulphide linked a
and P chains of the TCR (red) are incapable of mediating signal transduction. Association
with the CD3 complex (possibly through ionic interactions) links antigen reception to signal
transduction. The CD3 complex consists of a s8 dimer, sy dimer and a mainly cytoplasmic
QL, homodimer (purple). It is currently believed that two TCR afi dimers associate with a
single CD3 complex, balancing ionic charges of the transmembrane regions. Receptor
ligation induces phosphorylation of immunoreceptor tyrosine-activation motifs (ITAMs)
(yellow) by Src kinases, allowing binding and activation of signalling molecules. The Src
kinase fyn can be found associated with the TCR. Another vitally important Src family
member, lck, is recruited by the co-receptor CD4 (blue) which binds directly to the MHC
class II molecule.
T cell/APC interactions are initially mediated by adhesion molecule interactions,
allowing sampling of peptide/MHC class II complexes by the TCR (Figure 1.2A).
Recognition of specific ligand induces rapid organisation of surface receptors at the
point of contact between T cell and APC to form an immunological synapse (IS).
The IS is a three dimensional structure consisting of a "bull's eye" arrangement of
supramolecular clusters (SMACs) (Figure 1.2B) (2). Classically, central
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supramolecular cluster (cSMAC) and peripheral supramolecular cluster (pSMAC)
contain TCR/MHC and adhesion molecules respectively. Such organisation allows
concentration of signal transduction molecules associated with lipid rafts, increasing
sensitivity to antigen. Blockade of IS formation prevents full T cell activation.
Induction of strong TCR signalling is associated with rapid dissolution of the IS and




Figure 1.2: Interaction between APC and T cell. Naive CD4+ T cells follow
chemotactic gradients to reach the T cell dependent areas of secondary lymphoid tissues.
Chemokine reception induces polarisation of adhesion molecules and TCR complexes to the
leading edge of the T cell positioning surface receptors for APC/T cell interaction. Initial
foci develop consisting of adhesion molecules such as LFA-1 and CD2 (A), providing time
for TCR/MHC interactions to occur. Induction of TCR signalling is followed by a
conformational change in LFA-1, enhancing its affinity for ICAMs expressed by the APC.
This event is rapidly followed by organisation of surface molecules such as the TCR, CD4,
CD28, CD2 and LFA-1 into the immunological synapse (IS). This structure concentrates the
signal transduction machinery in the central supramolecular cluster (cSMAC), and adhesion
molecules to the peripheral SMAC (pSMAC) (B). IS formation augments T cell activation
by focusing the interaction between the APC and T cell. Release of cytokines into the IS may
also allow directed polarisation ofT cell effector function by APCs.
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The pivotal point in T cell activation seems to be the transduction of binding a
specific peptide/MHC class II complex into increased phosphorylation of the CD3
ITAMs (immunoreceptor tyrosine-based activation motifs) particularly those of the C,
chain (Figure 1.3). The mechanism leading to this has not yet been established but a
combination of recruitment of lck by co-ligation of CD4, IS concentration of src
kinases and target molecules, and possible exclusion of negative regulators (such as
Csk) may be responsible (1-3). Enhanced ITAM phosphorylation allows recruitment
and activation of zeta-associated protein-70 (ZAP-70). ZAP-70 is responsible for the
phosphorylation of the palmitoylated adaptor protein LAT (linker of activation in T
cells) and of SLP-76 (SH2-domain-containing leukocyte protein of 76kDa) (Figure
1.3)
Phosphorylation of LAT and SLP-76 allows recruitment of Tec kinases and GEFs
(guanine-nucleotide exchange factors) leading to the activation of PLCy
(phospholipase C-y) and the Ras/Raf MAPkinase cascade respectively (Figure 1.3)
(4, 5). Activation of these two pathways in concert generates functional NFAT
(nuclear factor of activated T cells), NFkB (nuclear factor kB) and, in the context of
appropriate co-stimulation, AP-1 (activator protein-1) (2, 5). The result is initiation
of new gene transcription, culminating in clonal expansion and development of
effector function.
Activated PLCy converts membrane PIP2 (phospho-inositol-biphosphate) into IP3
(inositol-triphosphate) and DAG (diacyl-glycerol), culminating in NFAT and NFkB
translocation to the nucleus (Figure 1.3) (3). IP3 allows release of intracellular
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calcium stores, required for calmodulin dependent calcineurin activation. Calcineurin
is a serine/threonine phosphatase that dephosphorylates the nuclear localisation
sequence of cytoplasmic NFAT allowing its nuclear translocation. DAG is required
for the activation of PKC (protein kinase C). This occurs directly as with nPKC
(novel PKC) or in conjunction with Ca2+ as for cPKC (conventional PKC). PKC
activation of IkK (IkB kinase) leads to the removal of IkB from NFkB, allowing
nuclear localisation of the active transcription factor.
AP-1 consists of dimers of Jun and Fos. Transcription of Fos is induced by TCR
activation of the Ras/Raf MAPkinase pathway (Figure 1.3) (3). Association of the
adaptor protein Grb2 with LAT/SLP-76 recruits the GEF Sos which activates the
small G-protein Ras. Ras in turn stimulates the MAP kinase kinase kinase Raf which
subsequently triggers Mekl and 2 activation of Erkl and 2. Erk MAPkinase is
responsible for increased transcription of Fos through stimulation of the transcription













Figure 1.3: TCR signal transduction. Ligation of the TCR and CD4 by specific
peptide/MHC class II stimulates Src kinase activity (lck and fyn), leading to ITAM
phosphorylation, recruitment and activation of ZAP-70. Subsequent phosphorylation of the
adaptor proteins LAT and SLP-76 stimulate MAPkinase cascades (Ras/Raf), cytoskeletal
reorganisation, increased calcium concentrations and PKC activity. Stimulation of these
pathways leads to induction of gene expression mediated by the transcription factors AP-I,
NFAT and NFkB.
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1.1.2 Costimulation (signal 2)
TCR stimulation is generally regarded as being insufficient for naive T cell priming,
with antigen presentation in the absence of costimulation resulting in anergy or
apoptosis. TCR stimulation in the absence of costimulation results in fyn
hyperphosphorylation of Cbl and generation of active Rapl by the Cbl/CrkL/C3G
complex (3). Subsequent sequestration of Raf by Rapl prevents activation of the
Ras/Raf MAPkinase cascade, blocking TCR mediated IL-2 induction. Increased
calcium flux promotes high levels of NFAT in the absence of AP-1 activity, again
blocking IL-2 gene transcription. It has also been recently suggested that NFAT on
its own may induce expression of specific anergy associated genes (6).
Approximately 95% of CD4+ T cells express CD28. TCR and CD28 co-ligation
prevents anergy induction by promotion of lck rather than fyn activity. CD28
signalling is also a major source of active Jun. Binding of CD28 to ligand (CD80/86)
triggers a second MAPkinase cascade induced by recruitment of the GEF, Vav, to
LAT/SLP-76. The generation of Rac-GTP (Rho family member of small G-proteins)
is followed by sequential activation of Mekk, Jnkk and then Jnk. Phosphorylation of
Jun then allows dimerisation with Fos and the generation ofAP-1.
The critical requirement for CD28 signalling has been a subject of much debate. T
cells from CD28 deficient mice are still capable of being activated, secreting IL-2
and dividing (7). This may be due to signals received from other costimulatory
molecules such as ICOS (8) or as yet unidentified surface receptors. The idea of a
strict two-signal model of T cell activation (9) has also been difficult to amalgamate
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with immunological synapse augmented TCR signalling hypothesises. CD28 is
believed to be recruited to the cSMAC (2), and as such supports the theory of co¬
operation with TCR signalling. While it is argued that CD28 may be redundant in
initial T cell activation it has a clear role in augmenting and sustaining TCR
signalling and may facilitate activation when antigen is limiting (10). CD28
signalling activates PI3K (Phosphatidylinositol 3-hydroykinase) (10, 11) also
believed to be stimulated by TCR, but the relative roles of the two pathways remains
controversial. PI3K catalyses transfer of ATP to the inositol ring of PIP, PIP2 and
PIP3 (3). Generation of PIP2 may contribute to TCR signalling by providing
substrate for PLCy; however the generation of hydroxylated phosphatidylinositol
products also recruit 3-phosphoinositide-dependent kinases (PDKs). PDK activity
generates functional PKB (protein kinase B) which inactivates glycogen synthase
kinase-3 (GSK-3) (3). In its unphosphorylated form, GSK-3 inhibits NFAT nuclear
activity by inhibitory phosphorylation (12). Stimulation of CD28 and subsequent
inactivation of GSK-3 would sustain the presence of nuclear NFAT promoting TCR
signalling.
It is generally believed that the combination of TCR and CD28 signalling starts entry
of the resting T cell into G1 phase of cell cycle, inducing expression of cyclins,
production of the T cell mitogen interleukin-2 (IL-2) and surface expression of the
high affinity a chain of the IL-2 receptor (IL-2R) (13). Reception of IL-2R signalling
drives the T cell through cell cycle allowing clonal expansion. Whether this process
still requires antigenic stimulation is unclear, but it has been suggested that T cell
division can continue after initial stimulation in the absence of antigen. This may be
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directly related to enhanced degradation of the cyclin-cyclin dependent inhibitor
p27kipl mediated by CD28 signalling and PI3K activity (3).
Successful initiation of T cell activation induces expression of CD40L (14). Binding
to CD40 on the APC produces a two way signal between the cells and enhances B7
expression by the APC, inducing further CD28 signalling (15). Establishment of T
cell/APC dialogue also induces expression of other costimulatory molecules.
Although some of these molecules are reported to sustain clonal expansion to some
degree (such as ICOS), their main role seems to be in development of effector cell
phenotypes, and direction of target cell function (discussed in section 1.2).
1.1.3 The activated CD4+ T cell
In brief, TCR signalling and costimulation induces expression of new genes. In
lymphoid tissue, dialogue between T cell and APC is established by up-regulation of
additional surface receptors that contribute to the development of effector function. T
cell stimulation is followed by clonal expansion, increasing the number of pathogen
specific T cells. Expression of chemokine and adhesion molecules is altered to allow
migration of the primed T cell to either B cell areas, promoting antibody production,
or from the lymphoid tissue to the site of infection, directing cell mediated responses.
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1.2 CD4+ T cell effector function - Th function
Priming of naive CD4+ T cells generates an activated T cell secreting large amounts
of IL-2, promoting clonal expansion. These activated but as yet undifferentiated T
cells (ThO) are subject to programmed development into T helper (Th) subsets that
mediate appropriate direction of immune response (Figure 1.4). This is associated
with the secretion of a variety of cytokines by particular subsets, influencing an array
of other immune system cells (Table 1.1). Th effector functions can fall into two
main categories, Thl or Th2 (16). Th responses are generally associated with
activation of either cell mediated (Thl predominant) or humoral (Th2 predominant)
responses (17, 18). This simplistic view allows classification of some diseases based
upon the Th response required for resolution. However, care should be taken not to
over-simplify the Thl/Th2 paradigm, as the distinction between Th responses is
often blurred, requiring both cell mediated and antibody responses.
Figure 1.4: Clonal expansion is followed by differentiation. Naive CD4+ T cells are
activated in the draining lymphoid tissue by mature dendritic ceiis (DCs). Activation induces
proliferation of an as yet undifferentiated population of T cells. External stimuli then





Division of cells into Thl and Th2 subsets does, however, give a more accurate
description of two distinct cytokines profiles that can be generated following CD4+ T
cell activation. An individual Th cell can be differentiated to produce either IFNy or
IL-4, being Thl or Th2 respectively (16). Although a particular cell may be either
Thl or Th2, a polarised clonal/polyclonal population will be generated when one or
other phenotype predominates. Factors influencing differentiation of Thl versus Th2
cells include responses of the innate immune system (19); the cytokine milieu at the
time of priming (20, 21); costimulation provided by APCs (22) and the strength of
TCR signalling induced (21). Yet the contribution and relative physiological
importance of these mechanisms remain controversial.
An additional effector function mediated by CD4+ T cells is the regulation of the
immune system. This can occur through cross-regulation between Thl and Th2 (23),
but also occurs through active regulation/suppression. Populations of CD4+
regulatory T cells (T regs) are important in the maintenance of peripheral tolerance,
both to self and non-pathogenic antigens (24, 25). Development of this effector
function depends on the nature of the regulatory population in question, but can be
either predestined or induced upon priming.
32
Table 1.1: Cytokines associated with Th effector cells
(Cope with cytokines: http://www.copewithcytokines.de/)
Cytokine Source Effect
IL-2 ThO, Thl T cell mitogen
IL-3 Thl, Th2 Progenitor growth factor
IL-4 Th2 Growth, B cell activation, class switching, macrophage activation
IL-5 Th2 Eosinophil differentiation
IL-6 Activated T cell Growth factor, acute phase response
IL-9 Th2 Mast cell infiltration and proliferation
IL-10 Th2, T reg Inhibition ofThl, macrophages
IL-12 APC Secreted by APC, drives Thl differentiation
IL-13 Th2 Similar to IL-4, alternative macrophage activation
IFNy Thl Inhibits Th2, macrophage activation, NK cell growth
TNFp Thl Macrophage and neutrophils activation, B cell inhibition
TNFa Thl, some Th2 Local inflammation, acute phase response
1.2.1 Effector functions of Thl/Th2
Thl and Th2 effector functions allow for the induction of a specific immune
response appropriate to the antigen encountered. Classically, Thl cells are associated
with the activation of cell mediated immunity, promoting CTL (cytotoxic T cell) and
macrophage activity, Th2 cells function to promote humoral immunity. However, it
is clear that this is an over simplification and that elements of Thl responses require
antibody and that removal of extra-cellular pathogens is affected by macrophage
function. The following paragraphs will give an indication of the main effects
mediated by Th activity and where appropriate indicate where both Thl and Th2
functions may overlap.
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Thl effector functions can act to promote CTL activity (26), enhance macrophage
activation and support production of antibody. These functions are elicited by both
secreted cytokines (characteristically IFNy, IL-2 and TNF(3) and cell/cell
interactions. Antigen presentation to CD4+ T cells not only activates the T cell but
can influence the function of the cell presenting antigen. CD4+ T cell activation
induces expression of the TNF family costimulator CD40L (27). Binding to CD40
expressed by DCs promotes the expression of CD80 and CD86 by the APC (28),
enhancing provision of costimulation. This Th function also serves to enhance
survival DC survival. Additionally, the contribution of enhanced PKB activity
following activation of DC expressed RANK by TRANCE (29) and likely other as
yet unidentified interactions serve to "licence" the DC for activation of naive CD8+ T
cells. It is generally regarded that activated CD8+ T cells are poor producers of IL-2,
necessary for their clonal expansion and survival. This T cell mitogen is produced in
large quantities by activated CD4+ T cells, particularly Thl cells. In this fashion, Thl
function also supports the proliferation and activity ofCD8+T cells 26.
Thl cell activation ofmacrophages is also of critical importance in the elimination of
some extracellular and intracellular pathogens (13). Normal macrophage activity is
usually sufficient for the destruction of many intracellular or phagocytosed
extracellular pathogens. However, some pathogens have developed potent evasion
strategies inhibiting normal macrophage functions. Binding of Thl cells recognising
specific peptide/MHC class II complexes on macrophages allows CD40L/CD40
interactions, enhancing macrophage expression of IFNy receptors (30). Synergistic
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effects of IFNy and TNFP released by the Thl cell enhances production ofNO (nitric
oxide) (30), a potent antimicrobial. IFNy stimulation of the macrophage also
enhances expression of inflammatory cytokines (13) (TNFa, IL-1, IL-6, IL-12),
MHC class I and II (31), costimulatory molecules (CD80/86, CD40L) and promotes
respiratory burst (13).
It must be stressed however that macrophages can also be activated by Th2 cells
(30). Th2 cells secrete both IL-4 and IL-13 which are able to enhance expression of
MHC class II and mannose receptors by macrophages (30). IL-4 and IL-13 do
moderately reduce respiratory burst and inflammatory cytokine synthesis, but this is
not comparable to inhibition by IL-10 (30) (although IL-10 has been classed as a Th2
cytokine its function does appear to be more related to immunoregulation, and will
be discussed in this context in the following T reg section, Chapter 1.2.3, page 39).
The key difference in the activation of macrophages by Thl and Th2 cells is in
arginine metabolism, which is higher following stimulation by Th2 cytokines (32).
The result of this is reduced synthesis and release of NO (32). Th2 activation of
macrophages in this fashion may serve to limit damage mediated by prolonged Thl
responses, and as such may also be important in mediating repair processes.
Humoral immunity can be influenced by Thl cells but is typically associated with
Th2 cells. Development of T-dependent-antibody production relies on the
recognition of linked antigens by the CD4+ T cell and B cell (33). B cells sample
specific antigen and are activated through the B cell receptor complex (34). This
primary activation event requires a second, accessory signal provided by the T helper
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cell in the form of CD40L/CD40 and IL-4, to drive germinal centre formation, class
switching and differentiation into plasma or memory cells (35, 36). The switch to a
particular isotype is directed by cytokine signalling, where IL-4 drives murine B cells
to secrete IgGl and IgE (13). Class switching is also induced by Thl cells with IFNy
driving expression of IgG2a in mice (13).
Th2 cells also secrete IL-5, and IL-9. These cytokines are associated with the
activity of two major cell types associated with Th2 responses, eosinophils and mast
cells. IL-5 acts directly on bone marrow precursor cells, enhancing their
proliferation, driving differentiation into eosinophils and prolongs the viability of
terminally differentiated cells (37). Mast cells are also central to Th2 responses, with
mastocytosis induction following IL-9 secretion by Th2 cells (37).
1.2.2 Commitment to Thl/Th2 cell fates
The presence of IL-12 or IL-4 at the priming of nai've CD4+ T cell is associated with
Thl or Th2 differentiation respectively. These observations lead to the idea that
Thl/Th2 cell fate decisions was an instructive event. It is now clear that numerous
mechanisms can influence Th polarisation, likely to be driven by the innate immune
system and the availability of antigen.
The existence of individual Thl and Th2 progenitor cells seems unlikely given the
plasticity of CD4+ T cells primed under polarising conditions. Changing the
differentiation stimuli could divert polarisation from one Th subset to the other (38,
39). The implications arising from these reports are that primed CD4+ T cells can be
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influenced to become one or other Th subset, and that this eventually becomes a
stable cell fate as the effect is not seen subsequent to four or five rounds of division.
So it appears that a naive CD4+ T cell has the capacity to develop either Thl or Th2
characteristics.
Based on the available literature, a likely explanation of how polarisation of Th
subsets occurs would encompass variations in costimulatory molecule expression by
DCs, the cytokines present during priming and clonal expansion, the biasing of
transcription factor expression over successive cell divisions and eventual epigenetic
alterations of cytokine loci.
A model of selective differentiation has been proposed, relating a balance of
transcription factor expression by the primed T cell. T-bet (a T-box transcription
factor) is induced upon activation as is GATA-3 (a zinc-finger transcription factor)
(21). Direction of expression in favour of T-bet or GATA-3 results in differentiation
of Thl or Th2 respectively (21, 39). IL-12 signalling is known to drive Thl cell
differentiation, possibly by direct action on T-bet expression. T-bet activity augments
sensitivity of CD4+ T cells to IL-12 and remodels the IFNy locus allowing STAT4,
NFkB and NFAT driven transcription (21). Reception of IL-4 during priming
promotes GATA-3 expression, which remodels the chromatin structure around the
IL-4 gene promoting transactivation by the Th2 specific transcription factor c-MAF
(40). GATA-3 also enhances its own expression and that of IL-5 (21).
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The factors influencing the biasing of T-bet/GATA-3 expression are likely to be
driven by the innate immune response responding to a pathogen. Inflammatory
mediators and direct recognition of the pathogen by DCs will influence the context in
which antigen will be presented to the nai've CD4+ T cell. IL-12 production by DCs
following ligation of particular Toll receptors (19) likely selects for T-bet expression
in CD4+ T cells, driving IFNy production and further Thl lineage commitment. Early
sources of IL-4 are somewhat more controversial, but it may be released following
NK T cell activation (20). As discussed earlier, this cytokine selects for GATA-3
expressing cells. It has been proposed that certain costimulatory molecules can
influence differentiation of Thl versus Th2. CD86 induced signalling has been
shown to promote Th2 development in some instances, while CD80 promotes Thl
(41). ICOS ligation is also believed to promote Th2 differentiation (41). These may
not reflect specific effects of a particular molecule but likely pertain to the overall
degree of signalling induced in the naive T cell.
Differences in signal transduction between Thl and Th2 cells have been reported and
possibly relate to observations that low amounts of antigen or low affinity peptides
tend to induce Th2 responses (21). Limiting antigen or low affinity interactions
between MHC class II and peptide (resulting in poorer surface stability of
MHC/peptide complexes) would reduce available TCR ligand. Low affinity
interactions between peptide and TCR would also reduce the degree of TCR
signalling. Ultimately in these cases, the reduced TCR signal could be translated into
Th2 differentiation. This correlates with reduced accumulation of ZAP-70 in Th2
cells (42, 43). However, this may be induction of a qualitatively rather than
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quantitatively different signal. Recently described adaptor proteins such as SAP
(SLAM associated protein) and SLAT (SWAT-70 like adaptor molecule of T cells)
have been implicated in recruitment of Thl or Th2 specific signalling complexes
(signalosomes) respectively (43). However, the time scale in which accumulation of
one "signalosome" at the expense of another occurs would suggest this system
functions to maintain Thl or Th2 differentiation on further TCR stimulation.
1.2.3 Regulatory CD4+ T cells
The existence of regulatory T cells (T regs) was initially proposed before the
characterisation of Thl and Th2 populations. Such regulatory cells proved difficult to
clone and the recognition of the antagonistic effects of Thl and Th2 resulted in the
theory of active regulation being met with considerable scepticism. The increased
use of animal models of autoimmunity combined with techniques such as T cell
depletion and reconstitution has resurrected and confirmed the critical function of
this T cell subset in mediating active regulation.
Early evidence supporting the existence of T regs stems back to early studies by
Sakakura (44, 45). Thymectomy three days after birth (day 3Tx) rendered female
mice infertile secondary to development of oophritis. This pathology was not
observed when thymectomy had been carried out after one or seven days of life.
After demonstrating that grafted normal thymic tissue restored tolerance, while new¬
born spleen, adult d3Tx donor spleen or bone marrow injection could not, it was
proposed that thymus derived lymphocytes prevented disease. Indeed, thymocytes
from normal or d7Tx adults sustained tolerance in d3Tx recipients. Generation of the
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suppressor lineage was seen in the thymus but cells were not peripheralised before 3
days post birth.
Extensive characterisation of numerous models of autoimmunity (46) have resulted
in the general acceptance that such a regulatory population exists but has raised many
questions as to the generation of T regs and how they mediate their effector function.
The generation of CD4+CD25+CTLA-4+GITR+FoxP3+ naturally occurring T regs in
the thymus suggests that they are selected for their ability to respond to self antigens.
Thymic generation is thought to occur through a process of "altered negative
selection" where interactions with self not strong enough to induce cell death results
in T reg differentiation (47, 48). This hypothesis is based on findings that strong
antigenic signals are required to induce this regulatory population.
How natural T regs mediate suppression has proved to be a topic of hot debate. In
vitro, the main mechanism appears to be cell-cell contact dependent; however, in
vivo models support varying degrees of cytokine contribution (TGFp and/or IL-10).
In this context natural T regs may serve to contain pathology caused by chronic
infections, with secreted immunoregulatory cytokines having bystander effects. This
could prove to be an efficient method to prevent autoimmunity following exposure to
self in the context of pathogen derived "danger signals".
Although natural T regs can prevent autoimmune responses, tolerance to innocuous
non-self antigens is also required to prevent inappropriate immune system activation.
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As such it has been proposed that populations of T regs can be generated from
mature CD4+ T cells exposed to peripheral antigen, of which two populations have
been characterised to date, Trl and Th3 cells (24, 49). The immunological context in
which antigen is detected by a T cell is known to affect differentiation of Thl and
Th2 cells. A similar theory is proposed for generation of regulatory T cells other than
the natural CD4+CD25+ cells. Administration of antigen via intranasal or oral routes,
low level TCR stimulation or stimulation in the absence of costimulation may
represent contributing factors to peripheral T reg cell generation (46, 24). Repeated
in vitro antigenic stimulation of T cells in the context of IL-10 gives rise to such a T
reg subset termed Trl cells (50). These are high producers of IL-10 themselves,
which appears to be the predominant mechanism of regulation. IL-10 displays strong
immunosuppressive effects on pro-inflammatory cytokine release by neutrophils,
monocytes, macrophages, eosinophils and T cells. In vitro derived Trl cells are
capable of preventing pathology in vivo and this was demonstrated in both a colitis
and an airway hypersensitivity model (50, 51). High IL-10 titres associated with
reduced clinical symptoms following specific immunotherapy, and may represent in
vivo generation ofTrl cells (52).
A second population of peripherally generated T regs, Th3 cells, are high producers
of TGFp. Low dose myelin basic protein feeding in a TCR transgenic EAE model
lead to the generation of a Th3 population (53). Addition of TGFP or IL-10
neutralising antibodies revealed an important role for both these cytokines in disease
prevention. TGFp production is vitally important in maintaining tolerance,
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demonstrated as a lymphoproliferative disorder in TGFpi deficient mice (54),
similar to lpr and gld mice.
In reality, the distinction between highly polarised Th subsets is blurred and this
likely seems true for T reg subsets. It has been suggested that natural T reg activity
can induce peripherally derived T regs during ongoing inflammatory responses,
important in preventing pathology during chronic disease. What is clear is that T reg
cells do exist as a heterogeneous population that can mediate active regulation via
both cell-cell contact and cytokine production in a response appropriate to the
immunological stimulus.
1.2.4 Cell fate, Notch and T cells
The decision to respond to antigen and development of a particular effector function
are both critical cell fate choices in the generation of an appropriate immune
response. Although the developmental signalling pathway, Notch, is classically
associated with embryonic cell fate determination it is also known to influence T cell
lineage development. This has lead to speculation that if Notch is expressed by




The Notch signalling pathway controls a broad spectrum of cell fate decisions that
occur during multicellular eukaryotic development. The Notch receptor was initially
identified in Drosophila melangaster (55). Drosophila Notch has two ligands,
Serrate and Delta. Related proteins of this highly conserved developmental pathway
have been identified in numerous organisms ranging from the nematode, C. elegans,
to humans (mammalian homologues Notchl-4, the Serrate homologues Jagged 1/2,
and Delta homologues Delta-like 1, 3 and 4 have been documented) (Table 1.2) (55,
56).
Two types of Notch signalling process have been proposed, lateral induction and
lateral specification/inhibition (Figure 1.5). In lateral induction, signalling events are
occurring between non-equivalent cells (57), where one cell expresses the receptor
and the other bears ligand. This mode of signalling permits establishment of distinct
cell boundaries. In the case of the developing Drosophila wing margin, both dorsal
and ventral compartments express Notch whereas Delta and Serrate expression is
confined to ventral and dorsal regions respectively. Induction of Fringe expression (a
regulator of Notch signalling) by dorsal cells results in reception of Delta induced
signals enhancing dorsal expression of Serrate. This potentiates ventral cell reception
of Serrate induced signals, generating positive feed-back and maintenance of the cell
boundary (57).
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Lateral inhibition occurs between equivalent cells, expressing both ligand and
receptor. Acquisition of a bias in this expression (possibly due to stochastic events)
between cells is amplified until one cell type expresses ligand and the other receptor.
The resulting environment resembles lateral induction and the cell receiving the
Notch signal adopts the secondary cell fate. The classical example of this is observed
in Drosophila neurogenesis (57). Within the proneural cluster, all cells express the
bHLH transcription factor Achaete/Scute (Ac/Sc), Notch and Delta. Stochastic
increase in Delta expression by one cell induces Notch signalling in neighbouring
cells and E(spl) mediated inhibition of Ac/Sc activity, resulting in the adoption of the
secondary cell fate, development as epidermal cells. This decrease in Ac/Sc activity
reduces Delta expression by these cells. The primary cell fate, development as a
neuronal cell, follows enhanced Ac/Sc activity due to lack ofNotch signalling (57).
Table 1.2: Notch pathway homoiogues
(Locuslink: http://www.ncbi.nlm.nih.gov/LocusLink/index.html)




Drosophila Notch Delta Serrate Su(H) E(spl)
Human Notch 1-4 Delta-like 1, 3, 4 Jagged 1,2 CBF-1/RBP-JK HES and
HERP
Mouse Notch 1 -4 Delta-like 1,3,4 Jagged 1, 2 CBF-1/RBP-Jk family genes
Xenopus Xotch X-Delta 1, 2 XSu(H) 1-2
C. elegans Lin-12 Apx-1 Lag-2 Lag-1
& Glp-1
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Figure 1.5: Cell fate determination by Notch signalling. (A) Inductive signalling
occurs between two non-equivalent cells, one expressing receptor and the other ligand. Cell
fate decision of cell Y is determined by the ligand bearing cell X. Signalling in this context
maintains defined boundaries between two different cells types. (B) Lateral inhibition occurs
between initially equivalent progenitors. Stochastic events or asymmetric cell division can
lead to differences in Notch pathway regulator concentrations in progeny resulting in biased
expression of receptors and ligands. Feedback signalling maintains and enhances this
difference resulting in adoption of primaiy cell fate by the ligand bearing cell and
development of the secondary cell fate by the Notch receptor expressing cell.
1.3.1 The mammalian Notch signalling pathway (Figure 1.6)
The mammalian Notch family consists of four receptors, Notchl, 2, 3 and 4 (56).
The mature receptor is generated from a single polypeptide cleaved (SI cleavage
event) by a furin-like convertase in the trans-Golgi (58), producing the functional
neterodimeric single-pass transmembrane receptor. Activity of the Fringe family of
glycosyltransferases (mammalian Lunatic, Manic and Radical fringe) is also
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necessary in the production of a mature receptor (59, 60). Addition of O-linked
glucose/fucose to the extracellular domain is vital in mediating ligand binding (59).
The extracellular domain consists of multiple epidermal growth factor (EGF)-like
repeats (29-36 repeats, depending upon the receptor homologue) (61) and three
Linl2/Notch/Glp-l (LNG) domains (Figure 1.7). Binding of the ligand DSL
(Delta/Serrate/Lag) domain to Notch EGF repeats induces signal transduction
(Figure 1.6) by allowing ADAM metalloprotease-mediated release of the Notch
extracellular domain (S2 cleavage) (62). Subsequent y-secretase cleavage (S3
cleavage) (63, 64) of the remaining Notch receptor releases the intracellular domain
(NICD), allowing nuclear translocation.
The y-secretase complex is generated from presenilin, nicastrin, Aphl and pen-2
(65). The exact role played by each component is unclear; however, each is required
to produce a functional complex. Mutations in presenilin result in developmental
phenotypes similar to those observed in the absence of Notch, and as such presenilin
has been suggested to constitute the catalytic subunit (66, 67). A proposed
mechanism for generation of functional y-secretase involves stabilisation of
presenilin by Aph-1 and nicastrin (68). Generation of y-secretase activity requires
endoproteolysis of presenilin favoured by pen-2 expression (68). The two resulting
presenilin subunits are proposed to constitute the catalytic region of the y-secretase
complex (69). Nicastrin has been shown to bind to Notch (70) and in this context is
thought to facilitate binding of the y-secretase complex to the receptor and guide the
catalytic domain to the Notch transmembrane region.
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Nuclear translocation of NICD is mediated by two nuclear translocation sequences
either side of the RAM23 domain. Once inside the nucleus, NICD binds CBF-
1/RBP-Jk via the RAM23 domain and ankyrin repeats. Binding of NICD converts
CBF-1 from a transcriptional repressor to an activator by displacing histone
deacetylases and recruiting histone acetylases along with co-activators such as
Mastermind-like 1 (71), p300 (72) and the adaptor protein SKIP (73). Typically, this
pathway activates transcription of the basic helix-loop-helix (bHLH) proteins hairy-
enhancer of split family (HES and HERP) (74).
Notch can also signal independently of CBF-1 via a less well defined pathway
involving the zinc-finger containing cytoplasmic protein Deltex (75). The role of this
protein in augmenting or inhibiting Notch signalling remain to be clarified, but what
is known is that Deltex is able to bind Grb2 and modulate Ras and consequently c-
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Figure 1.6: Notch signal transduction. Binding of ligand by Notch allows receptor
cleavage by a metalloprotease (possibly TACE). The intra-membrane region of the receptor
is then cleaved by the y-secretase complex, releasing the Notch intra-cellular domain
(NICD). NICD translocates to the nucleus where it binds to CBF-1 and displaces co¬
mpressors and recruits co-activators inducing transcription of hesl. Signalling by Notch
through the Deltex pathway is little understood but does inhibit the Ras/MAPK pathway







Figure 1.7: Structure of the Notchl receptor. EGF repeats, epidermal growth factor
repeats; LNR, Linl2/Notch/GLPl repeats; NLS, nuclear localisation sequence; RAM
domain, RBP-J association molecule; ANK, Ankyrin repeats; OPA, proline rich domain;
TAD, transcriptional activation domain; PEST, proline-glutamate-serine-threonine rich
domain.
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1.4 Notch and T cell development
Aberrant Notch signalling was linked to dysregulated T cell development in a subset
of human T cell leukaemia (78). Since this initial observation a complex interplay
between Notch signalling and other signal transduction pathways has been proposed
to regulate cell fate decisions in the generation ofmature T cells from haematopoietic
progenitor cells. Four mammalian Notch homologues have been identified (Notch 1-
4), the expression of which fluctuates through different stages of thymocyte
differentiation (79, 80). Correlation with expression of the Notch target gene hes was
also observed throughout T cell development (81), indicative of Notch signal
transduction.
1.4.1 Notch signalling in thymocytes
Over-expression and abrogation of Notch signalling has emphasised the critical role
of this pathway in T lineage commitment (both thymic dependent and independent)
(Figure 1.8). Induction of Notch signalling in bone marrow progenitors leads to
abnormal T cell development at the expense of B cell generation (82). Conversely,
inhibition of Notch signalling supports thymic differentiation of B cells (83, 84). In
addition to deletion of Notch, over-expression of molecules known to attenuate
Notch signalling prevents T cell but promotes B cell development (85). Inhibition of
E2A transcription factors (bHLH transcription factors required in the earliest stages
of B cell development) by Notch signalling is the most likely mechanism by T cell
development is favoured (86).
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Notch signalling also promotes the development of aP TCR expressing cells rather
than y5 TCR. Over-expression of Notch 1 signalling in thymocytes drives expression
of a,p TCRs even in yd T cells and P loci disrupted mice (87). This was further
highlighted during reconstitution of mice with mixed Notch1+/+ and Notch1+/- bone
marrow stem cells (87). In addition to implicating Notchl as favouring aP versus yd
development, the observation that this only occurred in the presence of the Notch+/+
cells suggested that yb/ap commitment may occur via a process similar to lateral
inhibition.
Notch3 transgenic mice develop aggressive T cell neoplasias (88). Development of
tumours was associated with mature T cells expressing pre-Ta transcripts (89), not
normally associated with this cell type. The surrogate a chain, pre-Ta, is central to
expression of the pre-TCR complex at the cell surface (13). Signalling through this
complex also drives the selection of successful P chain expression, induce
proliferation and differentiation into DP thymocytes (13). Although not fully
investigated, this may also support generation of aP TCR cells at the expense of yd
cells by selection for P locus rearrangements. Further to this observation, pre-Ta has
been identified as a direct target of Notch signalling, with the pre-Ta enhancer
containing CBF-1 binding sites (90).
The ability of Notch signalling to influence CD8 versus CD4 commitment has been
somewhat controversial. Initial studies suggested that Notch signalling favoured
development of CD8+ T cells and rather than CD4+ T cells (91). The development of
CD8 SP thymocytes could even be induced by Notch signalling in the absence of
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MHC class I or class II (91). However, Notch signalling did not support CD8+ T cell
development in the absence of both class I and class II MHC molecules, highlighting
the importance of TCR signalling in this process. Further investigation of this
phenomenon has given rise to contradictory results, with some reports indicating that
Notch 1 signalling supports both CD4 and CD8 SP differentiation (92) while others
demonstrate blockade of either SP phenotype (93). To date this area remains
controversial but does highlight another role for Notch in thymocyte development
and hints at an interplay with TCR signalling (94).
Study ofNotch signalling in thymocyte development has revealed possible functions
of Notch that may be relevant to mature T cells. Of particular note was the activation
of NFkB in Notch3 transgenic thymocytes (88). This transcription factor is well
known as a mediator of inflammatory responses (95), and is activated by TCR
signalling (Chapter 1.1). Additionally, Notch signalling in thymocytes has been
shown to reduce expression of CD25 and inhibit activity of an NFAT/AP-1 reporter













Figure 1.8: Notch signalling and thymocyte development. A simplified over-view
of thymocyte development is shown, indicating stages where Notch signal transduction has
been shown to promote a particular fate commitment. Thymocyte development is strongly
influenced by a combination of pre-TCR/TCR and Notch signalling. Arrows indicate fate
decisions favoured by Notch signalling. Common lymphoid progenitors (CLPs) can develop
as either B cells or T cells in the bone-marrow or thymus respectively. Development ofCD4-
CD8- TCR- (DN, double negative) cells is promoted by Notch signalling, resulting in
expansion of a DN1 population. At this time the first TCR gene rearrangements are made.
Enhanced Notch signalling at this stage increases the number of cells eventually expressing
a,p TCRs at the expense of y5 expression. The role that Notch has in determining
development of MHC class I or class II restricted T cells is controversial. However, it
appears that Notchl signalling promotes CD8 development in the absence of MHC class I
but not CD4 in the absence of class II.
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1.5 Notch and CD4+ T cells
The adoption of a particular effector function after recognition of specific antigen is
the most crucial fate decision a CD4+ T cell will make. The known processes leading
to the stimulation and differentiation of nai've CD4+ T cells are complex and
integrated at many levels to ensure the appropriate immune response develops. The
Notch signalling pathway can regulate the development of thymocytes through
integration with signalling pathways that are also present in mature T cells. Notch
receptors and signalling targets are expressed by mature CD4+ T cells and the
identification of Notch ligand expression by APCs has generated interest in Notch as
a regulator of CD4+ T cell function. Since completion of the laboratory work
presented in this thesis, several publications have detailed roles for Notch signalling
in T cell function. The findings presented in these publications both complement and
conflict with the data presented herein. These aspects will be discussed in
subsequent chapters; however, the findings of the aforementioned publications will
also be detailed as part of this introduction.
1.5.1 CD4+ T cell expression of Notch signalling components
Gene expression of notch 1 receptor and the Notch ligand jaggedl (1) can be detected
using RT-PCR. Detection of protein has been hampered by the highly conserved
nature of this pathway, making generation of high affinity antibodies difficult.
Notchl has been identified in unstimulated spleen and lymph node cells by western
blot (96). Activation of these cells with anti-CD3- and anti-CD28-antibodies
enhances expression of Notchl (97, 96). Real-time PT-PCR confirmed this but also
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revealed differential expression of the other Notch family receptors by purified CD4+
T cells (97). Notch 1, 2, 3 and 4 expression was up-regulated after 16 hours (97).
It has been shown that APCs express Notch ligands and as such it has been assumed
that they deliver Notch signals to T cells. Human CD25+CD4+ T regulatory cells
have been shown to express high levels of the Notch ligands delta-1 and jaggedl
(98) suggesting that CD4+ T cell sub-populations may differentially express
components of the Notch signalling pathway. This raises the possibility that some T
cells may also be capable of influencing other cell types by delivery ofNotch signals.
1.5.2 Notch signalling in activated CD4+ T cells
Expression of the Notch target gene hesl is up-regulated upon CD4+ T cell
activation, by western blot and real-time RT-PCR (96, 97).The significance of this is
unclear but is likely to be related to increased Notch receptor expression and
enhanced signal transduction (97).
Inhibitors of y-secretase activity were initially developed as a therapy for
Alzheimer's disease. They have also been demonstrated to be potent inhibitors of
Notch signalling (97). Inhibition of the y-secretase complex prevents release of
NICD upon ligand binding, and hence blocks signal transduction. Blockade of Notch
signalling in mature CD4+ T cell activation has produced some exciting results
although somewhat contradictory to those discussed earlier by Izon et al (99).
Reduced CD4+ T cell proliferation was observed in the absence of Notch signalling
(96, 97), accompanied by reduced IL-2 secretion (97). IL-2 secretion by anti-CD3-
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Ab treated splenocytes from Notchl anti-sense transgenic mice was found to be
significantly reduced but proliferation was unaffected (96). Anti-CD3- and anti-
CD28 antibody induction of IL-2 gene transcription is known to involve activation of
NFAT, AP-1 and NFkB. Electromobility shift assays (96) have revealed that
inhibition of Notch does not affect NFAT activity. However, NFkB activity is
dramatically reduced (96), consistent with other findings demonstrating enhanced
activity of this transcription factor when T cells are subject to constitutive Notch3
signalling (88) and is decreased in haemopoietic progenitors from Notchl anti-sense
mice (100).
Anti-CD3-Ab induced proliferation in the absence of Notch signalling was not
restored on addition of IL-2 to cultures (97). Flow cytometric analysis revealed
down-regulation of CD25 expression when Notch signalling was inhibited,
suggesting that an inability to respond to IL-2 was responsible for reduced
proliferation (97).
Contradictory evidence to the idea that increasing Notch signalling enhances
proliferative responses comes from the use of a recombinant Deltal-Fc fusion
protein. Delivery of Notch signals using this recombinant ligand did not affect T cell
proliferation at doses affecting cytokine production but addition of high
concentrations inhibited clonal expansion (101). This may also reflect differential
signals derived from different Notch receptors since Deltal-Fc can potentially
activate all four Notch receptors. The binding of ligand may also induce a
qualitatively different signal in comparison to simply over-expressing truncated
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Notch receptors. However, this does not detract from the fact that Notch signalling
can influence T cell proliferation in response to TCR stimulation.
Apparent contradictions as to how Notch may affect T cell activation may stem from
the differences in TCR signalling strength and consequent masking of any effect
Notch may exert on the system. This was demonstrated by inhibition of Notch
signalling in DO11.10 TCR Tg mononuclear cells (97). At low dose OVA, cells
proliferated less in the absence of Notch. Increasing the concentration of OVA
restored proliferation in the absence ofNotch. This suggests that Notch may function
as a co-stimulatory molecule increasing the sensitivity of TCR signalling, and is
consistent with Notch activation ofNFkB activity (88, 96, 100). Although no effect
on proliferation is seen in the absence of Notch when strong TCR signals are
induced, it would be of value to examine other aspects of the system. Notch
signalling can rescue DO 11.10 hybridoma cells from TCR induced apoptosis by
inhibiting activity of the orphan nuclear steroid receptor Nur77 (102). Expression of
Nur77 is a feature of activation-induced cell death (103), a key mechanism in the
termination of T cell responses (104). TCR/CD3 mediated stimulation can result in
proliferation or apoptosis depending on additional signals present at the time of T
cell activation (103). Enhanced Notch signalling may promote survival of activated T
cells, maintaining immune responses.
1.5.3 Notch and CD4+ T cell effector function
The first publication detailing how Notch signalling could influence T cell function
utilised Serrate 1 transfected dendritic cells as APCs. Mice were immunised with
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either Serrate 1 (Jagged 1) transfected or control dendritic cells pulsed with the house
dust mite antigen Der pi (1). Antigen presentation in the context of Serrate 1 resulted
in tolerance, which could be transferred by the CD4+ T cell compartment, suggesting
generation of antigen specific regulatory T cells.
Consistent with Notch signalling inducing tolerance, use of allogeneic EBV-
lymphoblastoid B cells over-expressing Jagged 1 reduced allo-induced proliferation
of CD4+ T cells and was associated with reduced levels of IFNy, IL-2 and IL-5 (most
likely due to cell numbers) (105). CD4+ T cells activated in this way produced
increased levels of TGFp. IL-10 secretion appeared unchanged even in the absence
of proliferation, perhaps suggesting that more IL-10 was being produced per cell.
This cytokine phenotype most likely relates to generation of an antigen specific Th3
regulatory population, capable of transferring hyporesponsiveness to fresh cultures
yet not affecting responses to third party antigens (105). These regulatory cells also
expressed higher levels of hesl transcripts than cells stimulated with normal
allogeneic cells, indicating that they had received increased Notch signal
transduction.
Mice transgenic for a lck-promoter driven constitutively active Notch3 receptor were
protected against induction of experimental autoimmune diabetes (106). Transgenic
spleens contained significantly higher levels of CD25+CTLA-4+CD4+ T cells, a
phenotype shared by naturally occurring T regulatory cells. The CD25+CD4+ T cells
were also found to express higher amounts of IL-10, at both transcript and protein
level (106). Additionally, adoptive transfer of the transgenic CD4+ T cells could
58
prevent recipient mice developing diabetes. Whether these cells do represent the
naturally occurring thymically derived T regulatory cells is uncertain. Stimulation of
transgenic spleens also induced elevated levels of IL-4, so perhaps protection against
diabetes in this system is due to lack of Thl polarisation. The data however does
strengthen the link between Notch and CD25 expression. It might be speculated that
differential Notch signals are induced when cells undergo altered negative selection,
a process thought to generate naturally occurring CD25+CD4+ T regs. Whether this
signal is directly responsible for generating T regs is not clear, however, differential
expression of Notch pathway associated genes has been observed in both human and
mouse CD25+CD4+ T regulatory cells (98, 106).
The use of a recombinant Deltal-Fc fusion protein has been reported to inhibit
secretion of pro-inflammatory cytokines by activated CD4+ T cells. Delivery of
Notch signalling in this context enhances secretion of IL-10, with the resulting
polarised population having a cytokine profile reminiscent of Trl cells, but it is
unclear as to whether these cells have regulatory capacity (107). In a different
system, high doses of Deltal-Fc inhibited proliferation of CD4+ T cells, this aspect of
Delta induced Notch signalling has not been fully explored but seems not to be IL-10
or TGFp mediated (101). Interestingly, cells activated in the presence of this Deltal-
Fc protein developed Thl like cytokine profiles with high IFNy secretion (101).
Deltal-Fc could even induce CD4+ T cell secretion of IFNy in unstimulated cultures
and under Th2 promoting conditions (101). This phenotype was mimicked by over-
expression of constitutive Notch3 signalling (101), in direct contrast to a previous
report detailing that Notch3 signalling promoted regulatory T cell generation (106).
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Hypothesis:
Based on published data relating notch signalling to T cell development it was
suggested that Notch signalling may also influence mature T cells. Since CD4+ T
play a central role in organisation of immune responses and that this depends on how
they differentiate following activation, the following hypothesis was generated:
Notch signalling has a role in peripheral CD4+ T cell differentiation.
The following experimental aims were developed to address this hypothesis. These
form the basis of subsequent results chapters and as such give a brief insight into the
basis of the work presented herein.
Aims:
Notch pathway expression by CD4+ T cells
• Determine Notch pathway component expression by RT-PCR
• Assess differential expression of these genes following CD4+ T cell stimulation
• Ascertain the possibility of an interaction between the Notch receptor and TCR
Inhibition of Notch signalling in CD4+ T cells
• Develop inhibition protocol
• Assess effects ofNotch inhibition on cell viability and proliferation
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• Characterise cytokine profile in the absence ofNotch signalling
• Address possible transcriptional regulation of T effector phenotype
Characterisation of Notch signalling in regulatory CD4+ T cell
populations
• Isolate naturally occurring T regs and generate Trl cells
• Demonstrate regulatory capacity of these cells
• Determine expression of Notch components by regulatory CD4+ T cells
• Assess contribution ofNotch signalling to active regulation
Induction of Notch signalling in CD4+ T cells
• Over-express Notch ligands on APCs and use to prime nai've CD4+ T cells
• Characterise cytokine profiles of cells in context of ligand induced Notch
signalling
• Transfect CD4+ T cells with a constitutively active Notch 1 signal
• Characterise proliferative and cytokine responses in the context ofNotch 1
signalling.
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2 Materials and Methods
2.1 Materials
All reagents were purchased from Sigma, Poole, UK, unless otherwise stated.
CFSE (5-(-and 6)-carboxylfluorescein diacetate succinimmidyl ester): CFSE
(Molecular Probes, Leiden, Netherlands) was dissolved to a concentration of 5mM in
DMSO. Aliquots were prepared and stored at -20°C.
Complete RPMI medium: Murine cells were cultured in RPMI 1640 (Life
Technologies, Paisley, U.K.) with 10% FCS (heat inactivated), lOOU/ml
penicllin/streptomycin (Life Technologies), 2mM L-glutamine plus 50pM (32-
mercaptoethanol. Stored 4°C.
Complete ISCOVE'S medium: human cells were cultured in ISCOVES (Life
Technology), with 10% FCS (heat inactivated), lOOU/ml penicillin/streptomycin
(Life Technologies) and 2mM L-glutamine.
DC complete medium: As complete RPMI but without the addition of (32-
mercaptoethanol.
DO11.10 NFAT-GFP Hybridoma (108): Kindly gifted by Dr James Brewer
(University of Glasgow). The cell line was grown in complete RPMI plus lmg/ml
geneticin. Cells were grown in a 75cm flask, standing upright, in a humidified
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incubator at 37°C/5% CO2. Cultures were split every four to five days depending on
cell density.
ELISA Block buffer: PBS containing 1% BSA, 5% sucrose and 0.05% Tween-20,
stored at 4°C.
ELISA Reagent diluent: PBS containing 1% BSA (Sigma), stored at 4°C.
ELISA Stop solution: 0.5M H2SO4.
ELISA substrate solution: TMB liquid substrate system for ELISA (R&D Systems,
Abingdon, UK).
ELISA wash buffer: 0.05% Tween-20 in PBS
FACS wash: 0.1% sodium azide and 0.5% BSA in PBS (without calcium or
magnesium). Stored 4°C.
FACS fix: 4% paraformaldehyde in PBS, stored 4°C.
y-secretase inhibitor: The y-secretase inhibitor II (MW167) (Merck Biosciences,
Darmstadt, Germany) was dissolved in lOmM DMSO to a final inhibitor
concentration of ImM.
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GM-CSF supernatant: GM-CSF supernanant was kindly gifted by Dr G. Perona-
Wright. Supernant was collected from the X63-gmcsf hydridoma (109). Supernantant
contained 200-300ng/ml GM-CSF (by ELISA).
LB medium: Ten capsules of media (Sigma, 1-7275) in 500ml distilled water;
autoclaved. Ampicillin or kanamycin at 50p,g/ml if required.
LB agar: Ten agar capsules in distilled water; autoclaved. Ampicillin or kanamycin
at 50p.g/ml where required.
LPS: Escherichia coli lipopolysaccharide serotype 055:B5 powder (Sigma)
reconstituted to lmg/ml in PBS (without calcium or magnesium).
MACs buffer: 0.5% BSA in PBS (without calcium or magnesium), stored at 4°C.
Mowiol Mounting medium: 2.4g of Mowiol (Merck Biosciences) was added to 6g
of glycerol and stired briefly with a pipette. 12ml of deionised water was then added
and stirred overnight at room temperature 12ml 0.2M Tris (pH 8.5) and heat to 50°C
for 1-2 hours while stirring. Once the Mowiol had dissoled, the solution was then
spun at 5000 x g for 15 minutes. DABCO was added to 2.5%. The solution was
stored at -20°C.
Ovalbumin peptide (OVAp): OVAp 323-339 was purchased from Albachem
(Edinburgh, UK). The peptide was reconstituted in dH20 to give a 3mM stock.
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6x PCR loading buffer: 0 .25% weight/volume of bromophenol blue and 40%
weight/volume of sucrose in distilled water, stored at 4°C.
Recombinant cytokines: IL-2 (R&D Systems) and IL-10 (BD Pharmingen, Oxford,
UK) were reconstituted in O.lmg/ml BSA in PBS (without calcium and magnesium).
Red cell lysis buffer: ImM NH4HCO3 (ammonium hydrogen carbonate) and
114mM NH4CI (ammonium chloride) in distilled water. Stored 4°C.





6-8 week old female BALB/c mice were purchased from B & K (Hull, U.K.) and
housed in the University of Edinburgh Animal Facility in accordance with Home
Office guidelines. RAG-/- DO 11.10 TCR Tg mice were maintained as an in house
breeding colony, housed in isolators.
2.2.2. Cell purification
Spleens were removed from BALB/c or DO11.10 TCR Tg female mice aged 6-8
weeks. Tissue was ground using 1 ml syringe plunger through a 70pm cell-strainer
(Becton Dickinson, Oxford, UK) into complete RPMI. Cells were then pelleted
(300g for 7 minutes) and resuspended in 4 ml of cold red cell lysis buffer and left on
ice for 2 minutes. Cells were then diluted in complete RPMI and washed 300g for 7
minutes at 4°C. Cells were then resuspended in 10ml complete RPMI for counting.
To remove dead cells, spleen suspensions were resuspended in 2ml of complete
RPMI and layered gently onto 2ml of room temperature lympholyte-M (Cedarlane,
Ontario, Canada) per spleen. Cells were then spun for 25 minutes at 1500g. The
interface was then removed and washed twice in complete RPMI. Cells were then
resuspended in 10ml and counted using a haemocytometer.
CD4+ T cells were purified from mouse spleens using MACS CD4 isolation kit by
autoMACS (Miltenyi Biotech, Bisley, U.K.) according to manufacturers intructions.
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Cell purities were 95±4% by flow cytometry. Briefly, cells were resuspended in
MACsbuffer and incubated with biotinylated antibodies against CD8a, CD lib,
CD45R, DX5 (anti-NK cell) and Ter-119 (anti-erythrocyte) for 10 minutes at 4°C.
Anti-biotin microbeads were then added and incubated for a further 15 minutes. Cells
were then washed and resuspended in MACSbuffer for running through the
autoMACs (using "Deplete" program).
Purification of murine naturally occurring T regs employed the MACs CD25+CD4+
purification kit. CD4+ T cells are isolated (using autoMACs program "depl025") then
stained with anti-CD25-PE. CD25+ cells were then positively selected using anti-PE
magnetic beads. Cell suspensions were passed through the autoMACs using the
"possel DS" program. CD25+CD4+ cells were 89.7+1.6% pure. However, the purity
of the CD25"CD4+ population derived from this protocol was consistently below
70%. To combat this, CD4+ cells were then positively selected from the negative
fraction using MACs L3T4 magnetic beads (autoMACs "possel" program), raising
the CD25"CD4+ purity to 91 ±3%.
Human CD4+ T cells were isolated from single donor Buffy coats, obtained from the
Blood Transfusion Service (Royal Infirmary of Edinburgh, UK) after viral screening.
Briefy, one Buffy coat was made up to a volume of 200mls with PBS (without
calcium and magnesium). 25ml of blood was layered onto 15ml Histopaque 1077, in
50ml Falcon tubes. These were then spun at 800g for 25 minutes at room
temperature. The mononuclear cell layer was aspirated and washed with PBS twice
(300g for 7 minutes). Cells were then counted using a haemocytometer before red
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cell lysis, pelletted cells being resuspended in 4ml RBC lysis buffer per lxlO8 cells.
Cells were incubated on ice for 2 minutes, then washed twice in PBS. Cells were
then resuspended in complete ICOVES and counted using a haemocytometer.
CD4+ T cells were then purified from mononuclear cell suspensions using MACs
CD4+ T cell Isolation Kits (Miltenyi Biotech), according to manufacturer's
instructions. Labelled cells were isolated using the autoMACs "Deplete" program.
2.2.3. Flow cytometry
Flow cytometric analysis was carried out on a Becton Dickinson FACSCalibur (BD
Immunocytometry Systems). 2xl05 cells per sample were washed with FACS wash
for 7 minutes at 300 x g at 4°C. Cells were then incubated in FACS wash plus 10%
normal mouse serum (Scottish Antibody Production Unit - SAPU, Carluke,
Scotland) for 15 minutes at 4°C to decrease non-specific binding of labelled
antibody. Cells were suspended in 50pl of FACS wash prior to addition of 0.2pg of
PE- and/or 0.5pg of FITC-labelled antibody. Cells were incubated at 4°C in the dark
for 20 minutes. Suspensions were then washed twice with cold FACS wash,
resuspended in lOOpI FACS wash combined with lOOpl FACS fix. Cells could then
be stored at 4°C for up to three days if analysis could not be carried out immediately.
Cell viability was assessed using Annexin V-PE/7AAD apoptosis detection kit (BD
Pharmingen). Briefly, cells were washed with cold PBS and resuspended in IX
binding buffer. Cells were then incubated with 5pi of Annexin V-PE and 5pi of
7AAD per lxlO5 cells (lOOpl volume). Cells were incubated for 15 minnutes at room
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room temperature in the dark. 400pl of binding buffer was then added and staining
analysed immediately by flow cytometry.
Deltal staining was perfomed using a goat anti-Deltal (T-20) antibody (Santa Cruz:
Insight Biotechnology, Middlesex, UK). 2xl05 cells were stained using the
unconjugated T-20 antibody at a dilution of 1 in 50, incubated for 30 minutes at 4°C,
then washed three times. Cells were then stained with a biotinylated bovine anti-
goat-IgG (Santa Cruz) diluted 1 in 100, for 15 minutes at 4°C, washed three times
and incubated with streptavidin-PE (Pharmingen) (1 in 400 dilution) for 10 minutes
at 4°C in the dark. Cells were washed three times, respspended in lOOpl FACS
wash/1OOpl FACS fix.
Table 2.3: Antibodies used for flow cytometry
Anti- Clone Isotype Conjugate Supplier
CD3e 145-2C11 HslgG, gpl, k PE BD Pharmingen
CD4 GK1.5 r!gG2b, k FITC/PE BD Pharmingen
CDllc HL3 HslgG, gpl, K PE BD Pharmingen
CD25 3C7 rIgG2a, k PE BD Pharmingen
CD80 16-10A1 polyclonal HslgG PE BD Pharmingen
CD86 GL1 r!gG2a, k PE BD Pharmingen
I-A/I-E 2G9 rIgG2a, k FITC BD Pharmingen
Ly-69 RB6-8C5 rIgG2b, k PE BD Pharmingen
Deltal N/A polyclonal goat IgG N/A Santa Cruz
Goat IgG N/A polyclonal bovine IgG Biotin Santa Cruz




For polyclonal stimulation of BALB/c CD4+ T cells, cells were seeded at 2xl03 cells
per well into a 96-well (round-bottom) plate and were unstimulated or treated with
plate bound anti-CD3- (eBioscience, San Diego, CA, USA) at O.lpg/ml in the
absence or presence of anti-CD28-Ab (eBioscience) at lpg/ml. Cells were incubated
at 37°C, 5% CO2 (humidified). Plates were pulsed with 0.5p.Ci [3H] TdR (Amersham
Pharmacia Biotech, Buckinghamshire, U.K.) 16 hours before harvesting. Plates were
harvested and read on a betaplate scintillation counter (Wallac, Milton Keynes,
U.K.).
For adenovirus infected DC (Chapter 2.2.12, page 79) activation of CD4+ T cells,
DCs were pulsed with 0.3pM OVAp for 2 hours. Pulsed DCs were then washed with
complete RPMI and seeded with purified DO11.10 CD4+ T cells at a ratio of lxlO4
DC to 5x104 T cells in 96 well plates. Plates were pulsed and harvested as before.
For polyclonal stimulation of human CD4+ T cells, cells were seeded as above. Cells
were stimulated with plate bound anti-CD3- (BD Pharmingen) in the absence or
presence of soluble anti-CD28-Ab (BD Pharmingen). Plates were pulsed and
harvested as before.
For CD25+CD4+ T cell cultures, CD4+CD25" T cells were seeded at 5xl04 cells per
well of 96 well plates, in ratios of 0:1, 1:2 and 1:1, CD25+CD4+: CD4+CD25". Each
well contained lxl05 mitomycin C treated BALB/c splenocytes. Control cultures of
105 CD4+CD25", the maximum number of T cells used in any well, were included to
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ensure reduced proliferation in co-cultures was not due to nutrient depletion. Cells
were stimulated using plate bound anti-CD3-Ab (O.lpg/ml) and soluble anti-CD28-
Ab (lpg/ml). Plates were pulsed and harvested as above.
Trl cell co-cultures were carried-out as for CD25+CD4+ T cell cultures, with the
exception that live splenocytes pulsed with 0.3pM OVAp (for 2 hours then washed)
were used as the activation stimulus.
2.2.5. Cytokine assays
CD4+ T cells were seeded and stimulated as for proliferation assays. Secretion of IL-
2, TNFa, IFNy, IL-4 and IL-5 was analysed by Thl/Th2 murine cytometric bead
analysis (CBA) (BD Pharmingen) from 24, 48 and 72 hour supernatants using the
FACSCalibur flow cytometer and BD CBA software. IL-10 secretion was assessed
by duoset ELISA (R&D Systems Europe, Abingdon, U.K.). For ELISA, enhanced
protein binding capacity 96-well flat-bottom plates were used (Fisher Scientific,
Leicestershire, UK). Plates were read using Biorad's Microplate Reader 450 (Biorad
Laboratories, Hemel Elempstead, U.K.).
2.2.6. RNA extraction
Total RNA was extracted from cells using the Qiagen RNeasy Mini kit (Qiagen,
Crawley, UK) according to manufacturer's instructions. Cells were resuspended in
the appropriate volume of supplied RLT lysis buffer and homogenised using
Qiagen's QIAshredder spin columns. 70% ethanol was added to the lysate and
transferred to RNAeasy spin columns and centrifuged. Columns were then washed
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with supplied RW1 buffer and contaminating DNA was digested using Qiagen
RNase-Free DNase according to manufacturer's instructions. Columns were then
washed with supplied RPE buffer and RNA was eluted in 30pl RNase/DNase free
water.
RNA concentration was determined based on absorbance at 260nm and 280nm
measured using a spectrophotometer (Ultraspec 200, Pharmacia Biotech,
Framingham, MA, USA). Concentration and a ratio of absorbance at 260 and 280
(for high quality, RNA around 1.8) were calculated by the spectrophotometer.
RNA samples were then checked for DNA contamination by running samples as
described for RT-PCRs using the Access RT-PCR kit (Promega, Southampton, U.K.)
but without addition of the reverse transcriptase, i.e. run as a PCR, for the house¬
keeping gene p-actin. Generation of a band of 153bp in the absence of reverse
transcription would indicate the presence of genomic DNA.
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2.2.7. RT-PCR
Reverse transcription of total RNA into cDNA and its amplification was performed
using the Access RT-PCR kit (Promega), according to the manufacturer's
intructions. Primers were purchased from MWG Biotech (MWG Biotech AG,
Ebersburg, Germany). After optimisation, thermocycler conditions were: 1 cycle at
48°C, 45 minutes; 1 cycle at 94°C, 2 minutes; 35 cycles of [94°C for 30 seconds, 1
minute at T annealing°C; 2 minutes at 68°C] and 1 cycle at 68°C for 7 minutes. The
thermocycler used was a Pelter Thermal Cycler (PTC)-200 (MJ Research,
Watertown, MA, USA).
Samples were loaded on 2% agarose gels (SeaKem LE agarose, FMC) containing
0.5pg/ml ethidium bromide. Gels were prepared using lx TAE buffer. 8pl of sample
was added to 2pl of 6x PCR loading buffer and loaded into a well. The gel was then
run for 1 hour at 80volts in lx TAE. PCR products were detected using an ultraviolet
transilluminator (UVP) in conjunction with UVGrab computer software. PCR
product size was determined using PCR marker (50-2000bp ladder).
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Table 2.4: RT-PCR primers
Gene








notch 1 fp 5' TGTTAATGAGTGCATCTCCAACCC 3'
rp 5" CATTCGTAGCCATCAATCTTGTCC 3*
638bp 58
notch 2 fp 5' CAGAGGAATAGCAAGACGTGCAAG 3'
rp 5' GATGAAGAACAGGATGATGACAACAG 3'
599bp 58
notch 3 fp 5' AGGATCAGTGCAGTAGAG 3'
rp 5" AGACTGAAGGTAGAGGAG 3'
526bp 48
notch 4 fp 5' CTACTGCCCACAAGTAGCTGG 3'
rp 5" CTCGGAGATAGCAGTGACTGG 3'
183bp 58
jagged 1 fp 5" AGATATACCGCACCCCTTCAG 3"
rp 5' GGGGGTCACTGTCAGAATGA 3"
289bp 58
jagged 2 fp 5" ATCTGCGAGCTGGTGGAT 3^
rp 5' TATACCAGAGGGTGCGACA 3*
282bp 58
delta-like 1 fp 5" CTGTGACAAACCAGGGGAGT 3'
rp 5' CCTCCGTCAGGGTTATCTGA 3'
458bp 60
hesl fp 5' AATGGAGAAAAATTCCTCCTCC 3"
rp 5' TCACCTCGTTCATGCACTCG 3'
350bp 58
fi-actin fp 5* CCACCAACTGGGACGACATG 3'




A Taqman based system and ABI Prism 7700-sequence detector were used for real¬
time PCR (Applied Biosystems, Warrington, UK). cDNAs were generated from
purified RNA samples using the MultiScribe RT kit (Applied Biosystems) using the
following reaction mixture: lpl 10X Taqman RT buffer; 2.2p,l magnesium chloride;
2pl dNTP mix; 0.5pl random hexamers; 0.2pl RNase inhibitor; 0.25p.l MultiScribe
RT; 3.85pl RNA (400ng) - per sample. The thermocycler (Perkin Elmer) conditions
were: 1 cycle at 25°C for 10 minutes; 1 cycle of 48°C for 45 minutes then 1 cycle at
95°C for 5 minutes. cDNAs were then diluted 5:1 in RNase free/Dnase free water
(Promega).
The real-time PCR reaction relies on 5' -3' nuclease activity of the ApliTag DNA
polymerase used. A 5" fluorescently labelled probe (FAM reporter for gene of
interest and VIC reporter for ribosomal 18S internal control) with a 3" fluorescent
quencher (TAMRA) anneals to the template between the unlabelled PCR primers.
Fluorescence is quenched while the probe is intact. The reporter is released by the
DNA polymerase degradation of the probe, resulting in an increase in fluorescent
emission. Measurement of amplification in direct proportion to increased
fluorescence by the sequence detector (ABI Prism 7700) is continuous. The Cj
(cycle threshold: point of recognition of threshold of exponential increase in
fluorescence) value is indicative of the quantity of input target (i.e. the higher the
concentration of template the lower the Ct value).
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Data was analysed using the comparative Ct method (as per manufactures
instructions). This generates a relative expression value compared to a calibrator
positive control, designated the numerical value of 1. The amount of target,
normalised to the rl8S endogenous reference and relative to the calibrator is given as
2~aact where ACt is the Ct of the gene of interest - Ct of rl8S (normalisation); and
AACt is the ACt for the target - ACt for the calibrator. A two fold change in relative
gene expression is considered to be biologically relevant (110, 111)








































Cells were smeared onto Superfrost slides (BDH Laboratory Supplies, Poole,
Dorset), air dried, fixed for 10 minutes in 90% dry acetone/ 10% methanol and
washed in PBS. Cells were blocked in Dako diluent (DAKO, Ely, U.K.) for 10
minutes, incubated with anti-CD4 Ab (BD Pharmingen), washed, and incubated with
goat anti-rat Alexa Fluor 594 (Molecular Probes, Leiden, The Netherlands). The
isotype rat IgG2bK (BD Pharmingen) was used as with the CD4 stain. Notch 1
staining was demonstrated using a mouse monoclonal antibody directed against the
Notchl EGF repeats 11 and 12, designated A6, isotype mouse IgG2bK. Cells were
stained with A6-FITC (kindly supplied by Yiragen, Watertown, USA), washed,
incubated with rabbit anti-FITC (DAKO), washed then stained with goat anti-rabbit
Alexa Fluor 488 (Molecular probes). All incubations were performed at room
temperature for 30 minutes. Slides were then incubated for 10 minutes with ToPro3
(Molecular Probes) to allow visualization of the nucleus, prior to cover slipping.
Images were captured using a Leica TCS NT confocal system and analysed using
LCS Lite software (Leica Microsystems, Mannheim, Germany).
2.2.10. Trl/Th cell line generation
This protocol was based on a 1997 Groux et al publication (50). Trl cell lines were
derived from CD4+ DO11.10 TCR Tg T cells. Spleens were homogenized, washed
and resuspended in 4ml complete RPMI per spleen. 1 ml of spleen cell suspension
was added per well of a 24 well plate. 0.5ml of CM was added containing OVA
peptide (OVAp, 323-339), IL-2 and IL-10 to final concentrations of 0.3pM, 20ng/ml
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and lOng/ml respectively. Cells were incubated at 37°C, 5% CO2. Cells were
passaged after 7 days: cells were harvested by pipetting, pelletted, resuspended in
complete RPMI (0.5ml per well collected). 2ml of cells were layered over 2ml of
room temperature lympholyte-M (Cedarlane). Cells were then spun for 25 minutes at
1500g. The interface was then removed and washed twice in complete RPMI. Cells
were then resuspended in 10ml and counted using a haemocytometer.
The cells were then seeded at 2xl05 per well of a 24 well plate in 1ml complete
RPMI. 0.5ml of 5xl06 mitomycin C treated BALB/c splenocytes (50pg/ml for 30
minutes at 37°C, then washed three times in complete RPMI) were added as feeder
cells. Peptide, IL-2 and IL-10 were added as before. Cells were passaged in this
fashion three times before use in experiments. Cells to be used experimentally were
harvested 7 days after their last passage and incubated for 7 days in 1.5ml (total
6xl03 T cells) with IL-2 at lpg/ml.
Th cell lines were generated following the same protocol but in the absence of IL-10.
2.2.11. DC enriched population
This protocol was based on the Inaba method for generating bone marrow derived
DCs (112). Bone marrow from BALB/c mice was extracted from cleaned the femurs
and tibiae (surrounding tissue was removed by rubbing with anti-bacterial
disinfectant wipes). Intact bones were rinsed in 70% ethanol and washed with PBS.
The bone ends were then cut using a disposable scalpel and the marrow flushed
through with DC complete medium (DC CM) using a syringe with a 0.45mm (26-
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gauge) diameter needle. Cells were centrifuged for 7 minutes, 300g. The pellet was
then resuspended in RBC lysis buffer (1ml per mouse) and incubated on ice for 2
minutes. Cells were then washed in DC CM and resuspended in 10ml for counting.
Cells were seeded at 3.75x103 cells/well of a 24-well plate in 1ml DC CM plus 5%
GM-CSF supernatant and incubated at 37°C, 5% CO2. Culture medium was aspirated
of after 3 and 6 days of culture. This involved gently swirling the plate before
aspiration so as to remove non-adherent granulocytes and B cells without dislodging
loosely adherent clusters of developing DCs. Medium was replaced with fresh DC
CM plus 5% GM-CSF supernatant. On day 7, loose DC aggregates were removed by
pipetting, washed and counted. Where matured DCs were required, day 7 cells were
stimulated with lOOng/ml LPS for 5 hours, washed, then used in culture.
2.2.12. Adenoviral infection of DCs
3xl06 bone marrow derived DCs were plated in 600pl DC CM per well of a 6 well
plate. Cells were infected with adenoviral constructs at MOIs (multiplicity of
infection) from 0 to 400. DCs were incubated at 37°C, 5% CO2 for 1 hour. Cells
were then washed and reseeded at 3xl06 cells in 3ml DC CM plus 5% GM-CSF
supernatant per well of a six well plate. Infected DCs were then cultured for a further
24 hours to allow for transgene expression. All adenoviral work was carried out in
Class II safety cabinets. All equipment in contact with adenovirus was thoroughly
bleached (Mini-Haz tabs, Guest Medical, Kent, UK) and the area treated with
germicidal ultraviolet light.
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Adenoviral constructs used were the dl70-3 empty control vector (113), Ad-GFP
(kindly gifted by Drs R. Marr and F. Graham, Department of Biology, McMaster
University, Flamilton, Ontario, Canada) and Ad-delta 1 (Dr S. Lindley,
Immunobiology Group, Centre for Inflammation Research, University of Edinburgh,
Edinburgh, UK). The Ad-deltal virus was generated as follows. Briefly, cDNA
encoding murine delta-like1 was inserted into pDK6, containing a MCMV promoter.
El transformed 293 cells were then co-transfected with this construct and pBHGlO
(an E1/E3 deleted Ad5 plasmid). The virus resulting from homologous
recombination was then isolated through plaque purification.
Figure 2.1: Ad-delta1. Ad-deltal was generated from the homologous recombination of
delta-likel cDNA inserted into the shuttle vector pDK6 and the E1/E3 deleted Ad5 plasmid
DNA pBHGlO in HEK293 cells transgenic for adenoviral El.
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2.2.13. Generation of pNICD
pNICD was generated by insertion of the human sequence for a myc-tagged Notch 1
constitutively active intracellular domain into the commercially available pEGFP-Nl
vector (BD Biosciences) (Accession number U55762). The human Notch ICD
sequence was a kind gift from Professor Raphael Kopan (114) in the form of the
pSC2-N-ICv construct (Ampicillin resistant vector).
pEGFP-Nl was digested using Hind III (Promega) and Apa I (Promega) in multicore
buffer (Promega) at 37°C for 3 hours. pSC2-N-ICv was also digested using Hind III
and Apa I in multicore buffer for 3 hours at 37°C to release the N-ICv sequence with
the myc tag. The digests were then run on a 0.8% agarose gel (SeaKem LE agarose,
FMC), revealing the linearised pEGFP-Nl, the pSC2 construct and N-ICv insert.
Product sizes were determined using a lkb ladder (0.25-lOkb, Promega). The
linearised pEGFP-Nl and N-ICv were then extracted using the Qiaquick Gel
Extraction kit (Qiagen). After extraction, DNA was resuspended in 30pl RNase and
DNase free water. pEGFP-Nl and N-ICv were then ligated overnight at 16°C at a
ratios of 1:1 and 1:3 (vector:insert), with T4 ligase. Competent cells were then
transformed with the ligation mix, then shaken at 37°C for 30 minutes in the
presence of kanamycin (50pg/ml). Transformed cells were then plated out and
cultured overnight on kanamycin LB plates. Colonies were picked the following day
and cultured in kanamycin LB medium for a further 24 hours before extraction of
plasmid DNA using the Promega Wizard plus SV Miniprep DNA purification kit.
The resulting plasmid preparation was assessed for the presence of the N-ICv insert
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by digestion with Hind III and Apa I (3 hours at 37°C). The successfully ligated N-
ICv and pEGFP-Nl was designated pNICD.
Competent cells were transformed with pNICD and cultured in 400ml cultures of LB
medium/kanamycin overnight. pNICD was then purified using the Qiagen Maxiprep
kit. Bacterial pellets were resuspended in RT cell lysis buffer for 5 minutes, then the
solution was neutralised. The preparation was then added to QIAfilters, incubated for
10 minutes then filtered by insertion of the plunger.
2.2.14. CD4+ T cell transfection
Purified human CD4+ T cells were transfected using Amaxa nucleofection
technology (Human T cell Nucleofector Kit, VPA-1002). Briefly, cells were
suspended in supplied transfection buffer and placed into the supplied transfection
cuvettes. Cells were either mock transfected or in the presence of lpg plasmid DNA.
Cells were then plated into 96 well plates (2xl05 cells per well) in pre-warmed
complete ISCOVE'S.
2.2.15. Statistical analysis
P values were calculated using the statistical analysis function available in Microsoft
Excel. A paired T test was carried out to test that the mean difference between paired
data in each experiment was not different. P values of less than 0.05 were considered
significant.
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3 Expression of Notch pathway components
by CD4+ T cells
3.1 Introduction/background
APCs have previously been reported as expressing Notch ligands and as such have
the potential to deliver Notch signals (115). Additionally, APCs over-expressing
Notch-ligands are capable of inducing populations of regulatory T cells (1,105,116).
The direct interaction of these ligands with receptors on T cells remains to be
established since Notch receptor expression by CD4+ T cells has not been formally
demonstrated. Thymocytes express Notch receptors and this pathway has been
shown to be vital in development of mature T cells (80,117-119). One particular
study implicated Notch in attenuation of TCR signalling where ICN1 (NICD1) over-
expressing DP thymocytes exhibited reduced ability to express CD5 and CD69 upon
TCR/CD2 co-engagement, proposing that Notch inhibits TCR signalling (99). This
effect was further demonstrated in Jurkat cells, Notch activity inhibiting activation of
an NFAT/AP-1 reporter construct (99). Extrapolation of this hypothesis to mature T
cells presents a mechanism by which Notch signalling may shape T cell responses.
The first step in addressing the overall hypothesis that Notch signalling is able to
influence CD4+ T cell effector function was to determine whether or not these cells
express components of the Notch pathway (Notch receptors 1, 2, 3, 4; the ligands
Jagged 1, 2, Delta-like 1; and downstream signalling molecule Hesl). Notch gene
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expression is differentially regulated in developmental systems as a means of setting-
up boundaries between different cell types (lateral induction). Little evidence
presently exists detailing factors regulating notch1, 2, 3 or 4 gene expression. Notch
signalling may itself regulate ligand expression, mediated by Hes (57). Further
examples of Notch pathway gene regulation are seen in activation of jagged and
delta transcription by NFkB and Ras activity respectively (95, 120, 121). This poses
the possibility that Notch genes may be differentially regulated by T cell activation,
both Ras and NFkB being targets of TCR/costimulatory signalling (2, 10, 122).
Altered expression of these genes may reflect changes in a T cell's requirement for
Notch signals and might relate to a particular T cell function.
Molecules capable of influencing TCR signalling such as CD4, CD28 and CTLA-4
are targeted to the immune synapse (2, 123). Localisation with the TCR brings
signalling components into close proximity facilitating augmentation or attenuation
of signal transduction (2, 124). For Notch to influence TCR signalling, Notch
receptors might be expected to localise to the immune synapse. This would also be
consistent with the hypothesis that Notch signalling attenuates TCR signalling in




• To purify CD4+ T cells from BALB/c spleens;
• Demonstrate activation using anti-CD3- and anti-CD3/28-Ab, measuring
proliferation and cytokine production;
• Determine expression ofNotch pathway components by RT-PCR;
• Assess differential Notch gene expression between unstimulated, anti-CD3-
and anti-CD3/28-Ab treated CD4+ T cells;
• Establish time course for visualisation of T cell polarisation based on
induction ofCD4 capping;
• Examine surface expression of Notch 1 and localisation with an immune
synapse-associated molecule (CD4) in resting and activated T cells.
85
3.2 Gene transcripts for Notch receptors, ligands and
downstream signalling components are present in CD4+
T cells
To address whether CD4+ T cells express Notch pathway components, cells were
MACs isolated from BALB/c spleens (Chapter 2.2.2, page 66). Purity was assessed
by flow cytometry, consistently 92-98% of cells were positive for CD3 and CD4
after gating on the viable lymphocyte population (Figure 3.1 A). Cells were then
cultured as unstimulated, anti-CD3-Ab or anti-CD3/28 treated cells for assessment of
proliferation (Figure 3.IB, C) and cytokine production (Figure 3.1D-G). Cells were
also harvested for extraction of total RNA to determine Notch pathway gene
expression by RT-PCR (Figure 3.2).
CD4+ T cell proliferation was measured at 24 hours and 48 hours. At 24 hours, little
[3H] thymidine incorporation was observed by cells stimulated with anti-CD3 or anti-
CD3/28 (Figure 3.IB). Stimulation of IL-2 production was measured at 24 hours also
(Figure 3.ID). Secretion by unstimulated cells was minimal. Anti-CD3-Ab treatment
induced low level IL-2 secretion increasing 3 fold when cells were activated with
anti-CD3/28-Ab.
Proliferation measured at 48 hours revealed enhanced [ H] thymidine incorporation
on stimulation with anti-CD3 alone compared to unstimulated cells, increasing
further on stimulation with anti-CD3/28 (Figure 3.1C). Secretion of IFNy, IL-4 and
IL-10 was assessed after 48 hours of culture. Anti-CD3 stimulation induced IFNy
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(Figure 3.IE), IL-4 (Figure 3.IF) and IL-10 (Figure 3.1G) secretion by CD4+ T cells,
with only marginal enhancement in secretion on stimulation with anti-CD3/28
(Figure 3.IE, F, G respectively).
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Unstimulated antiCD3 anti-CD3/28 Unstimulated anti CD3 anti-CD3/28
Figure 3.1: Purification and culture of CD4+ T cells. Cells were purified using
MACS CD4" T cells isolation kit with purities 95±3% cells positive for CD3 and CD4 (A).
Proliferation on activation was measured at 24 and 48 hours by [3H] thymidine incorporation
(B, C). Cytokine secretion was measured by CBA analysis (IL-2, IFNy, IL-4) or ELISA (IL-
10)(D, E, F, G, F). Data shown is representative of four experiments.
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Having established a purification protocol and demonstrated that the derived CD4+ T
cells were receptive to CD3 and CD3/CD28 ligation, total RNA was extracted.
Transcript expression of notch receptors 1, 2, 3 and 4 were detected in cells rested or
activated with anti-CD3 or anti-CD3/28 (Figure 3.2) over 48 hours. Expression of the
ligands jaggedl, 2 and delta-likel were also detected (Figure 3.2). The Notch target
gene hesl was not observed to be expressed by resting cells but transcripts were
detected in anti-CD3 and anti-CD3/28 T cells (Figure 3.2).
1 2 3
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526bp i""w ■ -i notch 3
183bp r i ■ ■ notch 4
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Figure 3.2: Expression of Notch pathway components by CD4+ T cells. RT-PCR
was used to demonstrate Notch pathway gene expression, with lanes 1, 2 and 3 representing
unstimulated, anti-CD3 and anti-CD3/28 treated cells respectively. Details of primer
sequences and annealing temperatures can be found in Materials and Methods (Chapter
2.2.7, page 73).
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3.3 Activation of CD4+ T cells induces differential transcript
expression of Notch pathway components
RT-PCR revealed expression of Notch pathway components by unstimulated, anti-
CD3 and anti-CD3/28 activated CD4+ T cells. T cell activation activates the Ras and
NFkB pathways, both developmentally linked to alteration of Notch signal
transduction and expression of Notch receptors and ligands (95,120,121). RT-PCR
data suggested that CD4+ T cell activation might indeed affect the degree to which
Notch pathway component genes are expressed in this cell type (seen as variations
seen in band intensity, particularly hesl). However, this method is somewhat
insensitive and consequently real-time RT-PCR was used instead. This method
allowed representation of gene expression by anti-CD3 and anti-CD3/28 treated
CD4+ T cells relative to unstimulated cells and a clear quantification of increases or
decreases in gene expression.
Cells were isolated and stimulated as before, and total RNA was reverse transcribed
into cDNA for analysis by real-time RT-PCR. Data was calculated as a relative
value, having been calibrated back to unstimulated cells (Chapter 2.2.8, page 75). A
relative 2-fold change or more was considered biologically relevant (Chapter 2.2.8,
page75). A list of primers and probes used can be found in the Materials and
Methods Section (Chapter 2.2.8, page 75)
The Notch target gene hesl was used as a read-out of the canonical Notch signalling
pathway. The influence Notch signalling normally has on deltex is unclear, but
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expression was analysed to characterise this pathway in CD4+ T cells. Transcription
of hesl was enhanced significantly upon T cell activation in three out of three
experiments. An average relative expression of 5.3±0.9 in anti-CD3-Ab treated
groups (Figure 3.3A) and 4.4±1.5 in anti-CD3/28-Ab treated groups (Figure 3.3A)
was observed relative to unstimulated cells. Unlike hesl, deltex transcript signals
were observed to decrease upon activation, this decrease neared biological relevance
when cells were treated with anti-CD3-Ab alone, dropping to 0.67±0.3 (Figure 3.3B)
from a relative unstimulated value of 1. The reduction in signal only became
significant on stimulation with both anti-CD3- and anti-CD28-Ab, falling to
0.36±0.08 (Figure 3.3B).
Analysis of Notch receptor gene expression did not reveal significant changes in
either notchl or notch2 expression (Figure 3.3C and D respectfully) after T cell
activation with either anti-CD3- or anti-CD3/28-Ab. Relative expression remained
similar to those observed for unstimulated cells in two out of three experiments.
Increased signals for notchl and notch2 upon T cell activation reached biological
relevance in one individual experiment, but this was not reproducible. Expression of
notchS and notch4 decreased on activation with anti-CD3-Ab, dropping to 0.3±0.13,
and 0.26±0.32 respectively (Figures 3.3E and F). Stimulation with anti-CD3/28-Ab
saw a further reduction relative to unstimulated cells, falling to 0.15±0.07 and
0.19±0.2 for notch3 and notch4 respectfully (Figures 3.3E and F).
Transcript expression relative to unstimulated cells for the Notch ligands jaggedl, 2
and delta-likel were all observed to decrease significantly on either anti-CD3- or
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anti-CD3/38-Ab activation. Expression ofjaggedl fell to 0.24±0.1 where cells were
stimulated with anti-CD3-Ab and to 0.14±0.02 in groups stimulated with anti-
CD3/28-Ab (Figure 3.3G).jagged2 expression also decreased upon activation, with
anti-CD3-Ab stimulation resulting in a relative jagged2 expression value of 0.3±0.05
and 0.3±0.07 upon anti-CD3/28-Ab stimulation (Figure 3.3H). This downward trend
was also observed for expression of delta-like 1, with a substantial drop in relative
expression values to 0.09±0.1 where cells were anti-CD3-Ab treated and to
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Figure 3.3: Changes in Notch pathway component expression after CD4+ T cell
activation. RNA from unstimulated, anti-CD3, or anti-CD3/28 treated CD4+ T cells was
harvested after 48 hours of in vitro culture, reverse transcribed and gene expression assessed
by real-time RT-PCR. Data is presented relative to unstimulated cells. Three individual
experiments are each represented as one colour of icon; the average value is depicted as a
black bar.
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3.4 Notchl co-localises with CD4 upon T cell activation
On T cell activation, signal transduction molecules aggregate forming
supramolecular activation clusters (SMACs). TCR induced SMAC formation aids T
cell activation, stabilising and enhancing signal transduction (2). Recruitment of co-
stimulatory molecules to the forming synapse further influences stabilisation and
augmentation of TCR signal transduction and consequently contributes to the
response made to antigenic stimulation. If Notch receptors are to influence T cell
activation/effector function directly, these receptors might be expected to localise
with TCR signalling apparatus. CD4 is recruited to the immunological synapse (125),
stabilising TCR/MHC II interactions by binding directly to the MHC class II
molecule. To assess the spatial distribution ofNotch receptors upon T cell activation,
resting and activated T cells were assessed for expression of CD4 and Notchl by
confocal microscopy. Co-localisation of these two molecules would imply Notchl is
also a component of the synapse, along with the TCR. The rat anti-mouse CD4 Ab
L3T4 was used in conjunction with a goat anti-rat Alexa Fluor 594 (red). Notch
staining was demonstrated using a FITC conjugated mouse anti-Notchl antibody,
designated A6, in conjunction with a rabbit anti-FITC Ab followed by a goat anti-
rabbit Alexa Fluor 488 (green). Cells were counter stained with ToPro3 (blue), and
examined using a Leica TCS MT confocal system.
Studies examining immune synapse formation have exhibited T cell polarisation
within 30 minutes of T cell interaction with target APC. Others have also
demonstrated similar time scales using soluble anti-CD3-Ab cross-linked with
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fluorescent secondary antibodies. To determine an appropriate time-point to harvest
cells for visualisation of T cell capping, unstimulated cells, cells activated for
30minutes, 16 hours and 24 hours were examined for polarisation of CD4 (red).
Initial staining of resting CD4+ T cells revealed a diffuse pattern throughout the cell
membrane (Figure 3.4A). Polarisation of CD4 was not evident 30 minutes after
activation with plate-bound anti-CD3- and soluble anti-CD28-Ab (Figure 3..4B).
Capped CD4 staining was observed at 16 hours post activation (Figure 3.4C).
Activated cells stained at 24 hours were visually larger than unstimulated cells and
activated cells at 30 minutes, however, CD4 polarisation was not evident (Figure
3.4D), perhaps consistent with disruption of synapses as cells prepare for division.
Cells were also examined for Notchl expression at these time points (Figure 3.5). As
with CD4 staining, Notchl was found to be dispersed throughout the membrane in
resting cells (Figure 3.5A). This staining profile did not alter after cells had been
activated for 30 minutes with anti-CD3/28-Ab (Figure 3.5B). By 16 hours post
activation, cells exhibiting polarised Notchl staining were observed (Figure 3.5C).
Notchl was not seen to cap in cells stained 24 hours after activation (Figure 3.5D).
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Figure 3.4: CD4 capping. Unstimulated cells (A) were stained for CD4 (red) and after 30
minutes (B), 16 hours (C) and 24 hours (D) anti-CD3/28 stimulation. Cells were
counterstained with ToPro3 (blue).
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Figure 3.5: Notchl capping. Unstimulated cells (A) were stained forNotchl (green) and
after 30 minutes (B), 16 hours (C) and 24 hours (D) anti-CD3/28 stimulation. Cells were
counterstained with ToPro3 (blue).
With both CD4 and Notchl being seen to cap by 16 hours, this time-point was
chosen to examine co-localisation of these molecules. Unstimulated and anti-
CD3/28-Ab activated cells were cultured for 16 hours, harvested and stained for
Notchl and CD4. Co-localised emissions of 488 and 594 appear as yellow,
indicating areas where CD4 and Notchl are in close proximity. No evidence of co-
localisation was found on overlay of unstimulated cell stains (Figure 3.6A, B and C),
as revealed by lack of yellow colouring (Figure 3.6C) and confirmed on analysis of
fluorescent pixel intensity in relation to cell surface position (Figure 3.6E).
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Distance from point A
Figure 3.6: Notchl and CD4 do not co-localise on resting T cells. Figures show
surface staining of CD4 (red) (A), Notchl (green) (B) and an overlay (C) respectively by
unstimulated CD4 T cells cultured for 16 hours. Cells are counter stained with ToPro3
(blue). Co-localization was assessed by analysing pixel fluorescent intensity relative to
distance from point A, marked in figure (D). Figure (E) depicts this data in graphical form.
Data shown is representative of four experiments.
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Analysis of anti-CD3/28-Ab activated T cells revealed polarisation of CD4 and
Notchl as previously described (Figures 3.4 and 3.5 respectively). Overlay of both
stains revealed localisation to the same area, seen as yellow (Figure 3.7C). Analysis
of pixel intensity for both red and green fluorescence in relation to their position on
the cell surface revealed correlation in the position of the major peaks of
fluorescence, confirming co-localisation of CD4 and Notchl (Figures 3.7D and E) in
the T cell cap. 92±4% of the 153 capped cells examined were found to exhibit co-
localisation of CD4 and Notchl. Isotype controls and single stains did not
demonstrate cross-reactivity of the two staining protocols (Figure 3.8, Table 3.1).
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Figure 3.7: Co-localisation of Notchl and CD4 upon T cell activation. Figures
show surface staining of CD4 (red) (A), Notchl (green) (B) and an overlay (co-localization,
yellow) (C) respectively by anti-CD3/28-Ab activated CD4' T cells. Cells are counter
stained with ToPro3 (blue). Co-localization was confirmed by assessing pixel fluorescent
intensity against distance from point A, marked in figure (D). Figure (E) depicts this data in
graphical form. Data shown is representative of five experiments.
97
Figure 3.8: Control staining: Panels display resting cells (A, B, C) and anti-CD3/28
activated cells (D, E, F). Negative controls (A, D); CD4 single stain (red) testing cross-
reactivity with Notch secondary and tertiary antibodies (B, E); Notch 1 single stain (green)
testing cross-reactivity with CD4 staining secondary (C, F) are depicted. For details of
antibodies used in each panel, see table 3.1.
Table 3.1: Key for Figure 3.8: Control staining.













(A) resting rat IgG2bK
mIgG2bK-FITC
no yes yes yes
(B) resting no CD4
(L3T4)
yes yes yes
(C) resting no Notch 1
(A6)
yes yes yes
(D) anti-CD3/28 rat IgG2bK
mIgG2bK-FITC
no yes yes yes
(E) anti-CD3/28 no CD4
(L3T4)
yes yes yes





The results presented here establish transcript expression of Notch receptors and
ligands by mature murine CD4+ T cells. These genes are differentially expressed
upon T cell activation. Notchl surface staining further confirmed receptor expression
but also revealed co-localisation with CD4 upon T cell stimulation with anti-CD3/28-
Ab.
Expression of Notch receptors and the demonstration that Notch signal transduction,
as measured by hesl transcription, occurs in CD4+ T cells supports a model in which
Notch ligands expressed by APCs engage Notch receptors on T cells and modulate
their activation, effector function and/or differentiation (1,126,127, 105). Stimulation
of CD4+ T cells with anti-CD3- or anti-CD3/28-Ab reduced transcription of notch3,
notch4,jaggedl,jagged2 and delta-likel. This was an unusual finding. It might have
been expected that ligand expression would have increased upon T cells activation.
TCR/CD28 signalling activates both NFkB and Ras pathways, known to increase
transcription ofjaggedl and delta-likel respectively (120, 95, 121). Increased levels
of hesl indicate enhanced Notch signal transduction. Classically cells receiving a
Notch signal down-regulate expression of Notch ligands, as observed in lateral
inhibition (128, 129) and this may explain the reduced ligand expression observed
here. Notch receptors are believed to differ in their affinity for ligands and in their
ability to induce transcription of hesl (130). T cell activation may promote hesl
transcription by altering which receptors/ligands they express. To help elucidate
possible mechanisms as to how these genes are differentially regulated, a time-course
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encompassing early time-points would be advantageous. This would allow
comparison to the timing of known TCR signalling events and possibly highlight
particular pathways in regulation ofNotch related genes.
RT-PCR and real-time RT-PCR were effective in establishing that Notch pathway
component genes are expressed by CD4+ T cells. Ideally, this study would have
expanded on the RNA derived data by examining protein expression, perhaps by
Western blot. Although some antibody reagents raised against components of the
Notch pathway are available, attempts to demonstrate protein expression by Western
blot or flow cytometry have been unsuccessful. This is not to say that the proteins of
interest are not present, rather that attempts to establish effective protocols to detect
them have been unsuccessful. Use of the anti-Notch 1 monoclonal antibody with
various Western blot techniques proved fruitless, but did however demonstrate
staining by confocal microscopy. This detection of Notch 1 upon CD4+ T cells
corroborates the RT-PCR data.
Activation of mature T lymphocytes induces aggregation of lipid rafts, containing
molecules known to influence TCR signalling, and formation of the immunological
synapse (2, 131). Activation induced recruitment of Notch 1 to the synapse could
potentially modulate TCR signal transduction. CD4 was used as a marker for
polarisation of T cells upon activation, this molecule is known to interact with the
TCR, stabilising its initial interaction with MHC class II molecules (132) and
enhancing signal transduction by recruitment of Lck (133). Confocal microscopy
revealed Notch 1 did not to co-localise with CD4 on unstimulated T cells, implying
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that these molecules are not in the same lipid rafts. Activation with anti-CD3/28-Ab
induced polarisation of Notch 1 and CD4, seen as co-localisation in the T cell cap.
Although this does not show direct interaction between the Notch receptor and TCR,
the implication is there. Notch and TCR association would support the existing
theory that Notch attenuates TCR signal transduction in thymocytes, where over-
expression of NICD1 inhibited CD5 and CD69 up-regulation (99). Notch is also
capable of negatively regulating Ras/JNK (120, 134, 135), AP-1 (136, 137) and
NFkB activity (138, 139), all of which are utilised in the activation of T cells. In this
context does Notch serve to resolve T cell activation, as with CTLA-4 or PD-1 (9)?
Direct induction of Notch signalling may represent a means of aborting T cell
activation.
Immunological synapses are the formation of a junction between T cell and APC.
The use of anti-CD3/28-Ab to induce T cell polarisation in the absence of APCs
could be viewed as being particularly artificial. However, findings from such systems
appear to correlate with those using APCs. By activating T cells in this fashion,
capping of Notchl has been driven by the T cell itself rather than being recruited by
Notch ligand bearing APCs, possibly representing a requirement for Notch signalling
upon T cell activation. Attempts to visualise T cell/APC interactions have been
fraught with difficulty, particularly in preserving the contacts made between cells.
This could be circumvented by staining in vitro and visualisation in real-time. The
development of a directly conjugated anti-Notchl antibody for use with confocal
would be required. Closer examination of the time-scales associated with Notchl
101
recruitment to the immunological synapse would facilitate an understanding of its
role in T cell activation.
3.6 Future work
To further enhance this study the following areas should be analysed. A detailed
time-course examining differential expression of Notch related genes following
activation would allow a more direct comparison to the now published literature
regarding Notchl and hesl expression by CD4+ T cells. Time points of closer to 30
minutes or 1 hour following stimulation may indicate possible links to TCR
signalling.
Protein expression information would be of considerable value and would
compliment gene expression data. As more reagents are becoming available, this will
facilitate further analysis of Notch pathway components by CD4+ T cells. Attempts
to detect surface expression of Delta-like 1 have been made, but with limited success
(Chapter 6.3, page 174). Use of Notch tetramers may prove useful in determining
overall expression of ligand, but may prove difficult in tailoring to detect specific
ligands.
Of particular interest was the finding that Notchl and CD4 co-localise on activated T
cells. However, the techniques employed to examine polarisation of T cells and
particularly capturing images of APC/T cell interactions are very much in their
infancy within the group. The acquisition of new computer software will facilitate a
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detailed analysis of co-localisation on cells. FRET would be the method of choice if
this aspect of the work is to be pursued. Additionally, generation of images showing
APC/T cell interactions would allow for a more physiological interpretation ofNotch
and CD4 co-localisation. Some "real-time" images were generated in an attempt to
visualise APC/T cell interactions, however this was very much a preliminary
experiment and was limited due to technical resources.
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4 Inhibition of Notch signalling
4.1 Introduction/background
Interactions between Notch receptors and their ligands results in regulated
intramembrane proteolysis (RIP) (140). RIP is mediated by sequential processing by
a disintegrin metalloprotease followed by presenilin/y-secretase, resulting in
shedding of extracellular domains and generation of soluble Notch intracellular
domain (NICD). NICD translocates to the nucleus where interaction with
transcriptional co-factors results in target gene expression (128). RIP also regulates
the cleavage of the amyloid precursor protein (APP) in a similar way to that directing
Notch signalling (64). APP processing yields amyloid P protein (AP) important in
mediating the pathogenesis of Alzheimer's disease (141, 142). Presenilin/y-secretase
activity mediates the final proteolytic event generating Ap fragments and as such this
activity has been targeted as having therapeutic potential (142, 64). Numerous
aspartyl protease transition state analogue inhibitors of y-secretase have been
developed that bind directly to presenilin subunits inhibiting y-secretase complex
function (143). In addition to inhibiting APP processing, Notch receptor cleavage is
also blocked (64). While this has raised questions as to the validity of using y-
secretase inhibitors in Alzheimer's disease, it has provided an additional tool for
studying Notch signalling.
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Inhibition of Notch receptor signalling by pharmacological inhibitors of y-secretase
activity was demonstrated in vitro using a luciferase reporter activated by a ligand-
independent truncated Notch receptor harbouring a GVP (Gal4 DNA-binding/VP16
transactivation) moiety (144). In the later study, use of y-secretase inhibitors
(specifically including that used in this thesis) decreased luciferase expression, and
therefore y-secretase activity, in a dose dependent manner. Further to this study,
zebrafish embryo incubation with the potent y-secretase inhibitor DAPT
demonstrated phenotypes indistinguishable from Notch pathway mutants (145).
In two independent studies, y-secretase inhibitors have been employed to interrupt
Notch signalling in thymocytes, demonstrating similar effects on thymocyte
development to those observed in conditional Notch knockout mice. These studies
not only confirmed the use of y-secretase inhibitors as a method of Notch inhibition
in lymphoid cells but that strength of Notch signalling is also a relevant factor in
directing thymocyte development.
The demonstration of co-localisation of Notch with CD4 on activated T cells
(Chapter 3.4, page 93) and numerous documented interactions between Notch and
components also utilised by TCR signalling implicate Notch as a potential modulator
of T cell function. TCR induced activation ofmature CD4+ T cells is associated with
proliferation and development of helper/effector function, predominantly mediated
by cytokine secretion. TCR activation of NFAT/AP-1, NFkB and Ras activity
induces transcription of IL-2, promoting clonal expansion, and is related to the
105
production of effector cytokines (e.g. IFNy and IL-4). NFAT/AP-1 activity was
shown to be attenuated by over-expression of Notch (99), while various
developmental studies have implicated Notch as influencing NFkB and Ras activity
(88, 100, 136, 137, 146, 147). Additionally, T-ALL studies demonstrate correlations
in constitutive Notch activity (either Notchl or Notch3) with increased proliferation
and NFkB activity (88). If Notch does influence TCR signalling, it might be
expected that inhibition of Notch signalling would affect T cell proliferation and/or
cytokine secretion. The difluoroketone aspartyl protease transition state analogue
MW167 was used to inhibit y-secretase activity (63, 69, 142, 66), preventing
endogenous cleavage of Notch receptors. Any alteration in CD4+ T cell response to
TCR stimulation in the presence of MW167 would formally link Notch to T effector
function.
Chapter aims:
• Determine optimal dose of y-secretase inhibitor (MW167) to prevent
endogenous Notch signalling in unstimulated, anti-CD3- and anti-CD3/28-
Ab treated CD4+ T cells by hesl transcription
• Assess cell viability in the presence ofMW167 to address any toxicity issues.
• Determine influence of Notch on CD4+ T cell proliferative responses when
unstimulated, anti-CD3- and anti-CD3/38-Ab treated.
• Characterise cytokine secretion profiles of unstimulated and activated CD4+
T cells in the absence ofNotch.
• Address possible transcriptional regulation of T effector function by Notch.
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4.2 y-secretase inhibitor reduces Notch signalling as
measured by hes1 expression
The y-secretase inhibitor MW167 was chosen for this study as unlike some inhibitors
of y-secretase activity it is not a proteasome inhibitor. Proteasome inhibition has been
used to alter Notch signalling. However, as this may have non-specific effects on T
cell biology such inhibitors were avoided. At low doses MW167 specifically inhibits
generation of presenilin (PS) N-terminal (NTF) and C-terminal fragments (CTF)
from full-length presenilin (PS FL), and at higher doses also inhibits activity of the y-
secretase complex (69). MW167 also functionally blocks generation of NICD,
confirming its use in blockade of Notch signal transduction (144). The
concentrations used in this study are based on the published IC50 for MW167 and
concentrations used in developmental systems that maximally inhibit NICD
generation (144, 69, 66).
Real-time RT-PCR was used to determine CD4+ T cell expression of the canonical
Notch target gene hesl in the presence of increasing concentrations of MW167.
Expression was assessed in unstimulated, anti-CD3- and anti-CD3/28-Ab treated
cells, in the absence or presence of the y-secretase inhibitor MW167 at both 24 and
48 hours. 2 fold changes in relative gene expression were considered biologically
relevant.
Increased hesl transcripts were detected in unstimulated CD4+ T cells when treated
with 5pM MW167 for 24 hours compared to untreated cells, with a mean relative
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expression of 4.7+2.1 (Figure 4.1 A). Little change in hesl expression was also
observed in unstimulated 5pM 48 hour cultures, relative expression 1.4±0.5 (Figure
4.IB). Increasing MW167 concentrations to lOpM and 20pM did not induce a
biologically relevant decrease in hesl transcription in unstimulated 24 hour cultures
(Figure 4.1 A). Equivalent 48 hour cultures revealed decreased hesl transcript
detection (Figure 4.IB). Reduced hesl expression in unstimulated lOpM MW167 48
hour cultures neared biological relevance with a mean relative expression 0.39±0.2
(Figure 4.IB). Increasing MW167 concentration to 20pM resulted in non-detection
of hesl transcripts in two of 4 samples, and those detectable returning relative
expression values of less than 0.04 (Figure 4. IB).
Stimulation of CD4+ T cells with anti-CD3-Ab in the presence of MW167 revealed
similar trends in regulation of hesl transcription to those observed in unstimulated
cultures (Figure 4.1C, D). In 24 hour anti-CD3-Ab cultures, incubation with 5pM
MW167 increased mean hesl expression relative to stimulated cells without MW167
(Figure 4.1C). Relative hesl expression appeared unaffected at 10pM (0.8±0.3) but
fell to a mean of 0.3±0.08 when anti-CD3-Ab treated cells were incubated with
20pM MW167 for 24 hours (Figure 4.1C).
No biologically relevant alteration in hesl transcription was detected at either 24 or
48 hours when anti-CD3/28-Ab stimulated cells were cultured with 5pM MW167. At
10pM MW167, a downward trend in relative hesl expression was observed at both
24 and 48 hours, mean relative expression values of 0.67±0.3 and 0.3±0.1
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respectively (Figure 4.IE, F). Incubation of anti-CD3/28-Ab stimulated cells with
20pM MW167 for 24 and 48 hours prevented biologically relevant amounts of hesi
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Figure 4.1: Reduced hes1 expression by CD4+ T cells on culture with y-
secretase inhibitor. Unstimulated, anti-CD3- or anti-CD3/28-Ab treated CD4+ T cells
were cultured for 24 or 48 hours with DMSO carrier control (equivalent to the amount
present with the maximal inhibitor dose) or with increasing quantities of y-secretase inhibitor
(MW167). Real-time RT-PCR was then used to determine expression of hesl relative to
cells control. Four individual experiments are each represented as one colour of icon; the
average value is depicted as a black bar.
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4.3 y-secretase inhibitor does not affect CD4+ T cell viability
Notch signalling has been related to enhanced survival of thymocytes undergoing
negative selection by providing increased resistance to glucocorticoid induced
apoptosis (119). This effect has not been attributed to one particular Notch receptor,
with Notch 1 deficiency not affecting viability of developing thymocytes, implicating
redundancy between the Notch family receptors (148). Given that y-secretase
inhibitors are not believed to be Notch receptor selective in inhibition of signalling,
CD4+ T cell viability in the presence ofMW167 was assessed.
Purified CD4+ T cells were cultured in the absence or presence of 20pM MW167, the
dose at which hesl expression was retarded most. Cells were unstimulated, anti-
CD3- or anti-CD3/28-Ab treated for 48 and 72 hours. Cells were then harvested and
stained with annexin V and 7AAD. Flow cytometric analysis did not reveal
significant differences in cell viability between cells cultured with DMSO carrier or



















































Figure 4.2: Cell viability is unaffected by y-secretase inhibitor (48 hours). Cell
viability for unstimulated, anti-CD3- and anti-CD3/28-Ab treated CD4+ T cells was assessed
by Annexin V/7AAD staining, after 48 hours. Figures A, C and E: cells cultured with










Figure 4.3: Cell viability is unaffected by y-secretase inhibitor (72 hours). Cell
viability for unstimulated, anti-CD3- and anti-CD3/28-Ab treated CD41 T cells was assessed
by Annexin V/7AAD staining, after 72 hours. Figures A, C and E: cells cultured with
DMSO. Figures B, D and F: cells incubated with 20p.M MW167. Data is representative of
three independent experiments.
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4.4 CD4+ T cell proliferation is unaffected by inhibition of
Notch signalling
The association of neoplastic T cell proliferation and enhanced Notch activity is well
documented. Based in this, it was decided to examine normal CD4+ T cell
proliferative responses in the absence of Notch signalling. Purified BALB/c CD4+ T
cells were cultured in the presence of increasing doses of the y-secretase inhibitor
MW167. Cells were unstimulated, anti-CD3- or anti-CD3/28-Ab treated and cultured
for 48 or 72 hours. Proliferation was measured using [ H] thymidine incorporation.
At the concentrations tested, MW167 was not observed to affect proliferation of
unstimulated, anti-CD3- or anti-CD3/28-Ab treated CD4+ T cells (Figure 4.4). This
was observed after both 48 and 72 hours of culture.
In conjunction, secretion of the T cell mitogen IL-2 was also assessed. The
concentration of IL-2 in supernatants from unstimulated, anti-CD3- and anti-
CD3/28-Ab treated CD4+ T cells in the absence or presence of 20pM MW167 were
assayed by cytometric bead analysis at 24 hours (Figure 4.5). IL-2 was undetectable
in unstimulated cultures. Low level IL-2 was detected in anti-CD3-Ab stimulated
cultures, but was unaffected by MW167. Stimulation with anti-CD28- in addition to
anti-CD3-Ab significantly enhanced IL-2 secretion (p=0.0002) but again was
unaffected by MW167.
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Figure 4.4: CD4+ T cell proliferation in the absence of Notch signalling.
Proliferation by unstimulated (A, B), anti-CD3- (C, D) and anti-CD3/28-Ab (E, F) treated
















1: unstimulated cells, DMSO
2: anti-CD3 cells, DMSO
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4: unstimulated cells, MW167 (20pM)
5: anti-CD3 cells, MW167 (20pM)
6: anti-CD3/28 cells, MW167 (20pM)
Figure 4.5: IL-2 secretion in the absence of Notch signalling by CD4+ T cells.
Cytometric bead analysis was used to assess release of IL-2 by unstimulated, anti-CD3- and
anti-CD3/28-Ab treated CD4+ T cells in the absence or presence of 20pM MW167. Four
individual experiments are each represented as one colour of icon; the mean value is
depicted as a black bar.
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4.5 Notch signalling is required for cytokine secretion in the
absence of CD28 co-stimulation
To further investigate a role for Notch in CD4+ T cell effector function, cytokine
secretion was analysed in the absence or presence of the y-secretase inhibitor.
Unstimulated, anti-CD3- and anti-CD3/28-Ab treated CD4+ T cells were cultured for
48 or 72 hours with either carrier DMSO or with 20pM MW167. TNFa, IFNy, IL-4
and IL-5 secretion were assessed by cytometric bead analysis.
Secretion of TNFa, IFNy, IL-4 or IL-5 by unstimulated cells was not detectable at
either 48 hours or 72 hours in the absence or presence ofMW167 (Figure 4.6).
Secretion of TNFa and IFNy was up-regulated upon 48 hour activation with
immobilised anti-CD3-Ab alone (Figure 4.6A, B). Addition of 20pM MW167
inhibited secretion of these Thl cytokines, reducing detectable TNFa levels by
53.7±5.5% (p=0.0007) and IFNy by 64.75+5.9% (p=0.01) (Figure 4.6A, B).
However, anti-CD3/28-Ab activated cells secreted comparable TNFa and IFNy
when cultured in the presence or absence of MW167 (Figure 4.6A, B). Secretion of
the Th2 cytokines IL-4 and IL-5 following anti-CD3-Ab stimulation in the presence
of Notch inhibitor was also repressed, with reductions of 71±9.8% (p=0.005) and
73.4±9.3 (p=0.007) respectively (Figure 4.6C, D). TCR ligation together with anti-
CD28 co-stimulation in the absence ofNotch signalling restored IL-4 and IL-5 levels
(Figure 4.6C, D).
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TNFa and IFNy were similarly found in supernatants collected after 72 hours of
culture with anti-CD3- and anti-CD3/28-Ab stimulation. Incubation in the presence
of MW167 reduced release of TNFa by 72.9±6% (p=0.026) and IFNy by 57.2±11%
(p=0.003) when cells were stimulated with anti-CD3-Ab alone (Figure 4.6E, F).
When cells were stimulated with anti-CD3/28-Ab, secretion of these Thl cytokines
appeared equivalent between control and MW167 groups (Figure 4.6E, F). As with
48 hour cultures, a trend for reduced IL-4 and IL-5 secretion upon anti-CD3-Ab
stimulation in the presence of MW167 was apparent in 72 hour cultures (Figure
4.6G, El). Reductions in IL-4 and IL-5 secretion in anti-CD3-Ab plus MW167 groups
were found to be significant (p=0.02 and p=0.04 respectively). Stimulation with anti-
CD3/28-Ab with 20pM y-secretase inhibitor did not significantly alter secretion of
these Th2 cytokines (Figure 4.6G, H).
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Figure 4.6: Cytokine secretion by anti-CD3- but not anti-CD3/28-Ab stimulated
CD4+ T cells is impaired in the absence of Notch signalling. Cytometric bead
analysis was used to assess cytokine secretion by unstimulated, anti-CD3- or anti-CD3/28-
Ab activated CD4+ T cells cultured for 48 hours (A-D) and 72 hours (E-H) in the absence or
presence of MW167 (y-secretase inhibitor). Supernatants were assayed for TNFa (A, E),
IFNy (B, F), IL-4 (C, G), IL-5 (D, H). Four individual experiments are each represented as
one colour of icon; the mean value is depicted as a black bar.
118
4.6 Notch signalling is required for IL-10 secretion even in
the presence of CD28 co-stimulation
After examination of cytokine secretion relating to potential Thl or Th2 effector
function, the release of the immunoregulatory/Th2 cytokine IL-10 was assessed. This
cytokine was of particular interest given the reported ability of APCs over-expressing
Notch ligands to induce a regulatory T cell phenotype. IL-10 secretion by
unstimulated cells, anti-CD3- and anti-CD3/28 treated CD4+ T cells was determined
by ELISA in the absence or presence of 20pM MW167.
IL-10 secretion by anti-CD3-Ab activated cells after 48 hour culture was impaired in
the presence of MW167 (Figure 4.7A) with a mean reduction of 77±8.3% in IL-10
levels compared to anti-CD3-Ab stimulated without MW167 (p=0.01). The addition
of anti-CD28 stimulation did not restore IL-10 secretion in the presence of MW167,
with a mean decrease of 83±5.8% from anti-CD3/28-Ab treated cells (p=0.009)
(Figure 4.7A).
The same trend was observed in groups cultured for 72 hours, with MW167
treatment reducing IF-10 secretion by 69.6±8.3% (p=0.001) by anti-CD3-Ab
stimulated cells (Figure 4.7B). Activation with anti-CD3/28-Ab did not over-come
inhibition of IL-10 secretion by MW167, down 58.4+19% (p=0.011) in MW167





















1000 A 2000 . *
■ * 1000 f ■4 • A
0 ♦ * ■ o * »
1 2 3 4 5 6 1 2 3 4 5 6
1: unstimulated cells, DMSO
2: anti-CD3 cells, DMSO
3: anti-CD3/28 cells, DMSO
4: unstimulated cells, MW167 (20pM)
5: anti-CD3 cells, MW167 (20pM)
6: anti-CD3/28 cells, MW167 (20pM)
Figure 4.7: IL-10 secretion by anti-CD3- and anti-CD3/28-Ab stimulated CD4+ T
cells is inhibited in the absence of Notch signalling. IL-10 secretion by
unstimulated, anti-CD3- or anti-CD3/28-Ab activated CD4 T cells cultured for 48 hours (A)
and 72 hours (B) in the absence or presence of MW167. Supernatants were assayed by
ELISA. Four individual experiments are each represented as one colour of icon; the mean
value is depicted as a black bar.
Real-time RT-PCR primers and probes were available for examination of IL-10 gene
transcription. Total RNA extracted from unstimulated, anti-CD3- and anti-CD3/28-
Ab treated cells in the absence or presence of MW167 after 48 hour culture. Data is
presented as expression relative to the unstimulated control cell group (cells plus
DMSO carrier). Four RNA sets were collected for this experiment. Unfortunately,
two sets were of too poor quality to yield interpretable results from the real-time RT-
PCR reaction.
IL-10 transcription was induced upon CD41 I cell stimulation with anti-CD3-Ab
alone. In one experiment, addition of anti-CD28-Ab to CD3 stimulation augmented
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transcription of IL-10. In both experiments, IL-10 transcription was inhibited in the
presence of 20pM MW167 when cells were stimulated with anti-CD3, with fold
decreases of 96.7% and 89.1% compared to control groups (Figure 4.8A and B
respectfully). Inhibition of transcription was also observed when cells were
stimulated with anti-CD3/28-Ab in the presence ofMW167 compared to stimulated
cells without y-secretase inhibitor demonstrating fold decreases of 89% and 82.9%






































(B) Relative IL-10 expression
experiment 2
| fa |Cells, DMSO carrier
MW167, 20uM
Unstimulated anti-CD3 anti-CD3/2 8
Figure 4.8: Transcription of IL-10 is inhibited in the absence of Notch
signalling. IL-10 gene expression by unstimulated, anti-CD3- and anti-CD3/28-Ab treated
CD4+ T cells was assessed by real-time RT-PCR, Expression is presented relative to
unstimulated cells cultured with DMSO carrier. Data from two independent experiments are
represented as figure A and B respectively.
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Having established that IL-10 gene transcription was attenuated in the absence of
Notch signalling, it was hypothesised that components of the Notch pathway may
interact directly with the IL-10 promoter. Examination of the IL-10 promoter
(Genbank accession: M84340) using the Transcription Element Search Software
(TESS) (http://www.cbil.upenn.edu/tess/) revealed a potential murine HES1 binding
site (1594-9), the relevance of which remains to be ascertained. Blasting this mouse
sequence against the human IL-10 promoter sequence (Genbank accession:
AF295024) to identify homologous regions revealed that the potential murine HES1
binding site was conserved between the two sequences (Figure 4.9). No putative
RBP-Jk binding sites were identified.
HES1 binding site
Mouse IL-10: 1570 gacttgctcttgcactaccaaagccacaaggcagccttgca 1610
Human IL-10: 726 ggcttgctcttgcaaaaccaaa-ccacaagacagacttgca 765
Figure 4.9: Identification of potential murine HES1 binding site in the IL-10
promoter. TESS revealed a potential murine HES1 binding site in the mouse IL-10 gene
sequence. Alignment with human IL-10 sequence revealed this region was conserved.
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4.7 NFAT activity is unaffected by inhibition of Notch
signalling
MW167 inhibition of cytokine secretion by anti-CD3-Ab stimulated CD4+ T cells
suggested that endogenous Notch signalling promotes cytokine secretion when co-
stimulation is limiting. The finding that blockade of y-secretase activity inhibits IL-
10 transcription, and documented interactions of Notch with numerous
transcriptional regulators, the effect of MW167 treatment on TCR targeted
transcription factors was examined. Classically, TCR signalling activates
transcriptional activity of NFAT, NFkB and AP-l(Jun/Fos). This section of work
aimed to examine NFAT activity, time constraints prevented follow-up ofNFkB and
Ap-1 activity.
A DO 11.10 hybridoma cell line stably transfected with GFP under the control of an
NFAT regulated promoter (108) (kindly gifted by Dr James Brewer, University of
Glasgow) was used to determine the effect of MW167 on NFAT activity. A
preliminary test for expression of hesl and IL-10 in the absence or presence of
MW167 was carried out before progression to analysis of NFAT activity. As with
primary murine CD4+ T cells, relative hesl expression increased upon stimulation
with anti-CD3-Ab compared to unstimulated cells (Figure 4.1 OA) by real-time RT-
PCR. Incubation with 20pM MW167 reduced hesl expression in unstimulated
hybridoma cells and prevented up-regulation upon CD3 ligation (Figure 4.1 OA).
Gene expression of IL-10 was also assayed, again revealing transcriptional
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Figure 4.10: Inhibition of hesl and IL-10 transcription in NFAT-GFP DO11.10
hybridoma by MW167. Real-time RT-PCR was used to confirm reduced hesl and IL-10
transcription in DO11.10 hybridoma cells in the presence of MW167 at 20pM (GSI: y-
secretase inhibitor). Cells were incubated in the absence or presence of MW167 for 4 hours,
then cultured for a further 8 hours as unstimulated or anti-CD3-Ab treated cells.
As NFAT activity is quickly induced after TCR ligation, cells were incubated for 8
hours post DMSO carrier or MW167 incubation, as unstimulated or anti-CD3-Ab
treated cells. Anti-CD3/28-Ab treated groups were not included in this series of
experiments as the aim was to determine a link between TCR signalling and Notch
activity. Additionally, many T cell hybridomas appear to be refractory to co-
stimulation. GFP expression was analysed by flow cytometry (Figure 4.11), a viable
cell gate was used based on forward and side scatter profiles (Figure 4.11A, B).
GFP expression was not evident in unstimulated cultures (Figure 4.11C, E),
consistent with the requirement for TCR engagement for activation of this reporter
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construct. Hybridoma treatment with MW167 did not affect GFP expression and
therefore NFAT activity in unstimulated cells (Figure 4.11C, E). Hybridoma
stimulation with anti-CD3-Ab induced GFP expression in both the absence and
presence of MW167 (Figure 4.1 ID, F). No discernable difference was evident in
percentage of GFP positive cells or the mean fluorescent intensity between DMSO
carrier and MW167 treated groups (Figure 4.1 ID, E).
(A) unstimulated (B) anti-CD3-Ab
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Figure 4.11: NFAT activity is unaffected by MW167. NFAT-GFP DOll.lO
hybridoma stable transfectants were incubated with carrier DMSO or MW167 (20pM) for 4
hours then cultured for a further 8 hours as unstimulated or anti-CD3-Ab treated cells. Cells
were harvested and GFP expression assessed by flow cytometry. A-B show forward and side
scatter profiles of unstimulated and anti-CD3-Ab treated hybridoma cells respectively.
Histogram plots show expression of GFP by unstimulated (C) and anti-CD3-Ab stimulated
cells (D) in the absence ofMW167. Panels (E) and (F) depict unstimulated and anti-CD3-Ab
treated cells in the presence of 20pM MW167. Percentages and mean fluorescent intensities
(MF1) for M2 are shown. Data is representative of three experiments.
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4.8 Discussion
Inhibition of the y-secretase complex has revealed that Notch signalling is required
for TCR induced TNFa, IFNy, IL-4 and IL-5 secretion in the absence of CD28 co-
stimulation in CD4+ T cells. Secretion of IL-10 appears to be dependent on reception
of Notch signalling and TCR ligation even in the presence of co-stimulation. Notch
inhibition did not affect cell viability, nor did it alter the proliferative response.
Treatment of unstimulated, anti-CD3- and anti-CD3/28-Ab treated CD4+ T cells with
the y-secretase inhibitor MW167 inhibited hesl transcription in a dose dependent
manner. Use of MW167 at 20pM yielded the most consistent inhibition of Notch
signalling, as measured by hesl expression. This dosage was found to be in keeping
with that used in developmental studies, where inhibition of Notch was measured
directly by quantification of NICD generation (67). y-secretase inhibition prevented
up-regulation of hesl upon TCR stimulation confirming that T cell receptor
signalling does not directly induce hesl expression, validating the use of hesl
transcription as a read-out of Notch activity. Since undertaking this section of work,
two independent studies have employed y-secretase inhibitors to interrupt Notch
signalling in thymocytes (149, 150), demonstrating similar effects on thymocyte
development to those observed in conditional Notch knockout mice. The use of y-
secretase inhibitors to influence peripheral T cell activation was also recently
documented, further confirming the validity of y-secretase inhibition as a means of
Notch signal disruption in lymphoid cells (97, 96).
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Disruption of Notch signalling did not affect cell viability, ruling out possible
toxicity effects of the inhibitor or that increased cell death had influenced detection
of hesl transcripts. This demonstrated that unstimulated CD4+ T cells, anti-CD3- and
anti-CD3/28-Ab treated cells lacking Notch signalling were no more susceptible to
death in culture than control cells. This is not to say that induction of Notch
signalling is not anti-apoptotic, as seen in thymocytes, where Notch can rescue cells
from glucocorticoid induced cell death (119).
Attenuation of Notch signalling in mature T cells has been shown to be detrimental
to activation induced proliferation (97, 96). Use of y-secretase inhibitors, Notchl
anti-sense transgenic mice (Notch AS) and retroviral Notch transduction have
recently linked this pathway with CD4+ T cell expansion (97, 96). y-secretase
inhibition limits secretion of IL-2, potentially limiting T cell proliferation (97). CD25
expression was reduced on addition of y-secretase inhibitor while over-expression of
Notchl enhanced proliferative responses (97). However, treatment of unstimulated,
anti-CD3- and anti-CD3/28-Ab treated CD4+ T cells with 20pM MW167 did not
affect proliferation. This discrepancy is most likely due to the different
pharmacological agents used and possibly to the strength of TCR signals delivered
(different sources and quantities of monoclonal antibodies having been used).
Although the y-secretase inhibitor, compound E, inhibited proliferation to 0.1pg/ml
OVAp, it had no effect when lpg/ml OVAp was used, demonstrating that the
strength of TCR signalling influences the effect of Notch. In the data set presented
here, purified CD4+ T cells are used whereas the studies using compound E and IL-
CHO y-secretase inhibitors look at T cell responses as part of mononuclear or whole
127
spleen populations (97, 96). This raises the possibility that y-secretase inhibitors
affect APCs, potentially limiting their ability to induce T cell proliferation and
cytokine secretion. Proliferation of Notchl AS splenocytes in response to anti-CD3-
Ab stimulation was normal, indicating that Notchl does not influence T cell
expansion (96). This indicates the likely difference in function between Notch family
members, but may also relate to the role of other y-secretase substrates influencing
lymphocyte proliferation. APP is known to be expressed by immune system cells
(151) and has been implicated in augmenting T cell proliferation (152).
Anti-CD3-Ab induced cytokine secretion by CD4+ T cells was inhibited in the
presence of MW167, indicating that Notch signalling is required for release of
TNFa, IFNy, IL-4 and IL-5. There did not seem to be preferential inhibition of Thl
or Th2 cytokine secretion by y-secretase inhibitor. The inability ofMW167 to inhibit
cytokine secretion by anti-CD3/28-Ab stimulated cells suggests that Notch may
function as a co-stimulator and may reflect parallel activation of analogous signalling
cascades by Notch and TCR/CD28, as Notch signalling can regulate both NFkB and
Ras activity (88, 134). IFNy secretion by IL-CHO treated, and Notchl AS transgenic
mouse anti-CD3-Ab-stimulated splenocytes was found to be significantly reduced
(96), confirming our own findings. In the aforementioned study, IFNy secretion was
not restored when CD28 signalling was present in y-secretase inhibitor treated,
activated cultures (96). This disparity is possibly due to different co-stimulatory
signals present in whole splenocyte populations and possible y-secretase inhibitor
effects on APCs, compared to the study of purified CD4+ T cells.
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NFAT function has been described in the regulation of numerous genes pertaining to
productive immune responses (153). NFAT interacts with IL-2, IFNy and IL-4
promoters, acting alone, with AP-1 or, as in the IL-4 promoter, with JunB (154). The
absence of IFNy and IL-4 secretion by CD4+ T cells stimulated with anti-CD3-Ab in
the absence of Notch signalling may have been due to reduced activity of NFAT
activity. To assess this possibility, NFAT activity was measured using a DO11.10
hybridoma cell line stably transfected with an NFAT-GFP reporter. The hybridoma
was shown to respond similarly to primary murine CD4+ T cells in that treatment
with MW167 inhibited transcription of hesl and IL-10. Flow analysis of GFP
expression did not reveal any alteration in NFAT activity by unstimulated or anti-
CD3 treated hybridoma cells when incubated in the presence of the y-secretase
inhibitor. This finding was corroborated by a recent publication demonstrating no
alteration in NFAT activity in splenocyte populations treated with the y-secretase
inhibitor IL-CHO (96). Although only NFAT data is presented in this thesis, the
prime candidate for mediating the observed Notch effect on cytokine secretion was
NFkB.
NFkB proteins consist of homo- or heterodimers of Rel family proteins (155). T cell
activation releases inhibition by IkB and allows DNA binding by NFkB. Many genes
are induced on Rel family binding, regulating proliferation, apoptosis and cytokine
production (156). Developmental studies have previously related NFkB as
determining and Notch as inhibiting cell fate (157), however this appears context
dependent and in some instances both pathways may work synergistically. It appears
Notch regulates NFkB family transcription factors both negatively and positively.
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NICD is able to bind NFkB in a mechanism similar to IkB, inhibiting its nuclear
activity (138, 158). A variation on this is the finding that p65/lKBa shuttles the co¬
mpressors N-CoR and SMRT to the cytoplasm, enhancing hesl transcription (146).
The authors of this paper propose an intriguing interaction between the two
pathways, with absence of NFkB activation augmenting Notch signalling, where
p65/IicBa associates with transcriptional co-repressors. Degradation of IkK releases
repression on NFkB and allowing kB gene transcription and re-association of CBF-
1/NICD/co-repressor complexes. This mechanism does not correlate with our
findings, where activation ofNFkB activity by Notch would relate to co-stimulatory
properties. In contrast, introduction of Notch3ICD under the control of the proximal
Ick promoter results in increased NFkB activity in thymocytes, with these mice going
on to develop T-lymphoblastic lymphomas (88). The idea that Notch signalling
promotes NFkB signalling is consistent with a role for Notch in augmenting T cell
activation. Anti-CD3/28-Ab activation of y-secretase inhibitor treated or Notchl AS
splenocytes was associated with reduced NFkB activity, and was a likely cause of
the reduced IFNy secretion observed (96). The finding that addition of CD28 co-
stimulation recovered TNFa, IFNy, IL-4 and IL-5 secretion supports the hypothesis
that Notch may facilitate cytokine production by increasing NFkB activity. NFkB
activity is reported to be a pertinent target of CD28 co-stimulation. CD28 assists
TCR in activation of the IKK complex via MAP3Ks, PKC9 and Akt, mediating
release ofNFkB repression (159).
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The observation that Notch signalling is required for CD4+ T cell secretion of IL-10
in the absence or presence of CD28 co-stimulation alludes to a role in
tolerance/regulation. IL-10 is important in the generation and/or function of various
regulatory T cell populations, in particular Trl cells (50, 160, 161). Human
CD25+CD4+ T cells express high levels of notch4 and deltal transcripts (98) and the
correlation between Notch signalling and IL-10 could suggest a mechanism for
CD25+CD4+ T reg induction of Trl cells. Indeed, over-expression of the Notch
ligand Jaggedl by APCs induces a population of regulatory T cells (1). The
mechanism by which these T regs mediate suppression is unclear, but it is possible
that Notch signalling does not induce a T reg phenotype directly but does so by
promoting IL-10 secretion. It has been proposed that Notch signalling, induced on
ligation by a Deltal fusion protein, stimulates IL-10 production (107). While
findings presented in this thesis support this hypothesis, the Deltal fusion protein has
been reported to inhibit inflammatory cytokine secretion (107). This difference may
be due to suppression of endogenous signalling, as opposed to over-induction of
Notch pathway activation.
IL-10 transcription is independent of NFkB activity, demonstrated by studies using
chemical inhibition or IkB over-expression (162, 163). Indeed, IL-10 transcriptional
control is different from that of pro-inflammatory cytokines as it lacks functional
binding sites for transcription factors such as C/EBP and AP-1 (162). The deficiency
of these transcription factor-binding sites may partly explain our observation that
addition of anti-CD28-Ab did not restore IL-10 secretion in the absence of Notch.
Examination of the IL-10 promoter (Genbank accession: M84340) using TESS
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revealed a potential HES1 binding site (1594-9), the relevance of which remains to
be ascertained. Further biochemical analysis of Notch signal transduction and its
interaction with TCR and co-stimulatory signals is required.
4.9 Future work
The use of y-secretase inhibitors to block Notch signalling in T cells was recently
demonstrated to attenuate proliferative responses (97, 96). However, y-secretase
inhibitors can block cleavage of the amyloid precursor protein (164). Addition of
APP peptides upon stimulation of mononuclear cells with anti-CD3 was observed to
enhance proliferative response (152). APP expression is also observed to be induced
upon T cell activation (151). The y-secretase inhibitor used throughout this PhD,
MW167, did not inhibit CD4+ T cell proliferation in response to polyclonal
activation. In an attempt to reconcile this difference between use of MW167 and
those in recent publications (Compound E and IL-CHO) (97, 97), a preliminary
experiment was carried out using a y-secretase inhibitor specific for APP (y-secretase
inhibitor XI) and Compound E. Inhibition of APP cleavage in anti-CD3-Ab and anti-
CD3/28-Ab stimulated CD4+ T cell cultures prevented proliferation, possibly
inducing cell death. Compound E marginally reduced proliferation but not to the
same degree as reported in the literature. MW167 was also used in culture with anti-
CD3-Ab stimulated whole spleen (using the lOOpM dosage) and did not affect
proliferation. These preliminary findings suggest that care should still be taken when
considering a role for Notch in T cell proliferative responses.
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Examination of surface marker expression by flow cytometry would be worth
pursuing given evidence that CD69 and CD25 levels are influenced by Notch
signalling (93, 97). This was addressed by another PhD student in the group (Dr
Karen Adamson) in conjunction with the experiments presented in this chapter and
suggested expression of neither CD25 or CD69 was affected by MW167. However,
this is only one y-secretase inhibitor and should be assessed in the context of others.
Gel shift and super shift assays would be the best method for further determining
whether HES1 or CBF-1 proteins are capable of binding directly to the IL-10
promoter. Attempts were made to achieve this, however, this aspect was abandoned
due to a lack of time and technical ability! All reagents are in place to pursue this
avenue and would prove informative.
Generation of the NFkB-GFP hybridoma cell line, use of Ras/Erk phosphorylation
ELISAs and cytometric bed analysis of Akt activity would have been the major
avenues pursued in dissecting the interaction between Notch and TCR/costimulatory
signalling.
Finally, restimulation of CD4+ T cells that were originally primed in the presence of
y-secretase inhibitors would have established if a lack of Notch signalling on initial
activation results in a terminal effect upon differentiation.
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5 Notch and regulatory CD4+ T cells
5.1 Introduction/background
Active regulation/suppression by CD4+ T cells has become the focus of many
tolerance models, encompassing responses to both self and foreign antigen (165).
Several types of CD4+ T regulatory cells have been described and can be generalised
as being CD25+CD4+ T regs, Trl or Th3 (166, 167). These may exist as naturally
occurring or antigen induced populations (24). Increasing evidence implicates a role
for Notch signalling in the adoption of T regulatory phenotypes by CD4+ T cells.
Direct evidence of Notch signalling mediating tolerance comes from two studies
where Notch ligands were over-expressed on APCs. Stimulation of naive CD4+ T
cells in vivo with antigen pulsed DCs over-expressing Serrate 1 (Jagged 1) prevented
induction of protective immunity (1). Tolerance could also be transferred by the
CD4+ T cell compartment, implicating active regulation. Unfortunately the
population of regulatory cells generated in this model were not characterised for their
ability to proliferate or secrete cytokines. A more recent study utilising a mismatched
haplotype system revealed that over-expression of Jaggedl on APCs induced
differentiation of a Th3 like regulatory population, further supporting a role for
Notch in mediating tolerance (105).
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Trl cell function and generation is heavily dependent on the immunoregulatory
cytokine IL-10 (168). In Chapter 4 of this thesis (Chapter 4.6, page 119), Notch
signalling was linked to the secretion of IL-10 by CD4+ T cells. Evidence in support
of this pertains to the function of the Notch ligand Delta-like 1. Incubation of anti-
CD3/28-Ab activated CD4+ T cells with an Fc-Delta-likel fusion protein is reported
to enhance IL-10 secretion and inhibits secretion of inflammatory cytokines (107). It
has been speculated that cells treated in this fashion function like Trl cells (107).
It has been hypothesised that CD25+CD4+ T regs are generated naturally in the
thymus through a process of "altered negative selection". In this model, cells
expressing an aP TCR with a relatively high affinity for self antigen/MHC class II
are not deleted, but exit the thymus as regulators of self (47). Progression of
thymocyte development is highly dependent on the Notch signalling pathway (169).
Notch signalling mediates commitment to the T lineage, but also regulates ap versus
y8 TCR expression, promotes progression to the CD4+CD8+ double positive
thymocyte stage and may influence commitment to CD4 or CD8 single positive cells
(169). It might be speculated that Notch may also be involved in the generation of
CD25+CD4+ T cells as they undergo selective pressures in the thymus. In line with
this idea is the demonstration that NICD over-expression in a T cell hybridoma
inhibited Nur77 dependent apoptosis, relevant for TCR induced cell death upon
negative selection (102). Additionally, since Notch regulates CD25 expression in T
cells (97, 170), could it also be involved in inducing constitutive expression of this
molecule in CD25+CD4+ T regs?
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Chapter aims:
• Purify CD25+CD4+ T cells from murine spleens;
• Demonstrate that these cells are capable of regulating CD4+ T cell
proliferation;
• Assess relative expression of Notch pathway components in CD25+ compared
to CD4+CD25" T cells;
• Determine a role for Notch in mediating regulation by CD25+CD4+ T cells;
• Generate Trl cells in vitro\
• Demonstrate regulatory capacity ofTrl cells;
• Assess relative expression of Notch pathway components in Trl cells
compared to non regulatory CD4+ T cells.
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5.2 Regulation by murine CD25+CD4+ T cells
CD25+CD4+ T cells were purified from BALB/c spleens using the Miltenyi
purification kit in conjunction with the autoMACs (Chapter 2.2, page 66). Release of
this optimised kit by Miltenyi overcame problems encountered by previous attempts
to purify these cells using various combinations of magnetic beads and FACs sorting.
An enriched population, 89.7±1.6% (n=6) CD25+CD4+ (Figure 5.1 A), was used
obtained. Proliferative responses of unstimulated, anti-CD3- and anti-CD3/28-Ab
stimulated CD25+CD4+, CD4+CD25" and co-cultures of these two populations were
compared to determine whether the CD25+ population could affect proliferation of
CD25 T cells (Figure 5.1).
CD4+CD25" T cells were seeded at 5xl04 cells per well of 96 well plates, in ratios of
0:1, 1:2 and 1:1, CD25+CD4+: CD4+CD25". Control cultures of 105 CD4+CD25", the
maximum number of T cells used in any well, were included to ensure reduced
proliferation in co-cultures was not due to nutrient depletion. Data from three
individual experiments is presented.
Unstimulated cells did not proliferate to any great degree over the 72 hour culture
period, as might be expected. However, at the maximal seeding density of 105 T cells
per well, CD4+CD25" T cells consistently incorporated more [3H] thymidine than
CD25+CD4+ T cells (p=0.005) (Figure 5.IB). CD25+CD4+ T cells were significantly
hypo-responsive to anti-CD3-Ab stimulation in comparison to CD4+CD25" T cells
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(p=0.000003, n=3) (Figure 5.1C). Stimulation of cells with anti-CD3/28-Ab
enhanced proliferation of both cell subsets relative to anti-CD3-Ab alone (p=0.0004
for CD25+CD4+ and p=0.003 for CD4+CD25") (Figure 5.1 C and D). A marked
difference between CD25+ and CD4+CD25" cell proliferation upon anti-CD3/28-Ab
stimulation was also observed, further demonstrating CD25+ T cell hypo-
responsiveness (p=0.00005) (Figure 5.ID). Regulation of CD4+CD25" T cell
proliferation by CD25+CD4+ T cells was not observed in unstimulated, anti-CD3- or
anti-CD3/28-Ab treated cultures (Figure 5.IB, C and D respectfully). Thus
CD25+CD4+ T cells are hyporesponsive and are unable to regulate CD25" T cells
proliferation in response to stimulation with anti-CD3- or anti-CD3/28-Ab. Lack of
regulation in these cultures was not unexpected given the body of evidence
indicating a role for APCs in suppression by murine CD25+CD4+ T cells. Flowever,
this was the first time these cells had been used in the group and as such full
characterisation was required to ensure that the purified cells were the same as those
detailed in published literature.
Co-cultures incorporating APCs were used to demonstrate active regulation. The
cultures utilised the same numbers of T cells as described above but with the addition
of mitomycin C treated splenocytes as APCs and anti-CD3-Ab. Three individual
experiments were carried out, assessing proliferation by [ H] thymidine
incorporation, harvesting cultures after 72 hours (Figure 5.2). Proliferation by
CD25+CD4+ T cells was minimal (Figure 5.2A). Co-culture of CD4+CD25" T cells
with CD25+CD4+ T cells using anti-CD3-Ab/APCs as the activation stimulus
allowed regulation to occur. CD4+CD25" T cell proliferation was reduced by
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70.9+7% in the presence of CD25+CD4+ T cells at a ratio of 1 CD25+:2 CD4+CD25"
(p=0.00013) (Figure 5.2A). CD4+CD25~ T cell proliferation could not be reduced
further by increasing the co-culture ratio to 1:1, with proliferation having been
reduced by 81.3±3% (p=0.00002) (Figure 5.2A).
Analysis of supernatants from CD25+CD4+, CD4+CD25" and co-cultures activated
with anti-CD3-Ab/APCs revealed that secretion of TNFa, IFNy, IL-4, IL-5 and IL-
10 (Figure 5.2B, C, D, E and F respectfully) mirrored proliferation data, in that
groups having low [3H] thymidine incorporation also secreted low concentrations of
cytokines. Low levels of TNFa were detected in CD25+CD4+/APC anti-CD3-Ab
stimulated cells (Figure 5.2B); IFNy secretion was undetectable (Figure 5.2C). Low
levels of IL-4 and IL-5 were detectable in CD25+CD4+ groups (Figure 5.2D, E).
CD4+CD25" T cells cultures secreted considerably higher levels of cytokines than
CD25+CD4+ cells. Co-culture of cells reduced cytokine secretion to levels equivalent
to mitomycin C treated splenocytes on their own (Figure 5.2). IL-10 secretion in 1:2
and 1:1 cultures remained relatively high given the absence of proliferation in these
groups (Figure 5.2F).
T cells incubated with mitomycin C treated splenocytes without anti-CD3-Ab did not
incorporate [3H] thymidine above the counts observed for splenocytes alone.
Cytokine secretion in these unstimulated cultures was below the limit of detection for
the assays used.
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CD25+CD4+ T cell hypo-responsiveness and inhibition of CD4+CD25" T cell
proliferation to anti-CD3-Ab/APC stimulation was visually evident, with smaller and














































2: CD25+ cells (5xl04)
3: CD25 cells (1x10s)
4: 0:1, CD25 :CD25 (5xl04)
5: 1:2, CD25+ (2.5xl04):CD25 (5xl04)
6: 1:1, CD25+ (5xl04):CD25 (5xl04)
Figure 5.1: Isolation of CD25+ CD4+ T cells hyporesponsive to TCR
Stimulation. CD25+ CD4+ T cells were purified by autoMACs separation using the
murine CD25+CD4+ T cell purification kit (A). Proliferation of unstimulated (B), anti-
CD3-Ab (C) and anti-CD3/28-Ab (D) treated CD25+, CD25" CD4+ and co-cultured
CD25+/CD25" CD4+ T cells was assessed by [3H] thymidine incorporation. Cells were
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1 2 3 4 5 6 7
1: CD25+cells (lxlO5)
2: CD25+ cells (5xl04)
3: CD25 cells (1x10s)
4: 0:1, CD25:CD25 (5xl04)
5: 1:2, CD25+ (2.5xl04):CD25 (5xl04)
6: 1:1, CD25+ (5xl04):CD25 (5xl04)
7: Mitomycin C treated splenocytes
Figure 5.2: Regulation of CD4+CD25~ T cell proliferation and cytokine secretion
by CD25+CD4+ T cells. CD25+ and CD25" CD4+ T cells were MACs purified and
cultured with CD4+ cell depleted mitomycin C treated anti-CD3-Ab pulsed splenocytes.
Proliferation was measured at 48 hours by [ H] thymidine incorporation, one representative
experiment of three is shown (A). Secretion of TNFa, IFNy, IL-4 and IL-5 was measured by
cytometric bead analysis (B, C, D and E respectfully). IL-10 secretion was assessed by
ELISA (F). Supernatants were harvested at 48 hours. Three individual experiments are each
represented by as one colour of icon; the average value is depicted as a black bar.
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Figure 5.3: CD25+CD4+ T cell suppression of CD4+CD25" T cell expansion.
CD25+CD4+ T cells were MACs purified and stimulated with anti-CD3-Ab pulsed,
mitomycin C treated splenocytes (A). CD4+ T cells depleted ofCD25+ cells were stimulated
in the same way (B). CD25+CD4+ T cells were added in increasing numbers to the
CD4+CD25" cultures (C, D), either 2.5x105 CD25+ cells (C) or 5x105 (D).
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5.3 Notch gene expression by CD25+CD4+ T cells
Human CD25+CD4+ T cells are reported to express elevated levels of notch4, hesl,
deltex and delta-likel (98). This prompted further investigation of expression of
Notch components in CD25+CD4+ T cells. Cells were purified as previously
described (Chapter 2.2, page 66) and incubated with mitomycin C treated
splenocytes, in the presence or absence of anti-CD3-Ab. Cells were harvested at 48
hours and total RNA extracted. Relative expression of hesl, deltex, notchl, 2, 3, 4,
jaggedl, 2 and delta-likel was then assessed by real-time RT-PCR (Figure 5.4).
Expression is plotted as a relative unit compared to unstimulated CD4+CD25" T cells.
Relative fold changes of 2 or greater are considered biologically relevant, relating to
relative gene expression values of 2 or 0.5.
No difference in expression of hesl expression between CD25+CD4+ and
CD4+CD25" T cells was observed (Figure 5.4A). Activation induced a slight increase
in hesl expression by CD25+CD4+ T cells, mean relative expression of 2.2±0.9
(Figure 5.4A). Activation of CD4+CD25" with anti-CD3-Ab/APCs induced a higher
relative hesl increase to 7.98±1 compared to unstimulated cells (Figure 5.4A).
Relative deltex expression by unstimulated CD25+CD4+ T cells was comparable to
unstimulated CD4+CD25" T cells (Figure 5.4B). Activation of both CD25+CD4+ and
CD4+CD25" T cells resulted in decreased deltex expression, with mean relative
expression of 0.06±0.04 and 0.11 ±0.03 respectively (Figure 5.4B).
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No biologically relevant difference in notchl, 2, 3, or 4 gene expression was evident
between unstimulated CD25+CD4+ and CD4+CD25" T cells (Figure 5.4C, D, E and
F). Activation induced a trend for increased notchl expression by CD4+CD25" T
cells, with a 2.78±3 relative fold increase being detected (Figure 5.4C). Activation
did not induce any biologically relevant change in notchl expression by CD25+CD4+
T cells (Figure 5.4C). Activation reduced expression of notch2 by CD25+CD4+ T
cells, mean relative expression 0.24±0.04, but not by CD4+CD25" T cells, mean
relative expression 1.09±0.2 (Figure 5.4D). A trend for reduced notch3 expression
was observed for both CD25+CD4+ T cells and CD4+CD25" upon activation (Figure
5.4E). Reduction in relative notch3 expression by anti-CD3-Ab/APC stimulated
CD25+CD4+ T cells was biologically relevant, falling to a value of 0.24±0.09 (Figure
5.4E). Mean relative expression of notch3 by stimulated CD4+CD25" T cells was not
deemed biologically relevant, 0.45±0.3 (Figure 5.4E). This may not be a true
reflection of the data, with two out of three results having relative expression values
of 0.4, an increased number of replicates are required for clarification. Anti-CD3-
Ab/APC stimulation of CD25+CD4+ T cells did not reduce relative notch4 expression
to any great extent, mean relative expression 0.77±0.04 (Figure 5.4F). Mean relative
expression by stimulated CD4CD25" T cells was 0.3±0.23 (Figure 5.4F), bordering
on biological relevance, again requiring increased numbers of replicates to clarify
this data.
Differences in jaggedl and 2 mean relative expression between unstimulated
CD25+CD4+ and CD4+CD25" T cells was minimal, never reaching biological
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relevance (Figure 5.4G, H). Activation of CD25+CD4+ T cells did not reduce
jaggedl expression but did decrease CD4+CD25" T cell mean relative expression to
0.33±0.03 (Figure 5.4G). This equates to an approximate 3.7 fold difference in
jaggedl expression between activated CD25+ and CD25" T cells. Relative expression
of jagged2 by CD25+CD4+ and CD4+CD25~ T cells was reduced upon stimulation,
mean relative expression falling to 0.2+0.09 and 0.37±0.05 respectfully (Figure
5.4H).
Relative expression of delta-like1 by unstimulated CD25+CD4+ cells was found to be
10.9+2.2 fold higher than unstimulated CD4+CD25" T cells (Figure 5.41).
CD25+CD4+ T cell expression was decreased upon anti-CD3-Ab/APC stimulation,
falling to a mean relative value of 2.34+0.22. Relative expression by stimulated
CD4+CD25" T cells was also reduced, 0.19+0.02 (Figure 5.41). This relates to a fold




































































3: Activated CD25+ CD4+
4: Activated CD4+ CD25"
Figure 5.4: Expression of Notch pathway components by CD25+CD4+ T cells.
Real-time RT-PCR was used to assess expression of Notch pathway associated genes by
CD25+CD4+ T cells. RNA was extracted from CD25+ and CD25" CD4+ T cells, unstimulated
(with APCs) or anti-CD3/APC activated. APCs were mitomycin C treated. Gene expression
is presented relative to CD4XD25" cells. Fold changes of 2.5 or more are considered
biologically relevant. Three individual experiments are each represented by as one colour of
icon; the average value is depicted as a black bar.
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5.4 Notch inhibition and CD25+CD4+ T cell function
Over-expression of Notch ligands on APCs is believed to induce differentiation of T
reg populations. This does not address the role of Notch in mediating suppression by
these cells. A possible role for Notch signalling in active regulation is hinted at by
increased expression ofjaggedl and delta-like 1 by CD25+CD4+ T cells (Chapter 5.3,
page 143). The potential role for Delta-like 1 in mediating suppression is supported
by an observed association of tolerance to house dust mite antigen with increased
expression of this gene. Additionally, retroviral mediated over-expression of Delta¬
like 1 by CD4+ T cells in the later system was reported to mediate linked suppression.
This chapter aimed to block Notch signalling in CD25+CD4+ T cell suppression
cultures, to determine whether Notch can mediate active regulation. Co-cultures of
CD25+CD4+/CD4+CD25" T cells stimulated with anti-CD3-Ab/APCs (as described in
chapter 5.2, page 137) were treated with the y-secretase inhibitor MW167 (chapter 4,
page 104). Cells were then assessed for inhibition of hesl transcription by real-time
RT-PCR to determine abrogation of Notch signalling. Proliferation and secretion of
IL-10 were also measured as indicators of active regulation and Notch inhibition
respectfully.
In previous experiments, use of the y-secretase inhibitor at 20pM was found to be
efficient in preventing Notch signalling in unstimulated, anti-CD3- and anti-CD3/28-
Ab treated CD4+ T cells. However, initial experiments using mitomycin C treated
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APCs and anti-CD3-Ab as an activation stimulus revealed that 20p.M MW167 was
insufficient for Notch inhibition in CD4+ T cells. Increasing the dose of y-secretase
inhibitor (GSI) to lOOjaM resulted in a 5.2±0.8 (n=3) mean fold decrease in hesl
expression by anti-CD3-Ab/APC stimulated CD4+CD25" T cells (Figure 5.5).
CD25+CD4+ T cells also stimulated in this fashion exhibited low levels of hesl,
mean relative expression 0.09±0.06. Treatment of activated CD25+CD4+ T cells with
GSI had little effect on hesl expression (mean relative expression 0.07+0.05), most
likely due to extremely low hesl expression by these cells normally.
Co-culture of CD25+CD4+ with CD4+ target T cells resulted in considerable
elevation in hesl expression, with mean relative expression values of 60+2.7 and
86.8+7.7 for ratios of 1 to 2 and 1 to 1 respectfully (Figure 5.5). Addition of y-
secretase inhibitor dramatically reduced hesl expression in both these groups,
reducing mean relative hesl expression to 0.3+0.2 for 1 to 2 and 0.2+0.18 for 1 to 1





































Figure 5.5: y-secretase inhibition prevents up-regulation of hes1 expression in
CD25+CD4+ T cell cultures. CD25+CD4+ T cell/CD4+CD25" T cell co-cultures were
stimulated with mitomycin C treated splenocytes and anti-CD3-Ab in the absence or
presence of lOOpM y-secretase inhibitor (GSI), using DMSO as a solute control. Cells were
harvested at 48 hours and total RNA extracted. Real-time RT-PCR was used to determine
expression of hesl relative to CD4+CD25" cells. Fold changes of 2.5 or more are considered
biologically relevant. Three individual experiments are each represented by as one colour of
icon; the average value is depicted as a black bar.
Proliferation of CD25+CD4+, CD4+CD25" and co-cultures in the absence of y-
secretase inhibitor (Figure 5.6A) was found to be consistent with that observed
previously (chapter 5.2, page 137). Addition of IOOjjM MW167 to cultures did not
affect proliferation of CD25+CD4+ T cells, remaining hyporesponsive in comparison
to CD4+CD25" T cells (Figure 5.6A). Proliferation of CD4+CD25" cells was also
unaffected by Notch inhibition (chapter 4.4, page). Addition of MW167 to co-
cultures neither significantly inhibited nor augmented proliferation (Figure 5.6A),
confirming that Notch signalling does not mediate the suppressor function of these T
legs.
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Analysis of IL-10 secretion revealed reduced levels in supernatants from y-secretase
inhibitor treated groups (p<0.01 for all groups, n=3) (Figure 5.6B), again consistent
with previous findings detailed elsewhere in this thesis (chapter 4.6, page 119).
Interestingly, even though suppression of CD4+CD25" proliferation on co-culture
was dramatic, an equivalent decrease in IL-10 was not observed, with only slight
decreases being observed in 1 to 2 and 1 to 1 ratio cultures, also previous observed
(chapter 5.2, page 137). It must be noted that these groups were found to have
extremely high levels of hesl expression (Figure 5.5).
To further confirm that MW167 treatment could not prevent suppressor function by
CD25+CD4+ T Cells, active regulation co-cultures were prepared as above but using
anti-CD3-Ab/APC as an activation stimulus and with CFSE labelled CD4+CD25"
target cells in the absence or presence of the y-secretase inhibitor (Figure 5.7 and 5.8
respectfully). Cultures were harvested after 48 hours and CFSE staining analysed by
flow cytometry. Addition of y-secretase inhibitor had no bearing on active regulation
or proliferation of CD4+ labelled cells alone (Figure 5.7 and 5.8). Target cells were
seen to go through five rounds of division in all cases, plus or minus MW167 and
even when cultured at a 1 to 1 ratio of CD25+CD4+ T regs to CD4+CD25" cells
(Figure 5.7 and 5.8). Addition of CD25+CD4+ T reg cells to labelled target cells did
reduce the number of cells going through successive rounds of division, reflected in
the decrease in events in gates R3, R4 and R5, combined with increases in R6, R7
and R8. Where active regulation was evident, cell appeared to have smaller forward



















































! f]Cells, DMSO carrier
i MW167, I00nM
1 2 3 4 5 6 7
1: CD25+ cells (1x10s)
2: CD25+ cells (5xl04)
3: CD4+ CD25 cells (1x10s)
4: 0 to 1, CD25+ to CD4+ CD25 (5xl04)
5: 1 to 2, CD25+ to CD4+CD25
6: 1 to 1, CD25+ to CD4+CD25
7: Mitomycin C treated splenocytes
Figure 5.6: Regulation by CD25*CD4+ T cells does not depend on Notch
signalling or the presence of IL-10. CD25+CD4+ T cell regulation cultures were
prepared as previously described. Cells were cultured in the presence or absence of 1 OOpM
MW167 for the duration of the experiment. Overall proliferation was measured by [3H]
thymidine incorporation (A). IL-10 secretion was measured by ELISA (B). Cells were
harvested at 72 hours. A representative experiment of three is shown. Error bars represent
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Table 5.1: Percentage of events falling in gates R3 to R8 for Figure 5.7A-D
R3 R4 R5 R6 R7 R8
(A) Unstimulated 0.16 0.71 0.26 0.13 0.29 98.51
(B) Activated CD4+CD25- 8.05 33.9 28.6 16.45 8.52 5.12
(C) Activated 1 to 2 7.97 31.34 27.05 16.66 8.95 7.54
(D) Activated 1 to 1 4.53 17.11 24.45 22.49 17.54 14.85
Figure 5.7: Suppression of CD4+CD25" T cell division by CD25+ T regs.
CD25+CD4+ T cell regulation cultures were prepared as previously described (Chanter 2.2.4,
page 70). CFSE labelled CD4 CD25" T cells were used as target cells. Cells were stimulated
with anti-CD3-Ab coated, mitomycin C treated splenocytes. Cells were harvested at 48 hours
and CFSE labelling examined by flow cytometry.
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Table 5.2: Percentage of events falling in gates R3 to R8 for Figure 5.8A-D
R3 R4 R5 R6 R7 R8
(A) Unstimulated plus GSI 0.16 0.71 0.26 0.13 0.29 98.51
(B)ActivatedCD4+CD25' plus GSI 7.02 32.97 28.6 17.27 8.41 6.79
(C) Activated 1 to 2 plus GSI 8.16 31.3 27.05 17.26 8.18 8.69
(D) Activated 1 to 1 plus GSI 4.32 20.6 24.45 19.77 17.05 11.52
Figure 5.8: Suppression of CD4+CD25" T cell division by CD25+ T regs is Notch
independent. CD25+CD4+ T cell regulation cultures were prepared as described in Figure
5.6. Cells were stimulated with anti-CD3-Ab coated, mitomycin C treated splenocytes in the
presence of lOOpM y-secretase inhibitor. Cells were harvested at 48 hours and CFSE
labelling examined by flow cytometry.
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5.5 Tr1 cell generation
OVA specific T regulatory 1 (Trl) cells were generated from the DO11.10 TCR
transgenic mouse. Generation of this population was achieved by repeated
stimulation in the presence of IL-10, as outlined by Herve Groux et al in 1997 (50).
These cells are characterised by their lack of proliferation, high IL-10 secretion and
ability to suppress proliferation ofCD4+ T cells in response to antigen.
Whole DO11.10 spleen was homogenised and pulsed with OVAp in the presence of
IL-10 plus IL-2 or IL-2 alone to generate a Trl and Th cell line respectfully. Cells
were then restimulated one week after previous antigen challenge. This was repeated
three times before testing cell phenotype. Some of the major obstacles encountered in
this section of work derived from the inability of Trl cells to proliferate. Addition of
IL-2 with IL-10 allowed minimal Trl cell expansion. The use of supernatant from
ConA stimulated spleen cells to expand cells was successful but prevented
generation of the Trl phenotype. As such the number of Trl cells was always a
limiting factor. Following successful induction of a Trl phenotype, lines never
survived beyond another three or four subsequent expansions, the most likely
explanation being exhaustion. Fortunately, sufficient Trl cells were derived from this
system to show regulatory capabilities and assess resting cells for Notch pathway
component expression.
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Th cells were used as target cells for Trl regulation. Cells were stimulated with
0.3pM pulsed BALB/c splenocytes, as Trl, Th or co-cultures of both cell lines,
lxl05 Trl or Th cells were cultured with splenocytes as controls for maximal cell
proliferation, enabling exclusion of nutrient depletion as a determinant of reduced T
cell expansion. A set number of 5x10s Th cells were used as targets for suppression
by Trl cells. Several attempts were made in generating Trl cells before success was
achieved. The functional Trl line derived was designated AT2. In three out of three
experiments using AT2, Trl cell proliferation was significantly lower than equivalent
Th proliferation (p<0.001) (Figure 5.9). Addition of Trl cells to Th cell cultures at a
ratio of one to 2 reduced Th proliferation, being reduced further when a 1 to 1 ratio
was used (p<0.01) (Figure 5.9). Previous trials using mitomycin C treated
splenocytes failed to demonstrate regulation, pertaining to the requirement for viable
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Figure 5.9: Tr1 cells inhibit Th cell line proliferation. Trl cells, Th cells or Trl/Th
co-cultures were activated with OVAp pulsed BALB/c splenocytes. Splenocytes were pulsed
with 0.3pM OVAp for 1 hour then washed to remove residual peptide. Pulsed splenocytes
were plated in 96 well plates at lxlO6 cells per well. Trl and Th cells were plated as donated
by the x-axis, "1 to 2" and "1 to 1" represent ratios of "Trl to Th". 1 to 2: 5xl04 Trl to lxlO5
Th and 1 to 1: lxlO5 Trl to lxlO5 Th. Proliferation was measured at 72 hours by [3H]
thymidine incorporation. Data shown is representative of three independent experiments.
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Trl cell activation is associated with high levels of IL-10 secretion, also believed to
down-regulate APC function in the system and thus attenuate T cell proliferation.
Supernatants from AT2 Trl/Th co-cultures were collected and the presence of IL-10
assessed by ELISA. Trl cells were found to secrete significantly higher levels of IL-
10 than Th cells (p<0.01 n=3) (Figure 5.10). Titration of Trl cells into Th cell
cultures up to a ratio of 1 to 1, significantly increased IL-10 levels compared to Th
cells alone (p<0.01 n=3) (Figure 5.10).
180 I
160 J
Tr1 10"5 Th 10*5 Tr1 5x10M Th 5x10M 1 to 2 1 to 1
Cell type and number
Figure 5.10: IL-10 is secreted by Tr1 cells and is associated with regulation.
Trl cells, Th cells or Trl/Th co-cultures were activated with OVAp pulsed BALB/c
splenocytes. Splenocytes were pulsed with 0.3pM OVAp for 1 hour then washed to remove
residual peptide. Pulsed splenocytes were plated in 96 well plates at lxlO6 cells per well. Trl
and Th cells were plated as donated by the x-axis, "1 to 2" and "1 to 1" represent ratios of
"Trl to Th". 1 to 2: 5xl04 Trl to 1x10s Th and 1 to 1: 1x10s Trl to 1x10s Th. IL-10 was
measured by ELISA from supernatants taken at 72 hours. Data shown is representative of
three independent experiments.
A preliminary experiment investigating cytokine secretion in Trl/Th co-culture
systems revealed AT2 Trl cells secreted low level TNFa, while Th cells secreted
high concentrations of this cytokine (Figure 5.11A). AT2 Trl cells secreted higher
levels of IFNy than Th cells (Figure 5.1 IB). Secretion of IL-4 or IL-5 by AT2 Trl
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cells was not detected (Figure 5.11C, D). Secretion of these Th2 cytokines by Th
cells was in contrast very high (Figure 5.11C, D).
TNFa secretion in co-culture groups was found to decrease with proliferation, falling
from 2214pg/ml to 267pg/ml (Figure 5.11A). IFNy secretion in 1 to 2 cultures was
found to slightly increase but was not detected when cells were cultured 1 to 1. IL-4
levels were still high in 1 to 2 ratio co-cultures, but undetectable at a cell ratio of 1 to
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Figure 5.11: Cytokine secretion by Tr1 cells and in inhibition assays. Cytometric
bead analysis was used to assess secretion of TNFa, IFNy, IL-4 and IL-5 by Trl, Th cells
and co-cultures (as shown along the x-axis). Only one CBA was carried out due to limiting
volumes of supernatant.
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5.6 Notch genes and Tr1 cells
Trl and Th cells were rested for one week after completion of the generation
protocol (Chapter 2.2, page 66). Total RNA was then extracted for a comparative
analysis of Notch pathway gene expression between Trl and Th lines by real-time
RT-PCR. Resting Trl cell expression of Notch receptors, ligands and downstream
signalling targets was determined relative to expression by resting Th cells. Relative
fold changes of 2 or more were considered biologically relevant.
Trl cells expressed considerably higher levels of hesl than Th cells, having a mean
relative expression value of 11. 1±1.6 (Figure 5.12A). No biologically relevant
difference in deltex or notchl, 2, 3 or 4 expression was observed (Figure 5.12B, C,
D, E, F respectfully). Increased expression ofjaggedl was evident in Trl cells, with
a mean relative expression of 2.75±0.3 (Figure 5.12G). No change in jagged2
expression was apparent (Figure 5.12H). High levels of delta-like1 expression was































































Figure 5.12: Relative expression of components of the Notch signalling
pathway by Tr1 cells. Real-time RT-PCR was used to assess expression of Notch
pathway associated genes by Trl cells. RNA was extracted from Trl and Th cell lines one
week post stimulation. Gene expression is presented relative to the Th cell line. Three
individual experiments are each represented as one colour of icon; the average value is
depicted as a black bar. Fold changes of 2 or more are considered biologically relevant.
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5.7 Discussion
Tolerance to a myriad of antigens has been attributed to the activity of regulatory
CD4+ T cells (46, 165, 24). IL-10 secretion has been associated with active
regulation, although not always responsible for mediating tolerance (167). Given the
impaired secretion of this cytokine by CD4+ T cells in the absence of Notch, this
chapter focused on how Notch signalling may be related to T reg cell function. Two
populations of T reg cells were used in this study and both were found to
differentially express components of the Notch signalling pathway when compared
to non-regulatory counterparts. CD25+CD4+ cells expressed high levels of delta-
likel, also observed for in vitro generated Trl cells. Trl cells expressed high levels
of hesl and to some extent jaggedl. Activation of CD25+CD4+ T cells maintained
high delta-likel expression, but also induced higher jaggedl expression than
equivalent CD25" cells. Additionally, activation did not induce increased hesl
expression as observed for CD4+CD25~ T cells. Notch did not mediate regulation by
CD25+CD4+ T cells but was responsible for IL-10 secretion in culture.
Purified murine CD25+CD4+ T regs were found to mediate in vitro suppression in an
APC dependent manner. This is consistent with the body of published literature on
suppression by these murine T regs, with human cells able to regulate with out APCs
present. In murine systems, the APC likely acts as a docking site allowing T reg and
target to come into close proximity, allowing cell contact dependent inhibition. APC
presence was also critical for suppression of in vitro generated Trl cells. Unlike
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CD25+CD4+ T cell cultures, Trl cells required the presence of viable APCs. Trl cells
are known to secrete high levels of IL-10, vital to active regulation by these cells. IL-
10 is known to act directly on T cells, binding to and inhibiting signalling by CD28
(171, 172). However, its primary role in mediating T cell tolerance is in down-
regulating MHC class II and co-stimulatory molecule expression by antigen
presenting cells, thus preventing T cell activation (13, 173, 174, 175). Trl cell
function has been demonstrated as altering the activation state of APCs consistent
with IL-10 activity. The Trl cell phenotype of the cells used in this study (AT2) was
confirmed not only by the ability to reduce proliferation of a Th cell line but also in
their high secretion of IL-10. These cells are unlikely to be Th2 cells as neither IL-4
or IL-5 secretion was observed. AT2 cells did secrete higher levels of IFNy than Th
cells.
Real-time RT-PCR revealed that both CD25+CD4+ and Trl cells expressed high
levels of delta-like1. CD25+CD4+ T cell expression of delta-like 1 remained high after
activation, but was also accompanied by increased jaggedl expression. These
findings in murine CD25+CD4+ T cells are in line with data on human CD25+CD4+,
also shown to express high delta-like 1 transcripts upon activation (176). Both Delta-
likel and Jaggedl have been implicated in mediating tolerance (1, 177). Increased
expression of delta-like 1 transcripts were reported in airways of mice tolerised to the
house dust mite antigen Der pi (116). Retroviral transfection ofmurine CD4+ T cells
with delta-likel produced a population of T cells capable of mediating tolerance in
the aforementioned system (116). Over-expression of Jaggedl by APCs also induced
a population of regulatory T cells able to transfer tolerance to Der pi (1). Both these
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systems involve the inhibition of Th2 responses, however, over-expression of
Jagged 1 on APCs was also shown to suppress alloresponses through generation of a
Th3 population (177). Combined with the finding of enhanced Notch ligand
expression by well established populations of T regs, these ligand over-expression
studies would imply that Notch signalling mediates active regulation. This promoted
the use of the y-secretase inhibitor to dissect out the role of Notch in mediating
suppression by T regs.
Activation of Notch signalling in T lymphocytes is normally associated with
lymphoma development (88). This effect is usually mediated by truncations of the
Notch receptor itself and is independent of ligand expression, but it remains likely
that there is a qualitative element to Notch signalling supplied direct by ligand type.
Indeed, Notch receptor preference for ligand binding is directed by glycosylation,
mediated by the fringe family of glycosyltransferases (178, 179). It seems unlikely
that such a mechanism would have evolved and be so highly conserved if it had no
biological relevance. It was therefore initially speculated that Delta-like 1 may be
mediating reduced proliferation. The finding that inhibition of Notch signalling
prevented IL-10 secretion by CD4+ T cells suggested that perhaps the role of Notch
in T reg cell function was indirect, being mediated by IL-10. The role of Notch in
mediating regulation was supported by the finding that extraordinarily high levels of
hesl expression were detected in CD25+CD4+/CD4+CD25" T cell cultures. Addition
of y-secretase inhibitor to these cultures blocked up-regulation of hesl transcription,
but did not influence regulation. Secretion of IL-10 in this system mirrored
transcription of hesl. This data reflects the finding that CD25+CD4+ active regulation
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is not mediated by IL-10. Indeed, the primary mechanism has already been shown to
be contact dependent (180, 181), but the data presented here confirms that
CD25+CD4+ T cells regulation is not mediated by Notch signalling.
Blockade of Notch signalling in Trl cell active regulation cultures was not tested.
This was due primarily to time restraints arising from the difficulty in generating
functional Trl cells. However, it seems likely that Notch inhibition in this system
would have yielded very different results from those seen in CD25+CD4+ T cells
studies. This speculation arises from the inherent dependency of Trl cell generation
and function on the secretion of IL-10 (182). Examination of these cells strengthens
the link between Notch and IL-10, with Trl cells having high levels of hesl
transcription and IL-10 secretion. High expression of delta-like 1 by these T regs may
relate to a homeostatic function, maintaining the high IL-10 secretion phenotype.
Treatment of activated CD4+ T cells with a Delta-like 1-Fc fusion protein is reported
to induce cells with Trl like cytokine profiles (107).
Evidently expression of the Notch ligand Delta is related to CD4+ regulatory T cell
phenotype. The role of this molecule in mediating active regulation is still unclear,
but seems to relate to IL-10 secretion. The requirement/role of IL-10 in active
regulation varies from model to model, being critical in some and irrelevant in
others. What is clear is that IL-10 does have immunoregulatory properties and can be
utilised in generating tolerance to self and foreign antigen. Further dissection of the
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role ofNotch signalling induced by Delta will prove useful in deciphering its role in
tolerance.
5.8 Future work
It would be of interest to generate another line of Trl cells for testing in the context
of y-secretase inhibition. Given the importance of IL-10 in mediating regulation by
these cells it might be expected that they would not suppress proliferation in the
presence ofMW167.
It has been suggested that CD25+CD4+ T cells may play a role in the generation of
Trl cells. For this reason it would be important to purify suppressed cells from the
co-cultures and ascertain whether they secrete IL-10. If this were to be the case,
would such cells be generated in the presence of the y-secretase inhibitor, i.e. does
Notch signalling facilitate the generation ofTrl cells by CD25+CD4+ T regs?
A possible link between delta-likel, hesl, IL-10 production and active regulation has
been the focus of this chapter. To further establish this relationship, more direct
inhibitors of the Notch signalling pathway would be of interest, possibly use of
RNAi in establishing specific roles for Delta-likel and HESL
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Indeed, the level of protein expression for Delta-like 1 and Hesl would be appropriate
and complimentary to the RNA data. Attempts at flow cytometric staining for Delta¬
like 1 have been made and are discussed in Chapter 6.3, page 174.
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6 Induction of Notch signalling
6.1 Introduction/background
In a previous chapter (chapter 4.5, page 116), y-secretase inhibitor attenuation of
Notch signalling reduced TCR induced cytokine secretion in the absence of CD28
co-stimulation by CD4+ T cells. Inhibition of Notch signalling also prevented IL-10
production even when co-stimulation was provided. It is accepted that y-secretase
inhibitors do target other surface receptors, such as APP (183), in addition to Notch,
albeit that the relevance of these other pathways to T cell function is not yet clear. To
compliment the inhibition study and allow specific effects of Notch signalling in
CD4+ T cells to be ascertained it was decided to stimulate Notch signal transduction.
Ligation of endogenous Notch receptors using recombinant ligand over-expressed on
antigen presenting cells (APCs) and over-expression of a constitutively active Notch
receptor in primary CD4+ T cells were the two methods adopted to further this
investigation.
Use of recombinant ligands presents a method of inducing more physiological levels
ofNotch signalling, as expression of endogenous receptors represents a "bottle-neck"
limiting the amount of signalling possible. Dendritic cells (DCs) are known to
express Notch ligands (184) and would be expected to be the main physiological
source ofNotch stimulation for T cells in vivo. Dendritic cells are regarded to be the
most efficient APC for activation of naive CD4+ T cells, being able to provide the
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necessary co-stimulation for full T cell activation. Over-expression of the Notch
ligand Delta 1 on such cells would provide an efficient way of activating CD4+ T
cells in the presence of enhanced Notch signalling. An adenoviral construct encoding
murine Delta 1 was already available on undertaking this PhD and as such presented
an efficient method of gene transfer. Once transfected, Deltal expressing DCs could
be used to present OVAp to CD4+ T cells derived from DO 11.10 TCR Tg mice.
Recombinant adenovirus gene transfer represents an effective method for
transfection of non dividing cells, such as fully differentiated DCs (185). In addition,
adenoviral DNA is episomal reducing the risk of insertional mutagenesis associated
with retroviral gene transfer. As a result expression is only transient, but this is of
little concern in the in vitro system in which the Deltal adenovirus (Ad-Deltal) was
to be employed as cells were not cultured past 72 hours. Adenoviral constructs used
in this chapter are both El and E3 deleted. Removal of the El genes (ElA and E1B)
render the virus replication deficient (113), while E3 deletion reduces
immunogenicity associated with adenoviral infection (113). Entry into the target cell
is mediated by viral fibre protein interaction with numerous cell surface molecules,
including MHC class I and primarily through the coxsackievirus-adenovirus receptor
(CAR), and some integrins (186, 187, 188, 189, 190), facilitating receptor mediated
endocytosis and internalisation of the virus. Of particular note is the use of the aVp5
integrin (187, 191), expression of which is known to be up-regulated when cells are
cultured with GM-CSF (192), used in generation of DC enriched populations.
Generation of the viruses employed, Aa-EGFr (A kind gift of Drs R. ivlarr and F.
Graham, McMaster University, Ontario, Canada) and Ad-Deltal, utilised
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homologous recombination between viral genome encoding and promoter-driven
gene of interest containing plasmids within a packaging cell line (El transformed
HEK293 cells) (193), the resultant virions being isolated by plaque purification.
Although over-expression of ligand will only activate endogenous levels of Notch
signalling, it may be difficult to attribute any effect to a single Notch receptor. Notch
receptors are believed to be promiscuous in their ability to bind members of the
Jagged and Delta ligand families (194, 195). Over-expression of a constitutively
active Notch receptor in CD4+ T cells would allow assessment of a specific Notch
signal. Although this system will potentially induce artificially high levels of Notch
signals, comparison to results received from ligand induced signalling will allow
attribution of specific effects on CD4+ T cell function to particular ligand/receptor
combinations.
Over-expression of truncated Notch receptors resembling the active intracellular
signalling portion is a well established method for inducing constitutively active
Notch signals (114). A construct encoding a truncated constitutively active form of
Notchl was obtained from Professor Raphael Kopan (Dept. Molecular Biology &
Pharmacology & the Dept. of Medicine, Washington University) (114). The insert
encoding Notchl-intracellular domain (NICD1) was then sub-cloned into a vector
suitable for transfection of T cells, detailed in the materials and methods section
(Chapter 2.2, page 66). It must be stressed that transfection of primary CD4+ T cells
is very difficult, with the majority of experiments opting to use cell lines.
Experiments using primary T cells have utilised retroviral gene transfer technology
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(196). Since naive T cells are not cycling cells, they need to be activated to induce
proliferation allowing retroviral infection (196), negating the possibility of looking at
truly naive T cells. Additionally, transferred genes are integrated with host DNA
(197), and can be associated with insertional mutagenesis. Electroporation has been
used to transfect T cell lines, however, such systems are associated with poor cell
viability when using primary T cells. Commercial release of nucleofection
technology (Amaxa) has allowed transfection of primary human CD4+ T cells (198).
Unfortunately the technology has not yet been extended to include murine T cells,
which this PhD has focused on. Having been presented with the opportunity to
transfect primary CD4+ T cells with a constitutively active Notch receptor, the cross¬
over to human cells was made. It is for this reason that experiments over-expressing
NICD1 were performed using CD4+ T cells purified from human PBMCs.
Chapter aims:
• Culture population of APCs enriched with DCs.
• Optimise viral infection protocol for DC enriched population..
• Over-express Deltal on DCs.
• Use Ad-deltal DCs to activate CD4+ T cells, assessing proliferative and
cytokine responses.
• Induce Notch 1 signalling directly in human CD4+ T cells using NICD1 over-
expression.
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6.2 Adenoviral infection of a DC enriched cell population
Bone marrow derived DCs were generated based on a previously published Inaba et
al protocol (112). This protocol has been used extensively by others within the
laboratory and was chosen as it would provide a ready supply of efficient antigen
presenting cells.
Single cell suspensions were prepared from BALB/c bone marrow and seeded in 24
well plates at 3.75x10s cells/ml. Cells were differentiated using hybridoma derived
GM-CSF supernatant over a period of seven days (Chapter 2.2, page 66). Cells were
cultured for a further 5 hours in the absence or presence of lOOng/ml LPS to induce
maturation before staining for flow cytometric analysis. Cells were stained for
CD lie, Gr-1, MHC class II and CD80 to give an indication of DC enrichment and
granulocytic contamination (Figure 6.1). In a representative experiment, the
population was found to consist primarily of CDllc+ cells, 79% before and 72%
after LPS stimulation (Figure 6.1G, H). 22% of cells were Gr-1+, before and after
LPS maturation (Figure 6.11, J). Maturation of cells by LPS was confirmed by
enhanced expression of MHC class II and CD80 after stimulation. Although the
percentages of positive cells changed only slightly, the mean fluorescence intensity
(MFI) of MHC class II and CD80 staining rose from 637 to 914 (Figure 6.IK, L)
and 245 to 396 (Figure 6.1M, N) respectively, indicating enhanced expression of
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Figure 6.1: DC enriched population. DCs were generated from BALB/c bone marrow
according to the Inaba et al method. Unstimulated and LPS treated cells (lOOng/ml for 5
hours) were characterised on the basis of flow cytometric analysis. Forward and side scatter
profiles for unstimulated and LPS treated cells are shown (A, B). FITC and PE isotype
controls are also show (C-F). CD1 lc (G, H), Gr-1 (I, J), MHC class II (K, L) and CD80 (M,
N) expression are depicted along with the percentage of gated events falling in M2 and mean
fluorescent intensity (MFI). One experiment of two is shown.
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An in house Ad-GFP construct was used to determine the optimal multiplicity of
infection (MOI) for use with the DC enriched population. Briefly, DCs were plated at
3xl06 cells in 500pl and incubated with the adenovirus for 1 hour. Cells were then
washed and re-plated at 3xl06 in 3ml in 6 well plates (Chapter 2.2.12, page 66). Cells
were harvested after 24 hours and GFP expression assessed by flow cytometry. Ad-
GFP MOIs of 25, 50, 100, 200 and 400 were used to determine to amount of virus
needed to achieve a maximal transfection efficiency (Figure 6.2).
Cells were analysed for GFP fluorescence on FL-1, allowing easy quantification of
infected cells (Figure 6.1A). The percentage of cells positive for GFP expression
increased from 37±11% to 81±4% at MOIs of 25 and 200 respectfully (n=3) (Figure
6.1 A, B). Increasing the MOI to 400 did not significantly enhance infection
efficiency (Figure 6.1A, B). Since infection rates peaked at an MOI of 200, this MOI
was used throughout the remainder of this chapter. The dendritic morphology of GFP
positive cells was clearly visible using fluorescence microscopy (Figure 6.1C).
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Figure 6.2: DC infection with Ad-GFP. Optimal MOI for DC infection was determined
using an Ad-GFP vector. DC enriched populations with incubated with increasing MOIs of
virus for 1 hour. Cells were then washed and incubated for a further 24 hours. Cells were
than harvested and GFP expression determined by flow cytometry. Representative histogram
plots are shown (A). The mean number of GFP positive cells from three individual titrations
was also plotted (B). (C) GFP positive cells under a fluorescent microscope (X400).
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6.3 CD4+ T cell activation by Ad-delta1 DCs
To ascertain effects mediated by ligand induced Notch signalling on CD4+ T cells,
DCs infected with an adenoviral construct encoding the Notch ligand Deltal (Ad-
deltal) (Chapter 2.1, page 62) were used to stimulate nai've T cells. Detection of
Deltal protein was hampered by a lack of efficient antibodies. Much time was spent
trying to develop western blot and flow cytometric protocols to establish induction of
protein expression by the adenoviral construct. Western blotting was unsuccessful
and although some positive results were obtained by flow cytometry (Figure 6.3), the
inconsistency of the method was of concern. Real-time RT-PCR also failed to
demonstrate enhanced deltal expression as the data was un-interpretable due to what
appeared to be a non-specific viral effect interfering with the real-time reaction.
Indeed, not only were genes of interest affected, interference was also observed for
the 18S internal control reaction. Despite lack of detection of transgene expression, it
was decided to continue with this part of the project and determine if use of the Ad-
deltal construct mediated any biological effect.
Figure 6.3: Deltal expression. Day 7 DCs were incubated with either dl70-3 (A) or Ad-
delta 1 (B) for 1 hour. Cells were then washed and cultured for a further 24 hours to allow for
protein expression. Cells were then stained with anti-Deltal (T-20), followed by a







Uninfected, dl70-3 (empty control vector) or Ad-deltal treated DCs were either
unstimulated or matured with LPS (believed to enhance expression of transgenes
driven by CMV promoters, such as that utilised by this construct). Cells were
incubated for 24 hours before mitomycin C treatment and pulsing with OVA peptide
(Chapter 2.2.4, page 70). DCs were then co-cultured with purified DO11.10 TCR
transgenic CD4+ T cells, lxlO4 DCs to 5xl04 T cells. Proliferation was measured by
[ H] thymidine, pulsed at 48 and harvested at 72 hours. Supernatants were harvested
at 48 hours and cytokine secretion assessed by cytometric bead analysis and ELISA.
In three experiments, proliferation of unstimulated CD4+ T cells in the presence
dl70-3 or Ad-deltal treated DCs was not found to differ significantly from that
induced by untreated DCs (Figure 6.4A). Incubation of CD4+ T cells with unpulsed,
LPS matured DCs or LPS, dl70-3 DCs did not alter T cell division. Culture with LPS
matured, Ad-deltal infected DCs did however induce a marginal increase in non¬
specific CD4+ T cell proliferation which was found to be significant compared to
LPS DCs and LPS dl70-3 DCs, p=0.007 and 0.047 respectfully (Figure 6.4A).
In five experiments, use of specific antigen (OVAp) pulsed DCs induced a
significant increase in CD4+ T cell proliferation compared to unpulsed DCs (Figure
6.4A, B), p=0.021. Antigen driven proliferation was enhanced using pulsed DCs
treated with either dl70-3 or Ad-deltal, p=0.007 and 0.004 respectfully. No
significant difference between dl70-3 and Ad-deltal groups were observed (Figure
6.4B). LPS matured OVAp pulsed DCs induced significantly higher levels of CD4+
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T cell proliferation than non LPS matured DCs, p=0.007 (Figure 6.4B). Pulsed-LPS-
matured-adenovirally infected DCs were able to induce greater levels of proliferation
than pulsed-LPS-uninfected DCs, p=0.05 and 0.04 for dl70-3 and Ad-deltal pulsed-
LPS-infected DCs respectfully (Figure 6.4B). No significant difference in T cell
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Figure 6.4: Ad-delta1 DCs and CD4+ T cell activation. DC enriched populations
were infected with dl70-3 or Ad-deltal, un-pulsed (A) or pulsed (B) with OVAp (0.3pM)
and mitomycin C treated. DC to DOl 1.10 CD4+ T cell ratio was at 1 to 5, proliferation was
measured using [3H] thymidine harvested at 72 hours. One colour of icon represents an
individual experiment, the black bar depicts the mean value.
177
CBA and ELISA failed to detect the presence of TNFa, IFNy, IL-4, IL-5 or IL-10 in
cultures where DO 11.10 CD4+ T cells were not activated with specific peptide.
Analysis of supernatants from OVAp activated T cells revealed significant induction
of TNFa secretion by CD4+ T cells stimulated by adenovirally infected DCs when
compared to uninfected DCs (dl70-3: p=0.03, Ad-deltal: p=0.02) (Figure 6.5A, B).
No difference in TNFa secretion between adenoviral groups was observed.
TNFa levels were found to be significantly higher when LPS matured DCs were
used rather than unstimulated DCs (p=0.01) (Figure 6.5A). No significant difference
in TNFa secretion was observed between LPS-dl70-3 and LPS-Ad-deltal
adenovirally infected groups. Higher levels of TNFa were detected relative to non-
infected LPS DC activated T cells (p=0.0004 and 0.007, dl70-3 and Ad-deltal
respectfully) (Figure 6.5A).
CD4+ T cell IFNy secretion was enhanced by treatment of DCs with LPS compared
to non-matured DCs (p=0.004) (Figure 6.5B). Adenovirally infected DCs did not
significantly enhance IFNy secretion. No significant difference between LPS-
adenoviral treated DC and LPS DC groups was observed. Neither was any significant
IFNy secretion difference between LPS-dl70-3 and LPS-Ad-deltal DC activated T
cells detected (Figure 6.5B).
IL-10 secretion by activated CD4+ T cells was found to be unaffected by introduction
of the control adenovirus dl70-3, but was enhanced when DCs had been treated with
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Ad-deltal, p=0.046 (Figure 6.5C). A trend for elevated IL-10 secretion by activated
CD4+ T cells was observed in LPS matured DC groups compared to non-LPS treated
DCs (Figure 6.5C). No significant difference was observed between LPS and LPS
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Figure 6.5: Cytokine secretion by CD4+ T cells activated by adenovirus
infected DCs. DC enriched populations were infected with dl70-3 or Ad-deltal, mitomycin
C treated then pulsed with OVAp (0.3pM) before incubation with purified DOl 1.10 CD4+ T
cells. DC to T cell ratio was at IxlO4 to 5xl04. Supernatants were harvested after 48 hours of
culture. TNFa (A) and IFNy (B) secretion was assessed using cytometric bead analysis. IL-
10 secretion (C) was determined by ELISA. One colour of icon represents an individual
experiment, the black bar depicts the mean value.
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Given that the primary role of DCs is to act as sentinels and alert T cells to danger
associated antigens, it seemed reasonable to assume that the adenoviral constructs
were perhaps activating the DCs by means of a danger signal. This signal could
possibly up-regulate co-stimulatory molecules on the DCs and may help explain the
observed increases in proliferation and cytokine secretion by CD4+ T cells incubated
with adenovirally infected DCs. Uninfected DCs, dl70-3 and Ad-deltal treated DCs
were stained for expression of CD80, CD86 and MHC class II to reveal any change
in maturation state.
The uninfected DC enriched population expressed low level CD80, CD86 and MHC
class II (Figure 6.6A, B and C, representative histogram plots). Incubation with
control virus dl70-3 enhanced expression of all three surface markers (CD80: p=
0.013, CD86: 0.016, MHC class II: 0.006) (n=4) (Figure 6.6D, E, F). Incubation with
Ad-deltal further enhanced expression of CD80, CD86 and MHC class II relative to
dl70-3 treatment ( CD80: p=0.007, CD86: 0.036, MHC class II: 0.01) (n=4) (Figure
6.6G, H, I).
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Figure 6.6: Maturation of DC enriched cell population by adenovirus. Bone
marrow derived DCs were incubated without virus (A-C), control virus dl70-3 (D-F) or Ad-
delta 1 (G-I) for 1 hour, washed and cultured for a further 24 hours before analysis ofCD80,
CD86 and MHC class II expression by flow cytometry. The mean fluorescent intensity for
region M2 is shown in each panel. One representative experiment of four is shown.
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6.4 Over-expression of NICD1 in human CD4+ T cells
Induction of Notch signalling using over-expression of ligand appeared inconclusive
and as such it was decided to try and induce a specific Notch signal by transfection
of CD4+ T cells with a constitutively active Notch receptor. In a "Letters to nature
paper" by Schroeter et al (114), the requirement for nuclear translocation of the
intracellular domain of Notch 1 in mediating signal transduction was demonstrated
using truncated receptors. One of these constructs was kindly gifted by Professor
Raphael Kopan (N-ICvl744) (114), encoding a myc tagged Notchl intracellular
domain. The inserted sequence was sub-cloned into a commercially available pEGFP
vector to generate the plasmid pNICDl (Figure 6.7). The insert was cloned keeping
the stop codon intact to prevent generation of an EGFP fusion protein that may have
affected the function ofNICD1. Sub-cloning allowed use of pEGFP as a transfection
control and to determine transfection efficiency.
mCMV
Figure 6.7: pNICDl. A myc tagged NICD1 sequence was sub-cloned into the
commercially available pEGFP-Nl vector. The myc tag was followed by a stop codon
preventing transcription of an EGFP fusion protein. The pEGFP-Nl vector was used as a
control vector allowing estimation of transfection efficiency. Details of the sub cloning are
detailed in Materials and Methods (Chapter 2.2.13, page 81).
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Amaxa nucleofection technology was used to transfect human CD4+ T cells (Amaxa
transfection of mouse cells is currently associated with high cell mortality). Human
CD4+ T cells were purified by MACs isolation. Transfection of cells with lpg
pEGFP gave transfection efficiencies of 54±6% (n=3) whether cells were anti-CD3-
or anti-CD3/28-Ab stimulated. Efficiency was lower, 37±4% (n=3) with
unstimulated cells. Use of larger amounts of DNA was associated with a decrease in
cell viability (based on forward/side scatter plots and a reduced ability of cells to
respond to anti-CD3/28-Ab stimulation). Little information regarding improving
transfection was available from Amaxa regarding the content of the supplied reagents
so no attempt could be made to further improve efficiency.
Purified CD4+ human T cells were transfected according to manufacturer's
instructions with no DNA (mock), pEGFP or pNICDl. Cells were then cultured for
48 hours, unstimulated, anti-CD3- or anti-CD3/28-Ab treated. Proliferation was
measured by [3H] thymidine incorporation and supernatants were assayed for
cytokine secretion.
Low level proliferation by unstimulated mock transfected CD4+ T cells was
unaffected by transfection with pEGFP or pNICDl (Figure 6.8). Mock transfected
cells proliferated in response anti-CD3-Ab, a response enhanced slightly by addition
of anti-CD/28-Ab (Figure 6.8). pEGFP transfected cells proliferated less than mock
transfectants to both these stimuli (Figure 6.8), most likely due to EGFP toxic
effects. Transfection with pNICDl further reduced proliferation in response to anti-














Figure 6.8: pNICDI reduces proliferation of human CD4+ T cells. CD4+ T cells
were isolated by MACs negative selection from human PBMCs. Cells were then transfected
using the Amaxa system, either as a mock transfer or in the presence of pEGFP or pNICDI.
Proliferation was measured at 48 hours of unstimulated, anti-CD3 or anti-CD3/28 treated
cells. One experiment is shown, error bars represent the standard deviation of four replicates.
Cytokine secretion by transfected CD4+ T cells was assessed by cytometric bead
analysis. Enhanced IFNy secretion was observed by both anti-CD3-Ab stimulated
pNICDI transfectants relative to mock and pEGFP groups (Figure 6.9A).
Stimulation with anti-CD3/28-Ab resulted in a similar trend, however the difference
between control groups and pNICDI was less pronounced (Figure 6.9A). The same
trend was evident when TNFa secretion was assessed (Figure 6.9B). pNICDI
enhanced TNFa secretion upon anti-CD3-Ab stimulation, but with a less distinct
difference detected when anti-CD3/28-Ab was used (Figure 6.9B).
pNICDI transfection also enhanced IL-10 secretion induced by anti-CD3-stimulation
(Figure 6.9C). However, a marked increase was still evident when pNICDI cells
were treated with anti-CD3/28-Ab (Figure6.9C), unlike IFNy and TNFa (Figure
6.9A, B). This same trend was also observed for IL-4, the difference between anti-
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CD3/28-Ab pNICDl and control groups being particularly pronounced (Figure
6.9D). IL-5 secretion was increased upon stimulation in the presence of pNICDl in
comparison to mock and pEGFP transfectants. Although a trend for enhanced
cytokine secretion was observed when pNICDl cells were activated, a difference
may be apparent when comparing anti-CD3- and anti-CD3/28-Ab stimulation. It
might be speculated that pNICDl transfection enhances IFNy and TNFa upon anti-
CD3-Ab treatment (Figure 6.9A, B), but when anti-CD3/28-Ab is used a more
profound difference is observed in IL-4 and IL-5 production (Figure 6.9D, E).
Enhanced IL-2 secretion was also observed by pNICDl transfectants (Figure 6.9F).
Unlike the other cytokines assayed, IL-2 secretion was enhanced in pNICDl
unstimulated cells as well as anti-CD3- and anti-CD3/28 stimulated transfectants

















































Figure 6.9: pNICDI transfection enhances cytokine secretion by activated
human CD4+ T cells. CD4+ T cells were isolated by MACs negative selection from
human PBMCs. Cells were then transfected using the Amaxa system, either as a mock
transfer or in the presence of pEGFP or pNICD 1. Cytokines were harvested at 48 hours from
unstimulated, anti-CD3- and anti-CD3/28-Ab treated cells. Secretion of IFNy, TNFa, IL-10,
IL-4, IL-5 and IL-10 was assessed using cytometric bead analysis. Data from an individual
experiment is shown.
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Real-time RT-PCR did reveal up-regulation of relative hesl expression in pNICDl
transfectants relative to mock cells (Figure 6.10). hesl expression was up 4.7 fold
relative to mock unstimulated cells, and 6 fold relative to EGFP transfected cells.
Anti-CD3 stimulation increased hesl expression relative to unstimulated cells (as in
murine CD4+ T cells, Chapter 3.3, page 89) in all groups. However, pNICDl
transfection induced a relative expression of 26.3 compared to 6.1 and 4.9 of mock
and pEGFP anti-CD3-Ab stimulated cells respectfully (Figure 6.10). The same
pattern was observed for anti-CD3/28-Ab treatment, pNICDl transfection enhancing
relative hesl expression from 6.67 and 5.7, mock and pEGFP respectfully, to 28.2
(Figure 6.10). Enhancement of hesl expression by pNICDl implies that the construct


























Figure 6.10: Relative hesl expression after pNICDl transfection. CD4+ T cells
were isolated by MACs negative selection from human PBMCs. Cells were then transfected
using the Amaxa system, either as a mock transfer or in the presence of pEGFP or pNICDl.
RNA was collected after 48 hours of culture as unstimulated, anti-CD3- or anti-CD3/28-Ab
treated cells. Real-time RT-PCR was used to assess expression of hesl relative to
unstimulated mock transfected cells. A single experiment is shown.
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Unfortunately, time restraints have only allowed this one initial experiment to be
carried-out. The results are however, intriguing, particularly given that pNICDl
enhances cytokine secretion while repressing proliferation. Having only carried out
this experiment once has meant that no suitable protein expression data has been
generated. From this single experiment, some immunohistochemistry was prepared,
using anti-myc antibodies. However, few cells were available for optimisation of the




Although no direct conclusions can be drawn from the experiments detailed in this
chapter, some interesting preliminary results were generated. Much of the adenoviral
work was carried out at the beginning of this PhD, but was fraught with difficulty
due to lack of effective reagents, rendering much of the data inconclusive. As such it
must be stressed that the following discussion provides only speculative points based
on the data and how interpretations may be made given current literature.
Notch signalling has been shown to affect CD4+ T cell proliferation and cytokine
secretion (97, 96). Much of this work has been established by prevention of Notch
receptor cleavage (97, 96) or induction of Notch signalling using retrovirally
transduced CD4+ T cells (97). This section of work aimed to compliment previous
chapters by stimulation of Notch receptor signalling, both ligand induced and by
transfection of CD4+ T cells with a constitutively active Notch receptor.
A DC enriched population over-expressing the Notch ligand Delta 1 was used to
activate CD4+ T cells in an antigen specific fashion, utilising the DO11.10 TCR Tg T
cells. The population of APCs generated was found to be rich in DC like cells
(positive for CD 11c, MHC class II and CD80), and could be infected with
recombinant adenoviral vectors. A transfection efficiency of 80% was readily
achievable using the protocol established. Attempts to demonstrate Deltal transgene
expression were of limited success, but were due to technical difficulties rather than
being specific to a failure in transgene expression. To date, only low affinity,
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polyclonal anti-Deltal antibodies are available. Numerous attempts to achieve
successful staining were made and in addition to using these antibodies, a recently
developed Notch 1-Fc fusion protein was used to try and demonstrate transgene
expression, again unsuccessful. If a functional protein was expressed by the Ad-
deltal construct, minimal biological effect was mediated on CD4+ T cells. Ad-deltal
DCs did enhance antigen non-specific CD4+ T cell proliferation, but no significant
difference was observed in antigen driven proliferation. Enhanced IFNy and TNFa
secretion reflected trends for increased [ H] incorporation induced by all adenoviral
treated groups. CD4+ T cell IL-10 secretion was elevated when activation was by Ad-
deltal DCs, however this effect was not observed when LPS matured Ad-deltal DCs
were used.
Examination of the maturation state of dl70-3 and Ad-deltal DCs revealed
significantly enhanced expression of CD80/86 and MHC class II compared to non-
virus treated. This would likely explain the trend for increased proliferation and
cytokine levels observed when adenovirus treated DCs were used to activate CD4+ T
cells. Although this was not an objective of the project, it was reassuring that the DC
population used did respond to viral infection, exhibiting that "danger signals"
actually do functionally mature APCs.
Of note was the pronounced maturation of the Ad-deltal DC population, even
compared to the dl70-3 DCs. It has been reported that Notch signalling induced using
Jagged 1 can mature human DCs, in terms of surface marker expression and ability to
enhance alloresponses (199). Greater maturation of the Ad-deltal DCs discussed in
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this chapter may indicate that the transgene is expressed and as a consequence the
DC population is functionally matured by induction ofNotch signalling.
Expression of high levels of co-stimulatory molecules may conceal minimal effects
mediated by the transgene. Effects ofNotch signalling on T cells have been shown to
be sensitive to TCR signalling strength (97). Anti-CD3-Ab stimulated CD4+ T cells
have reduced cytokine secretion and diminished proliferative responses in the
absence of Notch (97, 97). Addition of anti-CD28- as well as anti-CD3-Ab restores
cytokine secretion (Chapter 4, page 104) and proliferation (97), indicating that Notch
mediated effects may also be compensated for by co-stimulation. Adenoviral
infection of DCs likely enhances TCR signalling and co-stimulation received by the
T cell, masking any effect mediated by Delta 1 induced Notch signalling. Recent
work combining a technique developed for adenoviral infection of macrophages
(personal communication, P Enrickson, Gene Transfer Group, Centre for
Inflammation Research, University of Edinburgh) with the protocol established in
this thesis for infection of dendritic cells may circumvent the problem of cell
maturation upon encountering viral vectors. Transfection efficiency can be
maintained using lower MOIs when virus particles are mixed with lipofectamine
reagent (personal communication, A Roghanian, Gene Transfer Group, Centre for
Inflammation Research, University of Edinburgh). Repeating the Ad-deltal
experiments using less mature DCs may generate clearer results.
IE-10 secretion by CD4+ T cells induced by Ad-deltal DCs was found to be higher
than controls. This may be due to induced Notch signalling, particularly when
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considered in the context of previous y-secretase inhibitor experiments that
highlighted the requirement of Notch signalling for production of this cytokine
(Chapter 4.6, page 119). However, the maturation state of the Ad-deltal DCs was
also found to be significantly different from uninfected and control virus infected
DCs. It is therefore equally feasible that the enhanced IL-10 secretion is due to
differential co-stimulatory signalling.
Notch ligands have been over-expressed on APCs and used to activate T cells in two
other systems (1, 105). The first used splenic DCs retrovirally transfected with
human Serrate 1 (1). Mice immunised with antigen pulsed Serrate DCs were rendered
tolerant, which could be transferred to naive mice by Serrate DC primed CD4+ T
cells (1). The activation state of the APC in this system was not addressed, nor was
enhanced Notch signalling in the T cells demonstrated. This is not however, to
detract from the fact that this Notch ligand was linked to generation of a regulatory
population of T cells. It would be interesting to ascertain the mechanism of tolerance
in this system, particularly if there was a role for IL-10.
A regulatory population of CD4+ T cells was also generated in response to EBV-
lymphoblastoid B cells over-expressing Jaggedl (105). These cells exhibited a Th3
phenotype, likely mediating suppression of cytotoxic activity via TGFp (105). IL-10
secretion in this system was unaffected, as was the activation state of the transformed
B cells (105). However, these systems used Jagged family ligands. The effect
mediated by Delta induced signalling may be qualitatively different.
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Use of Delta 1-Fc fusion proteins has yielded conflicting data. Activation of CD4+ T
cells in the context of Delta 1 induced signalling is reported to induce IL-10 secretion
while inhibiting pro-inflammatory cytokine secretion (107). However, Delta 1
signalling through Notch3 has been shown to induce Thl polarisation (101), with
high doses of Deltal-Fc reducing activation induced proliferation. In either case, a
pronounced effect on CD4+ T cells was observed, unlike those seen using Ad-delta 1
DCs. A Deltal-Fc fusion protein has now been made commercially and if given the
opportunity to revisit ligand induced Notch signalling, use of the fusion protein
would be preferable to using Ad-deltal.
Nucleofection of primary human CD4+ T cells with constitutively active Notchl
yielded some exciting preliminary results, particularly in the inhibition of
proliferative responses. Cells transfected with pNICDl did express higher levels of
hesl, indicative ofNotch signalling. These cells did not proliferate to the same extent
as control groups, and this was not due to lack of IL-2 production. Transfection of a
Jurkat cell line with NICD1 revealed inhibition of TCR induced NFAT/AP-1 reporter
activity (99). Although NFAT itself may not be affected by Notch signalling as y-
secretase inhibition does not affect activity of this transcription factor (96, Chapter
4.7, page 123), repression of the aforementioned NFAT/AP-1 reporter is likely
linked to prevention of AP-1 transcriptional activity. The intracellular domain of
Notchl is capable of suppressing AP-1 transcriptional activity (136). It might be
speculated that TCR stimulation in the presence of Notch signalling sustains NFAT
activity in Ine absence of AP-1, activating transcription of anergy associated genes
(6), resulting in decreased proliferation. It is unlikely that the reduced proliferation
193
seen upon NICD1 transfection of human CD4+ T cells is classical anergy since cells
were still capable of secreting IL-2. It may simply indicate a switch to enhanced
effector function at the expense of clonal expansion. In contrast, retroviral
transduction of murine CD4+ T cells with NICD1 was shown to enhance
proliferation by up-regulating CD25 expression (97). Activation of T cell
proliferation by Notch is also associated with lymphoproliferative disorders, where
translocation events result in constitutively active receptors (78, 89). How this
activation of proliferation relates to the data presented in this chapter is unclear, but
may be a reflection of differences in transfection protocols or as with some Notch
induced lymphomas, sustained expression of proliferation inducing receptors such as
pre-TCR (89).
As with the retroviral transfer of NICD1 (97), induced Notch signalling in human
CD4+ T cells enhanced secretion of IL-2, even by unstimulated cells. Anti-CD3- and
anti-CD3/28-Ab induced TNFa, IFNy, IL-10, IL-4 and IL-5 secretion was also
enhanced by NICD1 expression. Although Alder et al do not discuss the effect of
NICD1 expression on cytokine secretion other than IL-2 (97), a similar system has
reported that NICD1 does not affect IFNy or IL-4 secretion (101). This effect was
attributed to activity of NICD3, again utilising retroviral gene transfer. Enhanced
cytokine secretion is likely to result from Notch enhanced NFkB activity (88, 96),
being reduced by y-secretase inhibition and constitutively active in NICD3 transgenic
T cells. While IFNy, IL-4 and IL-2 are known to have functional NFkB binding sites
(154), IL-10 production may be refractory to NFkB activity (162). The fact that IL-
10 secretion is also enhanced by pNICDl suggests that an additional mechanism is
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being employed. Regulation of IL-10 production by Notch was discussed in more
detail previously (Chapter 4.8, page 126), but in summary, Notch signalling may
regulate IL-10 gene transcription via HES1.
Continuation of the NICD1 work should prove fruitful, particularly if activity of
NFkB, NFAT and Akt signalling pathways can be assessed in the context of Notch
activation. However lack of detection of Delta 1 protein would mean a more reliable
system than using Ad-delta 1, perhaps using the now commercially available Delta 1-
Fc protein, would prove more successful for in vitro studies. Had the Ad-deltal
experiments been more productive, the adenovirus would have allowed for adoptive




The hypothesis behind this thesis was that Notch signalling has a role in peripheral
CD4+ T cell differentiation. To address this, CD4+ T cells were examined for the
expression of Notch pathway components. The ability of stimulated CD4+ T cells to
proliferate and secrete cytokines (important in mediating effector function) was also
assessed in the absence of Notch signalling. To further establish a role for Notch
signalling in CD4+ T cells, signalling was induced using both DCs over-expressing
Delta-like 1 and direct transfection of CD4+ T cells with a constitutively active
Notch 1 construct.
Transcripts of both Notch receptors and ligands were detected in unstimulated and
activated CD4+ T cells, expression being differentially regulated following priming
(Chapter 3.3, page 89). It was speculated that altered expression may reflect the
requirement for particular Notch signals following TCR stimulation and pertained to
development of effector function. Indeed the stimulation of a T cell by an APC
bearing Notch ligand (184) might be likened to lateral induction observed in
Drosophila, where Notch signalling occurs between two non-equivalent cell types
(57), establishing the cell fate of the signal receiving cell. Stimulation of purified
nai've CD4+ T cells is associated with an increase in expression of the Notch target
gene hesl (Chapter 3.3, page 89). This finding demonstrates that CD4+ T cells are
both receptive to Notch signals and must also be capable of delivering Notch signals.
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It has been suggested that Notch mediates its effects on T cells by interaction with
the TCR signalling pathway. Many surface receptors that have been shown to
augment or antagonise TCR signalling are believed to be recruited to the
immunological synapse where they are brought into close proximity to the TCR
signalling molecules (2). The finding that Notch 1 co-localises with CD4 on activated
T cells (Chapter 3.4, page 113) strongly suggests that Notch receptors may
physically associate with the TCR related signalling apparatus. An intriguing finding
was recently reported documenting activation of Akt/PKB by Notch 1 in a p561ck
dependent manner, with Notchl and p561ck co-immunoprecipitating (200). This adds
credence to the idea that CD4 and Notchl might co-localise, given the association of
CD4 with p561ck (201). It is of interest to note that the fine line between T cell
activation and anergy may relate to activity of lck relative to fyn, where higher fyn
activity results in anergy (3). Additionally, Notch activation of Akt/PKB, a major
target of CD28 signal transduction (202), would also support a role in augmenting T
cell activation. Identification of a possible crossover point between Notch and CD28
signalling is of particular relevance in relation to the presented data pertaining to
Notch and cytokine secretion.
Notch signalling was required for secretion of TNFa, IFNy, IL-4 and IL-5 by anti-
CD3-Ab stimulated CD4+ T cells (Chapter 4.5, page 116). However, Notch
signalling was not necessary for cytokine secretion when cells were stimulated with
anti-CD28- in addition to anti-CD3-Ab. The ability of CD28 to substitute for Notch
signalling in this context likely relates to the aforementioned activation of Akt by
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these pathways. This supports the idea that Notch functions as a costimulator of T
cells.
A key player in mediating Notch activity in a costimulatory capacity is likely to be
NFkB. NFkB family members are known to direct transcription of inflammatory
cytokines in T cells (203). Direct effects of Notch signalling on NFkB activity have
been demonstrated in Notch3 transgenic mice and y-secretase inhibitor experiments,
demonstrating enhanced and impaired NFkB activity respectively (88, 96). The
direct protein interactions linking Notch and NFkB have yet to be elucidated, but it
seems highly plausible that Notch stimulation of Akt via lck would lead to activation
ofNFkB as it does in CD28 mediated costimulation. Based on this idea, it would be
of value to examine Akt activity in anti-CD3-Ab stimulated CD4+ T cells in the
context of inhibited or induced Notch signalling (Figure 7.1).
Notch signalling may influence cytokine secretion more directly. The IL-6 promoter
has been shown to contain a functional CBF-1 binding site (204). In this context,
over-expression of CBF-1 inhibited secretion of IL-6. However, this paper did not
address the ability of Notch signalling to convert CBF-1 from a transcriptional
repressor to an activator. If this was found to be the case then perhaps the cytokines
looked at in this study contain CBF-1 binding sites. It would be of interest to assess
IL-6 secretion by CD4+ T cells in the presence of the y-secretase inhibitor to
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Figure 7.1: Potential interactions between Notch and TCR signalling. Red arrows
show where Notch mediated signals interact with components of the TCR signalling
apparatus, namely Akt, AP-1 and NFkB. The possible role of Notch as a costimulator of T
cells is highlighted in green indicating where CD28 signalling overlaps with possible Notch
targets.
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A key finding that has shaped much of this thesis is the link between Notch
signalling and IL-10 production (Chapter 4.6, page 119). Inhibition of Notch
signalling was associated with a dramatic reduction in IL-10 secretion by stimulated
CD4+ T cells (even in the presence of anti-CD28-Ab costimulation). This was found
to be an inhibition at a transcriptional level. The inability of CD28 signalling to
compensate for the lack of Notch and restore IL-10 production likely reflects the
profound differences between the IL-10 promoter and those of inflammatory
cytokines (lack of functional NFkB and AP-1 binding sites) (162).
It was initially speculated that the lack of IL-10 mRNA may be due to a direct effect
on transcription by Notch signalling. If this were the case, it might be expected that
the IL-10 promoter would contain a CBF-1 binding site. Analysis of gene sequence
showed that this was unlikely as no CBF-1 consensus site was identified, but a
possible HES1 binding site was found (Chapter 4.6, page 119). Time constraints and
a lack of technical skill meant that initial gel shift assays were unsuccessful in testing
this possibility. However, this aspect of the work would be worth pursuing if a
concrete connection between Notch signalling and IL-10 production is to be made.
The strong possibility that Notch and IL-10 are linked is evident in the data derived
from experiments using T regulatory cells (Chapter 5, page 134). CD25+CD4+ T cells
do secrete IL-10 in the system presented in this thesis. Where active regulation by
CD25+CD4+ T cells was occurring, very large increases in hesl transcription were
observed. Additionally, these cultures exhibited the largest amount of IL-10
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production in relation to their degree of proliferation. These cells had already been
shown to express high levels of delta-like1.
This begged the question as whether regulation was occurring via Delta-like 1
induced Notch signalling in the target cell, as a direct effect of Notch signalling or
due to induction of IL-10 secretion. Addition of high levels of y-secretase inhibitor to
CD25+CD4+ regulation cultures did not affect proliferation, but did result in a
reduced ability to secrete IL-10 (Chapter 5.4, page 147).
Interestingly, in vitro generated Trl cells were also found to be high expressers of
delta-like 1 (Chapter 5.6, page 158). This could perhaps relate to the ability of these
cells to secrete high levels of IL-10. Indeed, unstimulated Trl cells expressed higher
levels of hesl than non-regulatory counterparts, perhaps indicating that they have
been subject to Notch signalling. It could be speculated that Delta-like 1 expressed by
Trl cells helps maintain the population's ability to secrete IL-10, but it may also
provide a mechanism by which these cells could be generated (Figure 7.2). It has
been suggested that naturally occurring CD25+CD4+ T regs may promote the
generation of peripherally generated T regs (Trl, Th3) (24).
Given the strong circumstantial evidence that Delta-like1/Notch interactions could be
mediating the cell-cell contact dependent inhibition by CD25+CD4+ T regs, it was
disappointing to discover that y-secretase inhibitor attenuation of Notch signalling in
CD25+CD4+ co-cultures did not prevent active regulation. Further investigation of
Delta-like1/Notch interactions in this context would help to confirm this in the
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author's own mind. Published literature detailing the use of a Delta-like 1-Fc fusion
protein demonstrated inhibition of T cell proliferation at the higher doses used in the
study (101). Additionally, the presented data on transfection of human CD4+ T cells
with constitutively active Notch 1 resulted in reduced proliferation of these cells upon
polyclonal stimulation. This lends credence to the idea that Notch signalling may be
a cell-cell contact mechanism that could be utilised in active regulation by
CD25+CD4+ T regs. Pre-treatment of CD4+ T cells with y-secretase inhibitor before
use in CD25+CD4+ T reg co-cultures could rule out the possibility that suppression is
due to very early rather than prolonged Notch signalling. Use of RNAi technology to
prevent expression of Delta-like 1 by T cells may prove useful in determining if
Notch signalling induced by this ligand mediates suppression of CD4+ T cell
proliferation. In addition, an in-house inducible delta-like1 transgenic mouse has
been developed. The in vitro responses of CD4+ T cells derived from this mouse are
currently being investigated, but it would be interesting to compare these cells with
CD25+CD4+ T regs or Trl cells.
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Figure 7.2: Notch in active regulation by CD25+CD4+ T regs. CD25+CD4+ T regs
induce a Notch signal in target naive CD4+ T cell undergoing priming. High levels of
transduced Notch signals may result in anergy or allow generation ofTrl cells directly or by
inducing IL-10 production by an intermediate T primed cell, then when antigenic stimulus
persists, IL-10 induces Trl differentiation.
Reconciliation of the idea of Notch as a costimulator of CD4+ T cells with the idea
that it may also act to suppress their function is difficult. However, in an attempt to
do so, it might be proposed that Notch signalling in CD4+ T cells would initiate
receptiveness to polarisation stimuli (Figure 7.3). As such a biphasic system is
suggested where initial low level Notch activity facilitates activation of the T cell.
Once a certain threshold ofNotch activity is reached, signalling promotes a switch in
cell activity from clonal expansion to differentiation of effector function. Regulatory
populations of T cells may preferentially utilise the Notch pathway as a way of
shaping responses of target cells, perhaps by increasing their receptiveness to yet
unidentified signals from T regs. This may be reflected in the generation of Trl like
cells by CD25+CD4+ T cells.
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Interaction with an APC bearing Notch ligands would recruit Notch receptors to the
immunological synapse. Here Notch may initially function to augment TCR and
CD28 signalling, based on lck dependent Akt activation and data pertaining to
enhanced NFkB activity (200, 88, 96). Inhibition of Nur77 would also support
survival of CD4+ T cells, preventing TCR induced apoptosis (102), possibly
pertaining to later differentiation into memory cells. Induction of IL-2 and CD25
would also support clonal expansion of the ThO population (97).
The function of Notch signalling is closely related to cell cycle. G2 cell cycle arrest
is required for Drosophila neural cell fate determination (205). The effect of Notch
signalling following cessation of cell division may be different based on differences
in degradation resulting in disruption of signalling mediator equilibriums. Slowing of
clonal expansion due to limiting IL-2 levels may precede development of effector
function. Fully differentiated Thl and Th2 cells are poorer sources of IL-2 than ThO
cells. Indeed, after 48 hours of in vitro culture, it is often difficult to detect IL-2 in
supernatants. Perhaps during the intermediate stage between being a ThO and
terminally differentiated Thl/Th2 cell, slowing of proliferation switches the role of
Notch signalling in the cell. In this context Notch signalling may facilitate
receptiveness to particular polarisation stimuli, or might reinforce differentiation
through chromatin remodelling. The interplay between Notch signalling and histone
acetyltransferases and deacetylases is well documented and may link into epigenetic
views on helper ceil polarisation (206).
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Figure 7.3: A biphasic role for Notch in CD4+ T ceil function: Priming of naive
CD4+ T cells in the context of Notch signalling would promote clonal expansion through
augmentation of IL-2 secretion when costimulation is limiting, and stimulating expression of
CD25. Population proliferation begins to slow as ThO cells utilise the available IL-2.
Alterations in cell cycling enhances stability of Notch signalling components allowing the
primed T cell to become more receptive to polarisation stimuli such as cytokines, signalling
from Thl/Th2/T reg signalosomes or costimulation. Notch signalling may then function to
fortify helper/regulatory cell differentiation.
Studies into the subversion of immune responses by pathogens have advanced the
understanding how the immune system functions. Using this other perspective to
study Notch will likely be effective in understanding the role of this developmental
pathway in normal operation of the immune system. The EBV protein EBNA2 shares
much homology with the intracellular domain ofNotch. Many of the mechanisms by
which Notch signalling directs its influence have been shown to integrate with
EBNA2 signalling, including binding of CBF-1 (207), inhibition of Nur77 induced
apoptosis (208) and acetylation of histones (209). Of additional interest, particularly
in light of the IL-10 data presented in this thesis, is the identification of an EBNA2
binding consensus in the human IL-10 promoter (210). Although this study found
205
that EBNA2 was not required for LPS induced IL-10 secretion in a monocyte cell
line, it does raise the possibility that EBNA2/NICD may regulate lymphocyte
secretion of IL-10 more directly rather than expected.
It had been said that a PhD generates more questions than it answers, and this is
certainly true of Notch and CD4+ T cell function. Deciphering the current data
pertaining to this aspect of T cell biology and that still to come will likely highlight
the complexity of the system. Having numerous receptor and ligand homologues
providing qualitative and quantitative signals is complicated, but identification of
numerous molecules that can regulate these signals will no doubt add numerous new
levels of control to the system. Examination of these positive and negative regulators
in the context ofmature T cell function will likely prove fruitful as has been the case
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